IRRITABLE BOWEL SYNDROME A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Irritable Bowel Syndrome: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83946-8 1. Irritable Bowel Syndrome-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on irritable bowel syndrome. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON IRRITABLE BOWEL SYNDROME ................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Irritable Bowel Syndrome ........................................................... 27 E-Journals: PubMed Central ....................................................................................................... 64 The National Library of Medicine: PubMed ................................................................................ 64 CHAPTER 2. NUTRITION AND IRRITABLE BOWEL SYNDROME ..................................................... 109 Overview.................................................................................................................................... 109 Finding Nutrition Studies on Irritable Bowel Syndrome .......................................................... 109 Federal Resources on Nutrition ................................................................................................. 117 Additional Web Resources ......................................................................................................... 117 CHAPTER 3. ALTERNATIVE MEDICINE AND IRRITABLE BOWEL SYNDROME ............................... 119 Overview.................................................................................................................................... 119 National Center for Complementary and Alternative Medicine................................................ 119 Additional Web Resources ......................................................................................................... 119 General References ..................................................................................................................... 126 CHAPTER 4. DISSERTATIONS ON IRRITABLE BOWEL SYNDROME ................................................. 127 Overview.................................................................................................................................... 127 Dissertations on Irritable Bowel Syndrome ............................................................................... 127 Keeping Current ........................................................................................................................ 128 CHAPTER 5. CLINICAL TRIALS AND IRRITABLE BOWEL SYNDROME ............................................ 129 Overview.................................................................................................................................... 129 Recent Trials on Irritable Bowel Syndrome ............................................................................... 129 Keeping Current on Clinical Trials ........................................................................................... 131 CHAPTER 6. PATENTS ON IRRITABLE BOWEL SYNDROME ............................................................ 133 Overview.................................................................................................................................... 133 Patents on Irritable Bowel Syndrome ........................................................................................ 133 Patent Applications on Irritable Bowel Syndrome..................................................................... 151 Keeping Current ........................................................................................................................ 182 CHAPTER 7. BOOKS ON IRRITABLE BOWEL SYNDROME ............................................................... 183 Overview.................................................................................................................................... 183 Book Summaries: Federal Agencies............................................................................................ 183 Book Summaries: Online Booksellers......................................................................................... 186 The National Library of Medicine Book Index ........................................................................... 191 Chapters on Irritable Bowel Syndrome ...................................................................................... 191 Directories.................................................................................................................................. 196 CHAPTER 8. MULTIMEDIA ON IRRITABLE BOWEL SYNDROME ..................................................... 199 Overview.................................................................................................................................... 199 Video Recordings ....................................................................................................................... 199 Bibliography: Multimedia on Irritable Bowel Syndrome ........................................................... 201 CHAPTER 9. PERIODICALS AND NEWS ON IRRITABLE BOWEL SYNDROME .................................. 203 Overview.................................................................................................................................... 203 News Services and Press Releases.............................................................................................. 203 Newsletters on Irritable Bowel Syndrome.................................................................................. 207 Newsletter Articles .................................................................................................................... 207 Academic Periodicals covering Irritable Bowel Syndrome......................................................... 210 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 211 Overview.................................................................................................................................... 211 U.S. Pharmacopeia..................................................................................................................... 211 Commercial Databases ............................................................................................................... 212
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 217 Overview.................................................................................................................................... 217 NIH Guidelines.......................................................................................................................... 217 NIH Databases........................................................................................................................... 219 Other Commercial Databases..................................................................................................... 222 APPENDIX B. PATIENT RESOURCES ............................................................................................... 223 Overview.................................................................................................................................... 223 Patient Guideline Sources.......................................................................................................... 223 Finding Associations.................................................................................................................. 235 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 237 Overview.................................................................................................................................... 237 Preparation................................................................................................................................. 237 Finding a Local Medical Library................................................................................................ 237 Medical Libraries in the U.S. and Canada ................................................................................. 237 ONLINE GLOSSARIES................................................................................................................ 243 Online Dictionary Directories ................................................................................................... 245 IRRITABLE BOWEL SYNDROME DICTIONARY ................................................................ 247 INDEX .............................................................................................................................................. 325
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with irritable bowel syndrome is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about irritable bowel syndrome, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to irritable bowel syndrome, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on irritable bowel syndrome. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to irritable bowel syndrome, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on irritable bowel syndrome. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON IRRITABLE BOWEL SYNDROME Overview In this chapter, we will show you how to locate peer-reviewed references and studies on irritable bowel syndrome.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and irritable bowel syndrome, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “irritable bowel syndrome” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Irritable Bowel Syndrome: Still Far from a Positive Diagnosis Source: Digestive Diseases and Sciences. 37(2): 164-167. February 1992. Summary: A scoring system has been proposed for the positive diagnosis of irritable bowel syndrome (IBS) where more than 44 points excluded organic digestive disease. This article reports on a study that attempted to determine the usefulness of this scoring system in a different setting. Patients (1257) consecutively referred to the authors' medical division were admitted to the study and 270 of these, complaining of abdominal symptoms, were scored on the Kruis system method. The positive predictive value and the sensitivity of the system did not appear to be adequate. The negative predictive value and the specificity gave higher results, but did not identify 11 cases of organic
4
Irritable Bowel Syndrome
digestive diseases. The authors conclude that the scoring system may be useful only as a first step in a diagnostic flow chart. 4 tables. 5 references. (AA-M). •
Antibiotic Use, Childhood Affluence and Irritable Bowel Syndrome (IBS) Source: European Journal of Gastroenterology and Hepatology. 10(1): 59-62. January 1998. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866. Summary: Antibiotics cause well-defined short-lived disturbances in bowel habits. There is evidence to suggest that antibiotics may play a role in the pathogenesis of irritable bowel syndrome (IBS). This article reports on a study that consisted of a survey examining the relationship between drug use and other epidemiological correlates of IBS. Subjects were 421 people (46 percent male, mean age 47 years) attending a general practice health screening clinic. Subjects were interviewed by a research nurse and completed a previously validated questionnaire. IBS symptoms were said to be present if abdominal pain with two or more Manning criteria symptoms occurred more than once a month over the previous 6 months. Results showed 48 subjects with symptoms of IBS. The following were strongly related to its presence: antibiotic use, female sex, childhood living density of less than 1 person per room, and a manual occupation for the father. The use of nonsteroidal anti-inflammatory drugs, H2 antagonists, or other types of medication was not greater in this group. The authors conclude that antibiotic use is associated with IBS and call for further research into this association. In addition, privileged childhood living conditions were also an important risk factor consistent with an allergic etiology for IBS. 2 tables. 12 references. (AA).
•
Diarrhea-Constipation-Pain: When is It Irritable Bowel Syndrome? Source: Consultant. 41(8): 1089-1091, 1095-1096. July 2001. Contact: Available from Cliggott Publishing Company. 55 Holly Hill Lane, Box 4010, Greenwich, CT 06831-0010. Summary: Central to the diagnosis of irritable bowel syndrome (IBS) are the symptoms of abdominal pain and disordered defecation of at least 3 months' duration. This article helps physicians determine when the symptoms of diarrhea, or constipation, or pain are indeed due to IBS. Either diarrhea or constipation can predominate, although the defecation pattern may vary from day to day in some patients. In the absence of evidence of more serious disease, diagnosis is based largely on the results of a thorough history and examination. For most patients, general screening tests include a complete blood cell count, erythrocyte sedimentation rate, serum chemistry panel, stool guaiac test, and stool examination for ova (eggs) and parasites. For patients older than 50 years, flexible sigmoidoscopy, colonoscopy, or barium enema may be indicated. Management of IBS consists of patient education and reassurance; dietary modification, including increased fiber intake in patients with constipation; and in some cases, judicious use of medications or psychological interventions. 2 tables. 35 references.
•
Impact of Irritable Bowel Syndrome on Health-Related Quality of Life Source: Gastroenterology. 119(3): 654-660. September 2000. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000.
Studies
5
Summary: Few data are available to evaluate health related quality of life (HRQOL) of people with irritable bowel syndrome (IBS). This article reports on a study that evaluated and compared the impact of IBS on HRQOL using previously reported HRQOL data for the United States general population and for people with selected chronic diseases. Using the SF 36 Health Survey, the authors compared the HRQOL of IBS patients (n = 877) with previously reported SF 36 data for the general U.S. population and for patients with gastroesophageal reflux disease (GERD), diabetes mellitus, depression, and dialysis-dependent end stage renal disease (ESRD). On all 8 SF 36 scales, IBS patients had significantly worse HRQOL than the U.S. general population. Compared with GERD patients, IBS patients scored significantly lower on all SF 36 scales except physical functioning. Similarly, IBS patients had significantly worse HRQOL on selected SF 36 scales than patients with diabetes mellitus and ESRD. IBS patients had significantly better mental health SF 36 scale scores than patients with depression. The authors conclude that IBS patients experience significant impairment in HRQOL. Decrements in HRQOL are most pronounced in energy and fatigue, role limitations caused by physical health problems, bodily pain, and general health perceptions. 3 figures. 4 tables. 44 references. •
Symptomatic Presentations of the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 235-247. June 1991. Summary: Functional gastrointestinal disorders have no reliable physiologic, biochemical, or structural markers, therefore, they must be defined by their symptoms. This article discusses the classification of functional bowel disorders and describes the symptoms, particularly those of irritable bowel syndrome (IBS). Possible mechanisms underlying the symptoms are also mentioned. Disorders discussed include psychological disorders, IBS, burbulence, functional constipation, functional diarrhea, and unspecified functional bowel disorder. 1 figure. 2 tables. 71 references.
•
High-Fiber Diet Supplementation in Patients with Irritable Bowel Syndrome (IBS): A Multicenter, Randomized, Open Trial Comparison Between Wheat Bran Diet and Partially Hydrolyzed Guar Gum (PHGG) Source: Digestive Diseases and Sciences. 47(8): 1697-1704. August 2002. Contact: Available from Kluwer Academic Publishers. Customer Service Deparment, P.O. Box 358, Accord Station, Hingham, MA 02018-0358. (781) 871-6600. Fax (781) 6819045. E-mail:
[email protected]. Website: www.wkap.nl. Distribution Centre, P.O. Box 322, 3300 AH Dordrecht, The Netherlands. 31 78 6392392. Fax: 31 78 6546474. E-mail:
[email protected]. Summary: High fiber diet supplementation is commonly used in irritable bowel syndrome (IBS), although it poses several management problems. Partially hydrolyzed guar gum (PHGG) has shown beneficial effects in animal and human studies, but its potential role in IBS symptom relief has not been evaluated. This article reports on a study that investigated PHGG in IBS patients and compared it to a wheat bran diet. Abdominal pain, bowel habits, and subjective overall rating were longitudinally evaluated in 188 adults IBS patients (138 women, 49 men) for 12 weeks. Patients were classified as having diarrhea predominant, constipation predominant, or changeable bowel habits and were randomly assigned to PHGG or wheat bran. After four weeks, patients were allowed to switch group, depending on their subject evaluation of their symptoms. Significantly more patients switched from fiber to PHGG (49.9 percent) than from PHGG to fiber (10.9 percent) at four weeks. Per protocol analysis showed that both
6
Irritable Bowel Syndrome
fiber and PHGG were effective in improving pain and bowel habits, but no difference was found between the two groups. Intention-to-treat analysis showed a significantly greater success in the PHGG groups (60 percent) than in the fiber group (40 percent). In conclusion, improvements in core IBS symptoms (abdominal pain and bowel habits) were observed with both bran and PHGG, but the latter was better tolerated and preferred by patients, revealing a higher probability of success than bran and a lower probability of patients abandoning the prescribed regimen. 3 tables. 43 references. •
Psychophysiological Factors Associated with Irritable Bowel Syndrome Source: Gastroenterology Nursing. 17(2): 61-67. September-October 1994. Summary: In this article, the author reviews the psychophysiological factors associated with irritable bowel syndrome (IBS). The author addresses gastrointestinal neuroendocrinology; the effects of stress on gastrointestinal motility; and the nursing implications related to this syndrome. The mechanisms underlying the etiology of IBS remain to be elucidated. However, the author suggests that IBS is a stress-induced syndrome that involves the complex interactions between external or internal stressors, the central nervous system, and the enteric nervous system. 1 figure. 1 table. 44 references. (AA-M).
•
Serotonin-Transporter Polymorphism Pharmacogenetics in Diarrhea-Predominant Irritable Bowel Syndrome Source: Gastroenterology. 123(2): 425-432. August 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: Irritable bowel syndrome (IBS) affects approximately 15 percent of adults, causes abdominal pain, discomfort, and altered bowel habits, and predominantly affects women. This article reports on a study of the use of serotonin (5HT) receptor antagonists in women with diarrhea- predominant IBS (DIBS). 5HT undergoes reuptake by a transporter protein (SERT). In the study, 30 patients (15 men, 15 women) with DIBS received 1 milligram twice a day of alosetron for 6 weeks; colonic transit was measured by scintigraphy at baseline and at the end of treatment. Results showed that SERT polymorphisms tended to be associated with colonic transit response; there was a greater response in those with long homozygous than heterozygous polymorphisms. Age, gender, and duration of IBS were not significantly different in the three groups (long, short, heterozygous). The authors conclude that genetic polymorphisms at the SERT promoter influence response to a 5HT antagonist in DIBS and may influence benefit to risk ratio with this class of compounds. 3 figures. 1 table. 57 references.
•
Compliance, Tone and Sensitivity of the Rectum in Different Subtypes of Irritable Bowel Syndrome Source: Neurogastroenterology and Motility. 14(3): 241-247. June 2002. Contact: Available from Blackwell Science, Ltd. Journal Subscriptions, P.O. Box 88, Oxford OX2 OEL, UK. +44 1865 206180 Fax +44 1865 206219. E-mail:
[email protected]. Summary: Irritable bowel syndrome (IBS) consists of various subtypes; it is unknown whether these subtypes share a common pathophysiology. Evaluation of motor and sensory function of the rectum using a barostat may help to explore a common pathophysiological background or differences in pathophysiology in subtypes of BIS.
Studies
7
This article reports on a study in which authors evaluated compliance, tone, and sensitivity of the rectum, in both fasting state and postprandially (after a meal), using a computerized barostat in 15 patients with diarrhea-predominant IBS (IBSD), 14 patients with constipation-predominant IBS (IBSC), and 12 healthy controls. Rectal compliance was decreased in both IBS groups compared with controls. The perception of urge was increased only in IBSD patients, whereas pain perception was significantly increased in both IBS groups. Spontaneous adaptive relaxation was decreased in IBSD patients. Postprandially, rectal volume decreased significantly in the controls and in IBSD patients, but not in IBSC patients. In conclusion, both rectal motor and sensory characteristics are different between IBSD and IBSC patients. Therefore, testing of rectal visceroperception, adaptive relaxation, and the rectal response to a meal may help distinguish groups of patients with different subtypes of IBS. 5 figures. 2 tables. 23 references. •
Advances in the Management of Irritable Bowel Syndrome Source: Journal of Gastroenterology and Hepatology. 17(4): 503-507. April 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Irritable bowel syndrome (IBS) is a chronic, relapsing disorder of brain-gut regulation that can have disabling symptoms that significantly affect daily life. Recent advances in different aspects of IBS have led to a need to reassess the overall management of this common, complex disorder. Important areas include: first, the heterogeneity of symptom patterns and the role of specific diagnostic symptom criteria for use in both clinical practice and in clinical research; second, the growing interest in the potential interaction between 'peripheral' and 'central' pathophysiological mechanisms; and third, the development of new and effective drugs designed to target specific receptor systems in the enteric nervous system. This review article covers each of these aspects and emphasizes an approach to the management of patients based on pathophysiological considerations. 1 figure. 2 tables. 15 references.
•
Epidemiology of Irritable Bowel Syndrome in Chinese Source: Digestive Diseases and Sciences. 47(11): 2621-2624. November 2002. Contact: Available from Kluwer Academic Publishers. Customer Service Department, P.O. Box 358, Accord Station, Hingham, MA 02018-0358. (781) 871-6600. Fax (781) 6819045. E-mail:
[email protected]. Website: www.wkap.nl. Distribution Centre, P.O. Box 322, 3300 AH Dordrecht, The Netherlands. 31 78 6392392. Fax: 31 78 6546474. E-mail:
[email protected]. Summary: Irritable bowel syndrome (IBS) is common in Caucasians and Japanese persons, but its epidemiology has not been studied in urbanized Chinese populations. This study compares diagnostic criteria and explores the epidemiology of IBS in Hong Kong Chinese. In all, 964 subjects from public housing and 334 subjects from private housing were recruited for face-to-face interviews in Shatin, Hong Kong. A structured questionnaire was used to measure the prevalence of IBS. The prevalence of IBS, based on the Rome II criteria, was 3.6 percent in men and 3.8 percent in women. Men with IBS had significantly lower vitality scores on the SF-36 scale than the controls and women with IBS had significantly lower mental health scores than controls. The authors conclude that IBS is quite prevalent in Hong Kong Chinese and the quality of life of subjects with IBS is significantly affected. 3 tables. 35 references.
8
Irritable Bowel Syndrome
•
Use of Antidepressants in Irritable Bowel Syndrome Source: Practical Gastroenterology. 26(3): 13-14, 19-20, 22-23, 27. March 2002. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: Irritable bowel syndrome (IBS) is the most common bowel disorder seen in gastroenterology practice. IBS is characterized by a pattern of waxing and waning abdominal pain, bloating, and disturbance of bowel habits. This article describes the rationale for the use of antidepressants in IBS, the results of clinical trials, suggested treatment plan, and directions for future research. The authors note that IBS is a complex biopsychosocial disorder whose precise pathophysiology is unknown, although it is generally accepted that abnormal brain-gut interactions play a major role. At the time of clinical presentation, about 50 percent of IBS patients have a definable psychiatric disorder. Psychosocial stressors have been demonstrated to have an important modulatory role in IBS, affecting not only the illness experience but also health care seeking behavior and the clinical outcome. Antidepressants represent an attractive therapeutic approach for the treatment of IBS, not only for their psychotropic effects, but also for their neuromodulatory and analgesic properties. However, there is still a lack of well-designed, appropriately powered, randomized clinical trials examining the use of antidepressants in IBS. 1 figure. 4 tables. 51 references.
•
Irritable Bowel Syndrome: Streamlining the Diagnosis Source: Postgraduate Medicine. 102(3): 197-198, 201-204, 207-208. September 1997. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: Irritable bowel syndrome (IBS), a common gastrointestinal disorder, is the condition for which patients are most often referred to gastroenterologists. Symptoms may be distressing enough to cause avoidance of work and social activities. Stress often exacerbates symptoms, and sensory abnormalities are common in patients with the disease. In this article, the authors describe how careful history taking and physical examination can avoid the overuse of diagnostic testing and point to the most effective treatment. Differential diagnosis for IBS includes consideration of many common gastrointestinal illnesses, including parasitic infections, salmonellosis, celiac sprue (gluten intolerance), chronic pancreatitis, Crohn's disease, ulcerative colitis, peptic ulcer disease, colon cancer, Campylobacter jejuni infection, and endometriosis. A strong physician-patient relationship at the time of IBS diagnosis improves the patient's ability to cope with the disease and reduces the number of subsequent office visits. The physician needs to involve the patient as a collaborative partner in the decision-making process and to avoid extensive invasive procedures if there is no firm indication for them. The patient's concerns and fears need to be addressed. Dietary changes, specifically elimination of troublesome foods, such as sorbitol, alcohol, caffeine, fats, legumes, sugar and, in lactose-intolerant patients, milk products, may benefit IBS patients. Relief of colonic spasm may be obtained with short-acting anticholinergics and other antispasmodic medications. Loperamide may also prove to be beneficial, especially in reducing post-meal diarrhea. Antidepressants are now being evaluated as potential therapeutic agents for IBS. One sidebar lists sources of information on IBS for physicians and patients, including organizations and Internet sites. 1 figure. 1 table. 21 references. (AA-M).
Studies
•
9
Does a Physically Active Lifestyle Improve Symptoms in Women with Irritable Bowel Syndrome? Source: Gastroenterology Nursing. 24(3): 129-137. May-June 2001. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (410) 528-8555. Summary: It has been proposed that physical activity moderates physiological or psychological responses to chronic conditions. This article reports on a study undertaken to determine if women with a chronic functional gastrointestinal (GI) disorder (irritable bowel syndrome, or IBS) had less active lifestyles than healthy controls. The study also tested whether active women with IBS had less severe recalled or daily reports of GI, psychological, and somatic symptoms than inactive women with irritable bowel syndrome. Questionnaires were used to measure GI and psychological distress and somatic symptoms in 89 women who participated in the study. A daily symptom and activity diary was kept for one menstrual cycle. Women with IBS were significantly less likely to be active (48 percent) than control women (71 percent). Within the IBS group, active women were less likely to report a feeling of incomplete evacuation following a bowel movement than inactive women, yet active women did not have less severe recalled psychological or somatic symptoms than inactive women. Active women with IBS reported less severe daily somatic symptoms, which were accounted for by a lower level of fatigue, but not daily GI or psychological symptoms. These results suggest that physical activity may produce select symptom improvement in women with IBS. 4 tables. 55 references.
•
Naloxone Treatment for Irritable Bowel Syndrome: A Randomized Controlled Trial with an Oral Formulation Source: Alimentary Pharmacology and Therapeutics. 16(9): 1649-1654. September 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Opioids change gut motility and secretion, causing delayed intestinal transit and constipation. Endorphins play a role in the constipation troubling some patients with irritable bowel syndrome (IBS); hence naloxone, an opioid antagonist, may have a therapeutic role. This article reports on a study undertaken to assess the efficacy and safety of an oral formulation of naloxone in IBS patients with constipation. The randomized, double-blind, placebo-controlled trial included 25 patients with IBS (constipation-predominant and alternating types) who received 8 weeks of treatment with naloxone capsules, 10 milligrams twice daily, or identical placebo. Adequate symptomatic relief was recorded in six of 14 on naloxone and three of 11 on placebo. Whilst the differences were not significant, improvements in severity gradings and mean symptom scores for pain, bloating, straining and urgency to defecate were greater with naloxone than placebo for all parameters. In addition, quality of life assessments improved to a greater extent in patients taking naloxone. The authors conclude that preliminary results suggest that naloxone is well tolerated and beneficial in patients with irritable bowel syndrome and constipation. A larger clinical trial is needed to provide sufficient statistical power to assess efficacy. 4 figures. 2 tables. 29 references.
10
Irritable Bowel Syndrome
•
Double-Blind Study of Nicardipine in Irritable Bowel Syndrome Source: European Journal of Gastrenterology and Hepatology. 3(2): 181-184. February 1991. Summary: Previous studies have suggested that calcium antagonists inhibit colonic motility and therefore may have therapeutic potential in irritable bowel syndrome (IBS). This article reports on a double-blind cross-over trial of the calcium antagonist nicardipine in 62 patients with IBS. Nicardipine significantly decreased whole gut transit time in constipated patients, but there was no effect on transit time in those with diarrhea, or on those with an alternating bowel habit. However, significant effects on general well-being, abdominal pain, abdominal distension or bowel habit were not observed. The authors conclude that this study suggests that nicardipine does not have a useful therapeutic effect in irritable bowel syndrome. 1 figure. 2 tables. 19 references. (AA-M).
•
Irritable Bowel Syndrome and Psychiatric Illness Source: American Journal of Psychiatry. 147(5): 565-572. May 1990. Summary: Psychiatric illnesses such as mood, anxiety, and somatization disorders share many common features with irritable bowel syndrome. The authors of this article review recent developments in the definition of irritable bowel syndrome (IBS) and its relationship to psychiatric illness, discuss the diagnostic validity of IBS from several perspectives, and offer a pathophysiological model of IBS that integrates many of the biological and psychosocial findings of earlier studies. Psychiatric evaluation appears to be an important factor in the diagnosis and treatment of patients with IBS. 1 table. 96 references. (AA).
•
Anxiety and the Irritable Bowel Syndrome: Psychiatric, Medical, or Both? Source: Journal of Clinical Psychiatry. 58(supplement 3): 51-61. 1997. Contact: Available from Physicians Postgraduate Press, Inc. P.O. Box 752870, Memphis, TN 38175-2870. Summary: The association between the irritable bowel syndrome (IBS) and psychiatric disorders is well-known to most clinicians, but the nature of the relationship is far from clear. There is an increased prevalence of psychiatric illness in IBS patients and an increase in IBS in psychiatric patients. Whether this association exists outside of treatment-seeking populations (i.e., in people with IBS who do not seek treatment) has not been well investigated. This article selectively reviews the existing literature regarding the association of IBS and psychiatric illness in both patient and nonpatient samples. The author presents a model of the brain-gut interaction, and offers a discussion of the practical implications of this model for treating individuals with IBS. The author considers patients with IBS and general anxiety disorder (GAD), panic disorder, posttraumatic stress disorder (PTSD), social phobia, and mood disorders. The treatment model suggests that, even in patients without psychiatric disorders, neuroactive medications may be a useful tool in improving functioning in individuals whose functional GI disorders have not responded to standard, conservative measures. Appended to the article is a discussion between three physicians on the concepts presented. 2 figures. 2 tables. 51 references. (AA-M).
Studies
•
11
Irritable Bowel Syndrome: Managing the Patient With Abdominal Pain and Altered Bowel Habits Source: Medical Clinics of North America. 79(2): 373-390. March 1995. Contact: Available from W.B. Saunders Company, Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: The authors of this article outline the management of the patient with irritable bowel syndrome (IBS), particularly for abdominal pain and altered bowel habits. One goal of the article is to assist the practitioner in reaching a diagnosis of IBS efficiently by using a carefully obtained history, physical examination, and appropriate laboratory tests. The authors also hope to make the practitioner aware of advances in the understanding of pathophysiologic and psychosocial processes in IBS so that treatment may be tailored to an individual patient's needs. Specific topics include epidemiology, pathophysiology, diagnostic tests, and management, particularly the role of a supportive and empathetic physician-patient relationship. 5 tables. 107 references.
•
Treatment of Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 16(8): 1395-1406. August 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: The efforts of clinical researchers, lay organizations and pharmaceutical companies have increased the public profile of irritable bowel syndrome (IBS) and made it a respectable diagnosis. Diagnostic symptom criteria encourage a firm clinical diagnosis, which is the foundation of a logical management strategy. This article reviews the treatment of IBS, emphasizing that any plan of patient care begins with education. Reassurance that no structural disease threatens should be tempered with the reality that symptoms are likely to recur over many years. Patients expect diet and lifestyle advice, even if this is not specific to irritable bowel syndrome. Only a few of those with IBS see doctors, and even fewer see specialists. Therefore, the treating physician should ascertain the reason for the visit, the patient's fears and the presence of any comorbid illness, such as depression, that might require treatment in its own right. No drug treatment is useful for all of the symptoms of IBS, and many patients require no drug at all. If used, drugs should target the predominant symptom. Most patients with IBS need psychological support. Reassurance, discussion, and relaxation techniques can be provided by the family doctor. In all cases, successful treatment depends on a confident diagnosis and the strength of the doctor-patient relationship. 1 figure. 3 tables. 100 references.
•
Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome Source: Annals of Internal Medicine. 134(9 Part 2): 860-868. May 1, 2001. Contact: Available from American College of Physicians. American Society of Internal Medicine. 190 North Independence Mall West, Philadelphia, PA 19106-1572. Website: www.acponline.org. Summary: The irritable bowel syndrome (IBS) may lead to considerable impairment of health related quality of life (HRQOL) and high health care costs. It is not clear whether these poor outcomes directly result from severe bowel symptoms or if they reflect a
12
Irritable Bowel Syndrome
coexisting psychiatric disorder. This article reports on a study undertaken to determine whether bowel symptom severity and psychological symptoms directly influence HRQOL and health care costs. The cross sectional survey took place at secondary and tertiary gastroenterology clinics and included 257 patients with severe IBS who did not respond to usual treatments and who were recruited for a trial of psychological treatment. Predictors were abdominal pain, entries in a diary of 10 IBS symptoms, and measures of psychological symptoms. Outcomes were inability to work, HRQOL, and health care and productivity costs. Abdominal pain occurred on average 24 days per month and activities were restricted on 145 days of the previous 12 months. The mean Hamilton depression score was 11.3 plus or minus 6.1. The physical component summary score was low and the patients had incurred high health care costs over the previous year. Global severity and somatization scores on the Symptom Checklist, abdominal pain, and Hamilton depression scores independently contributed to the physical component score, but only psychological scores were associated with disability due to ill health. These variables did not accurately predict health care or other costs. History of sexual abuse was not an independent predictor of outcome. The authors conclude that both abdominal and psychological symptoms are independently associated with impaired health related quality of life in patients with severe IBS. Optimal treatment is likely to require a holistic approach. Since health care and loss of productivity costs are not clearly associated with these symptoms, alleviation of them will not necessarily lead to reduced costs. 2 figures. 3 tables. 28 references. •
Irritable Bowel Syndrome in Twins: Heredity and Social Learning Both Contribute to Etiology Source: Gastroenterology 121(4): 799-804. October 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: The irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by abdominal discomfort or pain that beings with a change in the frequency or consistency of stool (diarrhea or constipation), that is relieved by defecation, and that is present in the absence of other diseases that could explain the symptoms. Heredity has been suggested to explain the finding that irritable bowel syndrome (IBS) tends to run in families. This article reports on a study undertaken to assess the relative contribution of genetic and environmental (social learning) influences on the development of IBS by comparing concordance rates in monozygotic (identical) and dizygotic (fraternal) twins to concordance between mothers and their children. Questionnaires soliciting information on the occurrence of more than 80 health problems, including IBS, in self and other family members were sent to both members of 11,986 twin pairs. The authors' analysis is based on 10,699 respondents representing 6,060 twin pairs. Concordance for IBS was significantly greater in monozygotic (17.2 percent) than in dizygotic (8.4 percent) twins, supporting a genetic contribution to IBS. However, the proportion of dizygotic twins with IBS who have mothers with IBS (15.2 percent) was greater than the proportion of dizygotic twins with IBS who have co-twins with IBS (6.7 percent). Logistic regression analysis showed that having a mother with IBS and having a father with IBS are independent predictors of irritable bowel status; both are stronger predictors than having a twin with IBS. Addition of information about the other twin accounted for little additional predictive power. The authors conclude that heredity contributes to development of IBS, but social learning (what an individual learns from those in his or her environment) has an equal or greater influence. 1 figure. 2 tables. 18 references.
Studies
•
13
Review Article: An Integrated Approach to the Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 13(Supplement 2): 3-14. May 1999. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: The medical understanding of the pathophysiology of irritable bowel syndrome (IBS) has evolved from a motility disorder to a more integrated understanding of enhanced motility and visceral hypersensitivity associated with brain gut dysfunction. This article reviews recent work that supports an integrated approach to managing IBS. Psychosocial factors contribute to the predisposition, precipitation, and perpetuation of IBS symptoms and affect the clinical outcome. Newer brain imaging techniques (MRI, PET) may help physicians understand the relationship between altered emotional states with pain enhancement and other gastrointestinal symptoms. The author recommends diagnosis using symptom based (e.g., Rome) criteria and a conservative approach. A careful history will identify the need for diagnostic studies and treatments as determined by the nature and severity of the predominant symptoms. Treatment is based on an effective relationship between physician and patient and a combined pharmacologic and behavioral approach. For most patients with mild symptoms, dietary and lifestyle changes are usually sufficient for treatment. Newer medications acting at the 5-HT receptor may help reduce pain and bowel dysfunction. For more severe pain, antidepressants may be considered. 1 figure. 2 tables. 90 references.
•
Long-term Safety of Tegaserod in Patients with Constipation-Predominant Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 16(10): 1701-1708. October 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: The oral administration of the drug tegaserod causes gastrointestinal (GI) effects resulting in increased gastrointestinal motility (movement of contents through the GI tract) and attenuation of visceral sensation. This article reports on a study undertaken to determine the long term safety and tolerability of tegaserod in patients with irritable bowel syndrome (IBS) with constipation as the predominant symptom of altered bowel habits. The multicenter, open label study included 579 patients. Of these, 304 (53 percent) completed the trial. The most common adverse events, classified as related to tegaserod for any dose, were mild and transient diarrhea (10.1 percent), headache (8.3 percent), abdominal pain (7.4 percent), and flatulence (5.5 percent). Forty serious adverse events were reported in 25 patients (4.4 percent of patients) leading to discontinuation in 6 patients. There was one serious adverse event, acute abdominal pain, classified as possibly related to tegaserod. There were no consistent differences in adverse events between patients previously exposed to tegaserod and those treated for the first time in this study. The authors conclude that tegaserod appears to be well tolerated in the treatment of patients with constipation-predominant IBS. The adverse event profile, clinical laboratory evaluations, vital signs, and electrocardiogram recordings revealed no evidence of any unexpected adverse events, and suggest that treatment is safe over a 12 month period. 1 figure. 4 tables. 23 references.
14
Irritable Bowel Syndrome
•
Diet and the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 313-324. June 1991. Summary: There is a prevailing patient perception that diet plays a key role in precipitating or perpetuating symptoms of irritable bowel syndrome (IBS). This article provides dietary information for the physician treating patients with IBS. The author focuses special attention on diagnostic and therapeutic suggestions directed toward reducing the intensity and frequency of symptoms. Topics covered include diagnostic considerations; lactose intolerance; fructose intolerance; sorbitol intolerance; and dietary considerations in functional gastrointestinal disorders including the esophagus, gastricduodenum, small bowel, colonic motor dysfunction and gas syndrome. 29 references.
•
New Directions in the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 335-349. June 1991. Summary: This article about irritable bowel syndrome (IBS) focuses on possible subgroups of IBS and methods of diagnosis and treatment. The authors discuss treatments of IBS based on motility disturbances, psychologic problems, dietary intolerance, hormonal imbalance, and the effects of peptides such as cholecystokinin (CCK) and motilin. The authors note that future directions for psychologic treatment of IBS will likely depend on further investigation of the relative importance of psychologic factors in the etiology of and patient response to IBS. 349 references.
•
Treatment of the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 325-333. June 1991. Summary: This article addresses treatment issues in the management of irritable bowel syndrome (IBS). The author stresses that although there is not a specific agent to treat IBS, once organic illness has been ruled out, a basis for therapy options can be formulated. Topics covered include psychologic factors, including stress, anxiety, depression, and the use of anti-anxiety agents; the use of antidepressant agents; anticholinergic medications; food-related factors, including gas-related agents; the treatment of functional constipation; treatment of diarrhea; and the role of the physician-patient relationship. The author concludes that careful, continued follow-up assessment of therapeutic endeavors, a sincere interest in the patient's concerns, and surveillance for intercurrent organic illness are the basics of complete ongoing care. 2 tables. 31 references.
•
Irritable Bowel Syndrome: A Quick Review of a Common GI Problem Source: IM. Internal Medicine. 19(8): 24-25. August 1998. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Summary: This article briefly brings readers up-to-date on the diagnosis and treatment strategies used for irritable bowel syndrome (IBS). IBS is a functional disorder of the gastrointestinal tract that occurs in 10 to 22 percent of adults. The most common symptoms are abdominal pain and altered bowel habits, including diarrhea or constipation or a combination of the two. The author discusses pathophysiology, the criteria for confirming a diagnosis of IBS, laboratory tests that may contribute to this diagnosis of exclusion, and treatment options. Criteria for confirming a diagnosis require that symptoms be present for at least 3 months. Management begins with the
Studies
15
need for the physician to establish a therapeutic relationship. Because of their safety and frequent placebo effect, a trial of fiber supplements is reasonable in all patients with IBS. The author discusses the treatments for patients in whom diarrhea predominates; those in whom pain, gas, and bloating predominate; and those in whom constipation is the primary problem. The author notes that, in all cases of IBS, regardless of the predominating symptom, the use of antidepressants, anxiolytics, and psychotherapy may be indicated for patients with associated affective disorders. 1 figure. 4 references. •
Mental Medicine for Irritable Bowel Syndrome: Treatment Approaches for IBS Source: Mental Medicine Update. 1(1): 4-5. Spring-Summer 1992. Contact: Available from Center for Health Sciences, ISHK. P.O. Box 176, Los Altos, CA 94023. (415) 948-9428. Summary: This article brings readers up-to-date on irritable bowel syndrome (IBS). Topics include the symptoms of IBS; the role of stress and other psychosocial factors; and treatment modalities, including medical treatments, diet therapy, and psychological techniques for managing stress. Techniques covered in the latter section include the use of a symptom diary, relaxation techniques, psychotherapy, and hypnosis. The article concludes with a list of six references for readers who wish to obtain more information about IBS.
•
Irritable Bowel Syndrome Defined by Factor Analysis: Gender and Race Comparisons Source: Digestive Diseases and Sciences. 40(12): 2647-2655. December 1995. Summary: This article describes a study to examine the applicability across subgroups of the Manning criteria commonly used to diagnose the irritable bowel syndrome (IBS). A 22-item symptom questionnaire was administered to male and female African-American and Caucasian adults (n=1344). Consistent with the findings of a previous factor analytic study, three of the six Manning symptoms (loose stools and more frequent bowel movements with onset of pain, pain relieved by defecation) formed a cluster corresponding to the IBS in all subgroups. The researches conclude that the three core Manning symptoms have equal applicability to both genders and to African-Americans as well as to Caucasians. They are useful symptoms criteria for the diagnosis of IBS when used in conjunction with medical evaluation. 1 figure. 2 tables. 18 references. (AAM).
•
Diagnosis and Treatment of Irritable Bowel Syndrome Source: American Family Physician. 55(3): 875-880. February 15, 1997. Summary: This article discusses the diagnosis and treatment of irritable bowel syndrome (IBS), a common disorder characterized by symptoms of abdominal pain with diarrhea and or constipation. IBS is associated with significant disability and health care costs. The authors advocate a practical approach to diagnosis utilizing the symptombased Rome criteria. Management of patients has been helped by recent findings relating to the pathophysiology of the disorder. Dysregulation of intestinal motor functions, sensory functions and central nervous system functions is currently believed to be the basis for IBS symptoms. Symptoms are a result of both abnormal intestinal motility and enhanced visceral sensitivity. Psychosocial factors can affect the illness experience and the clinical outcome. The authors stress that an effective physicianpatient relationship is required for a successful outcome. Individualized treatment
16
Irritable Bowel Syndrome
involves an integrated pharmacologic and behavioral approach determined by the predominant symptom type, the severity of the symptoms, and the degree of disability. 5 tables. 11 references. (AA). •
Diagnostic Evaluation of the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 269-278. June 1991. Summary: This article explores the diagnostic evaluation of Irritable Bowel Syndrome (IBS), one of the most common of all gastrointestinal disorders. Topics include a definition of IBS; diagnostic accuracy; historical features, including pain, altered bowel habits, distention, and extracolonic and extraintestinal symptoms; significant clinical features, physical findings, and laboratory features; and a philosophy of diagnosis as it applies to IBS. 4 tables. 35 references.
•
Ileocecal Area and the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 297-311. June 1991. Summary: This article focuses on irritable bowel syndrome (IBS) and the ileocecal area, or the ileocolonic junction (ICJ). Topics covered include a summary of the normal physiology of the region; the symptoms of IBS; the role of altered functions of the distal small bowel-proximal colon in IBS; the role of ileal and colonic contractions; regulation of the motility of the ICJ; motility-transit relationships; and IBS as a grouping of symptoms that fulfill at least three of the Manning criteria. The author conclude that the ICJ, lying as it does at the gateway between the absorptive regions of the small intestine and the storage and excretory regions of the colon, may be important in the pathophysiology of pain, bloating, and altered bowel movements in patients with IBS. 8 figures. 52 references.
•
Irritable Bowel Syndrome: A Cost-Effective Approach for Primary Care Physicians Source: Postgraduate Medicine. 101(3): 215-216, 219, 220, 223-226. March 1997. Summary: This article outlines for primary care physicians a cost-effective approach to patients with irritable bowel syndrome (IBS). IBS is a symptom complex of altered bowel habits, abdominal discomfort, and the absence of detectable organic disease. The author stresses that the key to cost-effective management is identification of the characteristic symptom pattern. Topics include pathophysiologic factors, clinical features, diagnosis, treatment options, medications commonly used to treat IBS, and medications currently being developed that may be of use in IBS. The author stresses that patient education and reassurance about the benign course of the disease are important aspects of effective treatment. 1 figure. 2 tables. 20 references. (AA-M).
•
Interventions for Irritable Bowel Syndrome: A Nursing Model Source: Gastroenterology Nursing. 18(6): 224-230. November-December 1995. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (800) 638-6423 or (410) 528-8555. Summary: This article presents a nursing model for interventions for irritable bowel syndrome (IBS). Using the Human Response Model, the authors review intervention studies for IBS. The model provides a context for integration of Person (vulnerability) and Environment (risk) factors that may modify the patient's response to a given therapeutic regimen. Human responses are categorized as Physiological,
Studies
17
Pathophysiological, and Behavioral/Experiential. The authors discuss interdisciplinary therapeutic strategies including modility manipulations via pharmacological agents, dietary modifications, and self-care enhancement. Areas for nursing research are also described. 1 figure. 1 table. 34 references. (AA-M). •
Roundtable Conference on Irritable Bowel Syndrome, Part I Source: Practical Gastroenterology. 16(8): 12, 14-18, 21. September 1992. Summary: This article presents an edited transcript of a videotaped roundtable conference on irritable bowel syndrome (IBS) sponsored by Schwarz Pharma that took place in Chicago on June 13, 1992. Roundtable participants were Marshall Sparberg; Gerald Friedman; Norton Greenberger; Marvin Schuster; and William Snape. Topics include a definition of IBS; symptoms; etiology of IBS; the emotional components of IBS; extraintestinal manifestations of IBS; the interrelationship of IBS with menstruation and with diet; foods that may trigger, perpetuate, or accentuate IBS symptoms; the importance of a food diary in diagnosis and management of IBS; lactose sensitivity; dietary fiber; the use of psyllium products; bowel motility and dietary fat; motor dysfunctions in IBS; pain in IBS; and functional versus organic disease. 10 references.
•
American Gastroenterological Association Medical Position Statement: Irritable Bowel Syndrome Source: Gastroenterology. 112(6): 2118-2119. June 1997. Summary: This article presents guidelines to help physicians in the diagnosis and management of patients with irritable bowel syndrome (IBS). These guidelines were developed from a comprehensive review of the medical literature pertaining to IBS. The IBS is a combination of chronic or recurrent gastrointestinal (GI) symptoms not explained by structural or biochemical abnormalities, which is attributed to the intestines and associated with symptoms of pain and disturbed defecation and or symptoms of bloating and distension. The authors note that psychological stress exacerbates GI symptoms in everyone, but to a greater degree in patients with IBS. IBS adversely affects health-related quality of life, including impairment of physical and psychosocial function, disability, work absenteeism, and physician visits. A physical examination and the following studies are recommended for routine evaluation: complete blood count; sedimentation rate; chemistries; stool for ova, parasites, and blood; and flexible sigmoidoscopy or colonoscopy or barium enema with sigmoidoscopy if older than 50 years. The treatment strategy is based on the nature and severity of the symptoms, the degree of physiological disturbance and functional impairment, and the presence of psychosocial difficulties affecting the course of the illness. Patients with mild symptoms usually respond to education and reassurance and simple treatments not requiring prescription medication. A smaller proportion of patients with moderate symptoms have more disability and require pharmacological treatments directed at altered gut physiology or psychological treatments. 1 table. 1 reference. (AA-M).
•
Roundtable Conference on Irritable Bowel Syndrome, Part II Source: Practical Gastroenterology. 16(9): 30-39. October 1992. Summary: This article presents the second part of a videotaped conference on irritable bowel syndrome (IBS) that took place in Chicago in June 1992. Topics include the symptom of painless diarrhea; the role of fatty acids; the causes of constipation; hypersensitivity of the smooth muscle of the rectum and colon; colonic motility;
18
Irritable Bowel Syndrome
problems with excessive gas, including classification, etiology, and treatment; dealing with aerophagic patients ('air swallowers'); the role of biofeedback and other behavioral therapies; handling patients who have excessive bloating; problems with excessive rectal gas, including excessively odorous rectal gas; the role of rice and rice products in the diet; medical history and physical examination; and diagnostic tests used after the determination of IBS. 3 figures. 7 references. •
Challenge of Irritable Bowel Syndrome Source: American Family Physician. 53(4): 1229-1236. March 1996. Summary: This article provides general practitioners with an overview of irritable bowel syndrome (IBS), a common disorder with symptom complexes that can include diarrhea, constipation, pain, and bloating. Topics include epidemiology, pathophysiology, diagnosis and diagnostic criteria, treatment options, and the course to follow when initial treatment fails. Treatments include the use of dietary fiber, addressing the psychological factors involved, a bowel-training regimen, diet therapy, antispasmodic drugs, and antidepressants. The authors stress the importance of a supportive professional-patient relationship in treating patients with IBS. 4 tables. 52 references.
•
Health-Related Quality of Life Among Persons With Irritable Bowel Syndrome: A Systematic Review Source: Alimentary Pharmacology and Therapeutics. 16(6): 1171-1185. June 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This article reports on a literature review undertaken with three objectives: to compare the health related quality of life (HRQoL) of patients with irritable bowel syndrome (IBS) with that of health controls; to compare the HRQoL of irritable bowel syndrome patients to those with other diseases; and to examine therapy-associated changes in HRQoL of IBS patients. Searches of all English and non English articles from 1980 to 2001 were performed in MEDLINE and EMBASE and two investigators performed independent data abstraction. Seventeen articles met the selection criteria. Thirteen studies addressed objective number one; 11 of these studies showed a significant reduction in HRQoL among IBS patients. Of these, only one study was considered of high quality. Four studies addressed objective number two, none of which was considered to be high quality in addressing this objective. Four trials (three of high quality) addressed objective number three. One of these showed that symptomatic improvement with Leupron compared to placebo was accompanied by an improvement only in the comparative health domain of the HRQoL. The second study reported significant positive changes in HRQoL after 12 weeks of cognitive behavioral therapy. The third report of two placebo controlled studies indicated significant improvement with alosetron on most domains of IBS quality of life assessment instruments. The authors conclude that there is reasonable evidence for a decrease in HRQoL in patients with moderate to severe IBS. HRQoL in IBS patients is impaired to a degree comparable to other chronic disorders such as GERD and depression. A therapeutic response in IBS related pain has a corresponding improvement in HRQoL. 4 tables. 34 references.
Studies
•
19
Office-Based Physician Visits: A Comparison of Irritable Bowel Syndrome with Other Gastrointestinal Disorders Using National Ambulatory Medical Care Survey Data Source: Practical Gastroenterology. 26(9): 58, 60-62, 65-66, 68. September 2002. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: This article reports on a study in which National Ambulatory Medical Care Survey data were used to compare health care resource utilization and frequency of physician visits for irritable bowel syndrome (IBS) with other functional and organic gastrointestinal (GI) disorders. IBS accounted for more than four million ambulatory office visits between 1997 and 1999. A substantial proportion of these IBS visits were by female patients, and a high percentage of the visits were to a gastroenterologist. IBS visits frequently included diagnostic or screening tests and mentions of medications. This evidence suggests that patients with IBS require considerable medical attention, which incurs substantial costs. The emergence of effective medications, as well as education of both patients and providers, may reduce resource utilization associated with IBS and facilitate the delivery of quality health care to patients. 4 figures. 3 tables. 9 references.
•
Sleep Disturbance Influences Gastrointestinal Symptoms in Women with Irritable Bowel Syndrome Source: Digestive Diseases and Sciences. 45(5): 952-959. May 2000. Contact: Available from Kluwer Academic/Plenum Publishers. 233 Spring Street, New York, NY 10013-1578. (212) 620-8000. Fax (212) 807-1047. Summary: This article reports on a study that evaluated the association between sleep disturbance and gastrointestinal symptoms in women with and without irritable bowel syndrome (IBS). The study also examined the role of psychological distress in this relationship. Women with IBS (n = 82) reported considerably higher levels of sleep disturbance compared with controls (n = 35), using both retrospective 7 day recall and daily diary recall for two menstrual cycles. The authors used daily diary data to estimate the association between sleep disturbance and gastrointestinal symptoms, both across women (i.e., whether women with high average sleep disturbance have higher average gastrointestinal symptoms) and within women (i.e., whether poorer than average sleep on one night is associated with higher than average gastrointestinal symptoms the following day). The regression coefficients for the across women effect are large and highly significant in both groups. The regression coefficients for the within woman effect are considerably smaller and statistically significant only in the IBS group. These regression coefficients showed little change when daily psychological distress or stress was controlled for, the one exception being the coefficient for the across women effect in the IBS group, which decreased substantially but still remained highly significant. Because it is possible that gastrointestinal symptoms could, in fact, cause poor sleep, the authors also fitted the temporally reversed model to evaluate the association between gastrointestinal symptoms on one day and sleep disturbance that night. The authors conclude that their results are consistent with the hypothesis that poor sleep leads to higher gastrointestinal symptoms on the following day among women with IBS. 1 figure. 2 tables. 41 references.
20
Irritable Bowel Syndrome
•
Abdominal Pain and Irritable Bowel Syndrome in Adolescents: A Community-Based Study Source: Journal of Pediatrics. 129(2): 220-226. August 1996. Summary: This article reports on a study to determine the prevalence of gastrointestinal (GI) symptoms, including abdominal pain in a community-based population of adolescents; whether a subgroup of these subjects have symptoms resembling irritable bowel syndrome (IBS); and whether anxiety and depression are more commonly found in adolescents with IBS-type symptoms compared with unaffected adolescents. The study included 507 subjects; abdominal pain was noted by 75 percent of all students. The pain occurred weekly in 13 to 17 percent of the subjects and was severe enough to affect activities in approximately 21 percent. IBS-type symptoms were noted by 17 percent of high school students and 8 percent of middle school students who reported abdominal pain. Anxiety and depression scores were significantly higher for students with IBS-type symptoms compared with those without symptoms. Eight percent of all students had seen a physician for abdominal pain in the previous year. These visits were correlated with abdominal pain severity, frequency, duration, and disruption of normal activities but not with anxiety, depression, gender, family structure, or ethnicity. 3 tables. 23 references. (AA-M).
•
Pharmacologic Treatment of the Irritable Bowel Syndrome: A Systematic Review of Randomized, Controlled Trials Source: Annals of Internal Medicine. 133(2): 136-147. July 18, 2000. Contact: Available from American College of Physicians. American Society of Internal Medicine. 190 North Independence Mall West, Philadelphia, PA 19106-1572. Website: www.acponline.org. Summary: This article reports on a study undertaken to evaluate the efficacy of pharmacologic agents (drugs) for irritable bowel syndrome (IBS). The study featured an electronic literature search (1966 to 1999) and a manual search of references from bibliographies of identified articles. Studies chosen for inclusion were randomized, double blind, placebo controlled, parallel or crossover trials of a pharmacologic intervention for adult patients; the studies had to report outcomes of improvement in global or IBS specific symptoms. Seventy studies met the inclusion criteria. The most common medication classes were smooth muscle relaxants (16 trials), bulking agents (13 trials), prokinetic agents (6 trials), psychotropic agents (7 trials), and loperamide (4 trials). The strongest evidence for efficacy was shown for smooth muscle relaxants in patients with abdominal pain as the predominant symptom. Loperamide seems to reduce diarrhea but does not relieve abdominal pain. Although psychotropic agents were shown to produce global improvement, the evidence is based on a small number of studies of suboptimal quality. Other treatment options, including psychotropic drugs, 5 hydroxytryptamine (5 HT) receptor antagonists, peppermint oil, and Chinese herbal medicine, require further study. 3 tables. 109 references.
•
Management of Irritable Bowel Syndrome: A European, Primary and Secondary Care Collaboration Source: European Jounral of Gastroenterology and Hepatology. 13(8): 933- 939. August 2001. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866 or (215) 574-2210.
Studies
21
Summary: This article reports on the development of recommendations for the diagnosis and management of irritable bowel syndrome (IBS) for European doctors delivering primary medical care. These recommendations can be adapted by local medical groups according to their language, custom, and health care systems. The workshop, planned by a steering committee, was attended by 21 general practitioners and gastroenterologists from Europe. After a state of the art symposium, four working groups considered the following aspects of IBS management: what to tell the patient, diagnosis, non medical treatment, and psychosocial management. Current and future drug management was reviewed by the steering committee. The process permitted a unique dialog between general practitioners and gastroenterologists, in which it was necessary to reconcile the specialists' emphasis on thoroughness with the practical, epidemiological, and economic realities of primary care. The recommendations emphasize education of the patient, a positive symptom based diagnosis, dietary and lifestyle advice, psychological support, and a critical analysis of current specific psychological and pharmacological (drug) treatments. Patient education should be tailored to the patient's ideas, fears and expectations and should take into account their understanding of their IBS symptoms. The information can include the following elements: the symptoms are real, not imagined or merely psychological; IBS is chronic and fluctuates in severity and duration; factors that trigger symptoms are multiple and vary among patients and over time; the mind-gut link explains how stress, emotions, perceptions and thoughts can affect the symptoms; and the symptoms are not life threatening. The recommendations remind readers that some symptoms cannot be explained by IBS and should trigger further diagnosis; these include: fever, anemia, bleeding from the gut, significant weight loss, family history of cancer or inflammatory bowel disease, recent change in bowel habit, over 45 years of age, and physical findings (e.g., an abdominal mass). 2 tables. 48 references. •
Roundtable Conference on Irritable Bowel Syndrome, Part III Source: Practical Gastroenterology. 16(10): 20, 23-26, 28. November/December 1992. Summary: This article reprints part of an edited transcript of a videotape conference on irritable bowel syndrome (IBS) sponsored by Schwarz Pharma, that took place in Chicago in June 1992. Topics include dietary recommendations for patients with IBS; the role of dietary habits, including the aesthetics of mealtime; the role of stress; the link between anorexia nervosa and delayed gastric emptying; psychological factors that impact the motor function of the gastrointestinal tract; the use of anticholinergic medication; other medications used to treat IBS; timing of the dosing for IBS; sublingual administration of medications; the side effect of xerostomia; the importance of tailoring drug therapy for each individual with IBS; the emotional components of IBS; the role of sedatives or tranquilizers in IBS therapy; the effect of the menstrual cycle on symptoms of IBS; and the recent advances related to IBS. 5 references.
•
Review Article: Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 11(1): 3-15. February 1997. Contact: Available from Mercury Airfreight International, Ltd. 2323 EF, Randolph Avenue, Avenel, NJ 07001. E-mail:
[email protected]. Summary: This article reviews current knowledge on irritable bowel syndrome (IBS), the most common disease diagnosed by gastroenterologists and one that affects about 20 percent of all people at any one time. IBS can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. Symptoms
22
Irritable Bowel Syndrome
fluctuate, and the overall prevalence rate is relatively constant in Western communities. Ten percent of patients present to their physicians. The illness has a large economic impact on health care utilization and absenteeism. IBS is a biopsychosocial disorder in which three major mechanisms interact: psychosocial factors, altered motility, and or sensory function of the intestine. Management of patients is based on positive diagnosis of the symptom complex, limited exclusion of underlying organic disease, and institution of a therapeutic trial. If patient symptoms are intractable, further investigations are needed to exclude significant motility or other disorders. Symptomatic treatment includes fiber for constipation, loperamide for diarrhea, and low-dose antidepressants or infrequent use of antispasmodics for pain. The authors note that new pharmacological agents, psychotherapy, and hypnotherapy are being evaluated for their use in treating IBS. 5 figures. 6 tables. 109 references. (AA-M). •
Evolving Concepts in Irritable Bowel Syndrome Source: Current Opinion in Gastroenterology. 15(1): 16-21. January 1999. Contact: Available from Lippincott Williams and Wilkins Publishers. 12107 Insurance Way, Hagerstown, MD 21740. (800) 637-3030. Fax (301) 824-7390. Summary: This article reviews recent research in irritable bowel syndrome (IBS). The authors note that converging evidence from investigations of the peripheral and central aspects of bidirectional brain gut interactions is beginning to shape a pathophysiological model of IBS and related functional gastrointestinal (GI) disorders. This neurobiological model includes alterations in autonomic, neuroendocrine, and pain modulatory mechanisms. The frequent association of IBS and other functional GI disorders with comorbid affective disorders and the temporal association of symptom exacerbation with psychosocial or physical stressors are consistent with alterations in the neurobiological mechanisms underlying the central stress response. The author discusses work in the area of alterations in central nervous system responses of the brain, neuroendocrine responses, autonomic dysfunction, and altered viscerosomatic sensitivity; peripheral modulators of visceral sensitivity; symptom based diagnosis; and affective disorders and psychosocial stressors. Depression and anxiety are the most common comorbid affective disorders in IBS. Classification of functional disorders according to these evolving biological markers holds the promise of a rational treatment design for subgroups of patients in the future. Renewed interest in drug development for IBS treatment has resulted in the development of diagnostic instruments for assessing the impact of symptoms on quality of life and in the development of compounds (drugs) undergoing clinical evaluation. 53 references (16 annotated).
•
Psychologic Considerations in the Irritable Bowel Syndrome Source: Gastroenterology Clinics of North America. 20(2): 249-267. June 1991. Summary: This article reviews recent studies regarding the psychological considerations in the irritable bowel syndrome (IBS). Topics covered include the self-selection hypothesis; diagnostic criteria; the psychologic symptoms and personality traits associated with IBS; learned illness behavior; the role of psychologic stress; psychologic treatment of IBS, including education and reassurance, managing fears and misconceptions, and scheduling return appointments; the use of antidepressant medications; and the role of psychotherapy, including behavior therapy and hypnosis. The authors conclude that psychologically-oriented treatments have a role in the management of IBS, even in patients who do not have a psychiatric disorder. 5 figures. 1 table. 51 references.
Studies
•
23
Irritable Bowel Syndrome: A Continuing Dilemma Source: Gastroenterology Clinics of North America. 20(2): 363-367. June 1991. Summary: This article summarizes some of the dilemmas surrounding the diagnosis and treatment of the irritable bowel syndrome (IBS). The authors discuss the classification of IBS; the diagnostic challenge of demonstrating absence of organic disease; and therapeutic dilemmas including dietary adjustments, drug therapy, and limiting the diagnostic tests performed. The article serves as a concluding summary to a series of articles in this issue devoted to IBS. 34 references.
•
OTC Therapy of the Irritable Bowel Syndrome Source: U.S. Pharmacist. 15(8): 43-48. August 1990. Summary: This article was written to help pharmacists understand irritable bowel syndrome (IBS). The author notes that although the exact cause of IBS is still unknown, the symptoms may be treated by psychotherapy, changes in diet, and drug therapy. Possible causes of IBS are discussed, including food, drugs, dysentery, and stress. The use of fiber, simethicone, and/or lactase replacement as methods of treatment are discussed. Two sidebars present patient information on the proper use of over-thecounter fiber supplements and relieving IBS. References are available on request. 1 table.
•
Questions and Answers: Food Allergy and Irritable Bowel Syndrome; Elective Appendectomy During Abdominal Surgery Source: JAMA. Journal of American Medical Association. 265(13): 1736, 1738. April 3, 1991. Summary: This brief article, one of a regular series of questions and answers, addresses two issues of interest to digestive diseases professionals. The first exchange discusses the possible role of food allergy in triggering or exacerbating irritable bowel syndrome (IBS). The responding author discusses the difference between food allergy and IBS, mentions research support for this hypothesis, and concludes that food allergy as a contributing factor in the pathogenesis of IBS is valid. The second exchange involves elective appendectomy during abdominal surgery. The responding author notes that there is little, if any, morbidity and that there is apparent benefit gained from incidental appendectomies, provided certain contraindications are taken into account. 7 references.
•
Consensus Report: Clinical Perspectives, Mechanisms, Diagnosis and Management of Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 16(8): 1407-1430. August 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This consensus document reviews the current status of the epidemiology, social impact, patient quality of life, pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS). Current evidence suggests that two major mechanisms may interact in IBS: altered gastrointestinal motility and increased sensitivity of the intestine. However, other factors, such as psychosocial factors, intake of food, and prior infection, may contribute to its development. Management of patients is based on a positive diagnosis of the symptom complex, careful history and physical examination to exclude risk factors for organic disease, and, if indicated, investigations to exclude other
24
Irritable Bowel Syndrome
disorders. Treatment choices include dietary fiber for constipation, opioid agents for diarrhea, and low-dose antidepressants or infrequent use of antispasmodics for pain, although the evidence basis for efficacy is limited or in some cases absent. Psychotherapy and hypnotherapy are the subject of ongoing study. Treatment should be tailored to patient needs and fears. Patient and physician education, early identification of psychosocial issues, and better therapies are important strategies to reduce the suffering and societal cost of IBS. 2 figures. 9 tables. 236 references. •
'It's Not All in Your Head': Irritable Bowel Syndrome Source: AJN. American Journal of Nursing. 101(1): 26-34. January 2001. Contact: Available from Lippincott Williams and Wilkins. AJN, P.O. Box 50480, Boulder, CO 80322-0480. (800) 627-0484 or (303) 604-1464. Summary: This continuing education article reviews the nursing care for patients with irritable bowel syndrome (IBS). The authors note that it is now believed that IBS has a basis in visceral hypersensitivity (of the bowel wall) and abnormal gut motor function, possibly caused by anomalies in the gut brain connection. The syndrome is neither life threatening nor associated with the development of gastrointestinal diseases such as cancer, but IBS accounts for a significant number of medical visits and prescribed medications, as well as lost work time and reduced productivity. The syndrome tends to manifest with either diarrhea or constipation or with an alternating pattern of the two. Other common symptoms include mucus in the stool, a sensation of incomplete evacuation, looser or more frequent stools with pain, and relief of abdominal pain after defecation. It has been postulated that there are differences related to sex in motility patterns, symptom and psychological profiles, pain sensitivity, and access to health care. No one factor appears to be responsible for the symptoms in all patients with IBS. Diet, stressful events, and psychological distress may also exacerbate symptoms in vulnerable patients. Diagnosis of IBS occurs by exclusion; there is no biologic marker. Therapy usually focuses on the patient's predominant symptoms and can include patient education and reassurance, nonpharmacologic interventions, and pharmacologic (drug) interventions. One sidebar explores the connection between emotional (sexual) abuse and IBS, notably assessing the effect of self blame and self silencing. A posttest for receiving continuing education credits is appended to the article. 3 figures. 1 table. 50 references.
•
Treatment of Irritable Bowel Syndrome: New Approaches for a New Century Source: Practical Gastroenterology. 25(8): 13-14. August 2001. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: This editorial serves as an introduction to a series of articles on irritable bowel syndrome (IBS). The authors note that major events have occurred in the last five years that demonstrate the role of heightened sensation to visceral pain in patients with IBS. This work has been followed by a rapidly enlarging body of knowledge using PET scanning and functional MRI imaging to detect alterations in brain activation in IBS patients. The authors emphasize that IBS does not occur in a biological vacuum, i.e., patients who seek treatment for IBS are more psychologically disturbed than patients with IBS who do not choose to seek medical care, and patients with functional GI disorders are more likely to have suffered physical or sexual abuse than patients with structurally originated GI conditions. It has become clear that gender, psychosocial trauma, concomitant psychiatric disorders, and a patient's health beliefs all can influence
Studies
25
the acceptance of, adherence to, and improvement on a treatment regimen for IBS. The development of psychotherapeutic approaches, improvements in our understanding of the impact of gender and family history on treatment response, and the importance of screening for psychological disorders and psychosocial stress are all now recognized as key elements of optimal treatment. The series of articles (published in the same journal issue) reviews recent developments in the treatment of IBS using serotonergically active agents, antidepressants and antispasmodics, as well as the psychosocial dimensions that have an impact on optimal care of patients with IBS. 4 references. •
Irritable Bowel Syndrome: Simple Measures Often Relieve Symptoms Source: Mayo Clinic Health Letter. 10(12): 1-3. December 1992. Summary: This patient education article provides basic information about irritable bowel syndrome (IBS). Written in a question-and-answer format, the article covers topics including a definition of IBS; typical symptoms; and treatment options, including diet therapy and drug therapy. The author concludes that, with help from a physician and/or dietitian, patients can adopt diet and lifestyle changes that can help keep symptoms in check, usually without medication. 1 figure.
•
Management of Irritable Bowel Syndrome Source: Journal of Gastroenterology and Hepatology. Volume 8: 287-293. 1993. Summary: This review article discusses recent advances in the understanding of irritable bowel syndrome (IBS) that may help the clinician design a more effective management plan. Topics include the symptom complexes that constitute IBS; the objective measurement of patient symptoms; specific intestinal motor abnormalities that may exist in patients with IBS; abnormalities in visceral perception in IBS; the role of behavioral factors in IBS; the initial patient approach and management of mild to moderate symptoms; the role of dietary manipulation, explanation and reassurance, medications, and behavioral therapy; managing patients in whom symptoms are severe and intractable; and priorities for future work in this area. 3 figures. 2 tables. 10 references.
•
Review Article: Clinical Evidence to Support Current Therapies of Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 13(Supplement 2): 48-53. May 1999. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This review article summarizes the clinical evidence to support current therapies in irritable bowel syndrome (IBS). In patients with constipation predominant IBS, fiber is indicated at a dose of at least 12 grams per day. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhea predominant IBS; loperamide may also aid continence by enhancing resting anal tone. In general, smooth muscle relaxants are best used sparingly, on an as needed basis, since their overall efficacy is unclear. Psychotropic agents are important in relieving depression and are of proven benefit for pain and diarrhea in patients with depression associated with IBS. Further trials with selective serotonic reuptake inhibitors (SRRIs) are underway. Psychological treatments, including hypnotherapy are less widely available but may play an
26
Irritable Bowel Syndrome
important role in pain relief. The author concludes that current therapies targeted on the predominant symptoms in IBS are moderately successful. However, therapies are needed to more effectively relieve this syndrome, not just symptoms. 1 figure. 3 tables. 60 references. •
Meta-Analysis of Smooth Muscle Relaxants in the Treatment of Irritable Bowel Syndrome Source: Alimentary Pharmacology and Therapeutics. 15(3): 355-361. March 2001. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This review article updates previous overviews of placebo controlled double blind trials assessing the efficacy and tolerance of smooth muscle relaxants used to treat irritable bowel syndrome (IBS). A total of 23 randomized clinical trials were selected for meta analyses of their efficacy and tolerance. Six drugs were analyzed: cimetropium bromide (five trials), hyoscine butyl bromide (three trials), mebeverine (five trials), otilium bromide (four trials), pinaverium bromide (two trials), and trimebutine (four trials). The total number of patients included was 1,888, of which 945 received an active drug and 943 a placebo. The mean percentage of patients with global improvement was 38 percent in the placebo group (n = 925) and 56 percent in the myorelaxant group (n = 927). The percentage of patients with pain improvement was 41 percent in the placebo group (n = 568) and 53 percent in the myorelaxant group (n = 567). There was no significant difference for adverse events. The authors conclude that myorelaxants are superior to placebo in the management of IBS. These drugs showed significant efficacy on the global assessment despite a high placebo effect (38 percent global improvement), with a range of difference from 31 percent for cimetropium to 11 percent for hyoscin. The efficacy was also significant and in the same range for pain relief, as well as for abdominal distension relief, although lower. There was no significant difference for transit abnormalities, diarrhea, or constipation. 4 figures. 1 table. 37 references.
•
Characteristics of Patients with Irritable Bowel Syndrome Recruited from Three Sources: Implications for Clinical Trials Source: Alimentary Pharmacology and Therapeutics. 15(7): 959-964. July 2001. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Variation in the characteristics of irritable bowel syndrome (IBS) patients recruited for clinical trials from different sources could affect their response and the generalizability of trial results. This article reports on a study undertaken to describe and compare the characteristics of three different groups of IBS patients recruited into a 'mock clinical trial.' The authors enrolled 245 irritable bowel syndrome patients from three sources: 121 patients from British primary practitioners; 72 patients from California newspaper advertisements; and 52 from a California gastroenterologist's practice. The authors obtained demographic, clinical, and Hospital Anxiety and Depression (HAD) Scale data for each patient. Most patients were young to middle aged women; in all three groups, the majority reported symptoms for longer than 5 years. Subject characteristics varied among the groups. Typically, primary care patients were anxious, smokers, and daily alcohol drinkers who had sought care recently for IBS and had tried antispasmodic drugs. Their symptoms were intermediate in severity between
Studies
27
those of the other two groups. Advertisement subjects were the oldest, most highly educated, most often depressed, and were least likely to have sought care recently for symptoms, which were almost uniformly only moderate in severity. Gastroenterologist patients tended to be anxious and had nearly all sought care recently for symptoms, which were the most severe and most likely to include all three pain related Rome I criteria. The authors conclude that recruitment methodology affects important characteristics of an IBS study group. Trial reports should describe as completely as possible the recruitment method and the relevant subject characteristics to aid clinicians in deciding how the results might apply to their patients. 1 table. 26 references. •
Irritable Bowel Syndrome in the Elderly Source: Gastroenterology Clinics of North America. 20(2): 369-390. June 1991. Summary: Very little has been written about irritable bowel syndrome (IBS) in the elderly, although epidemiologic studies suggest that it is a common problem in this age group. This article discusses the definition, clinical features, epidemiology, causes and pathogenesis, diagnosis and differential diagnosis, treatment, and prognosis of IBS in the elderly. The authors stress that more study is needed, particularly in the areas of pathophysiology of IBS in the aged, investigation of personality, psychiatric symptomatology, mental state, and functional status in the elderly with IBS, and in documenting the prevalence and incidence of this phenomenon. 6 tables. 125 references.
•
Menstrual Cycle and Its Effect on Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Prevalence Study Source: American Journal of Gastroenterology. 93(10): 1867-1872. October 1998. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (800) 638-6423 or (410) 528-8555. Summary: Women with bowel disease commonly report that their symptoms worsen in relation to their menstrual cycle. This article reports on a study undertaken to determine the nature of gastrointestinal (GI) symptoms correlating with the menstrual cycle in women with inflammatory bowel disease and irritable bowel syndrome (IBS). This retrospective study involved 49 women with ulcerative colitis, 49 women with Crohn's disease (CD), 46 women with IBS, and 90 healthy community controls. Participants were interviewed using a questionnaire that included information on general health, medication history, pregnancy, and premenstrual and menstrual symptoms. Premenstrual symptoms were reported by 93 percent of all women but statistically more often by patients with CD. Patients with CD were also more likely to report increased GI symptoms during menstruation; diarrhea was the symptom reported most often. All disease groups had a cyclical pattern to their bowel habits significantly more than controls. Cyclical symptoms included diarrhea, abdominal pain, and constipation. The authors conclude that the prevalence of menstruation related symptoms is high and appears to affect bowel patterns. The physiological and clinical effects of the menstrual cycle should be taken into consideration when assessing disease activity. 3 figures. 2 tables. 13 references. (AA-M).
Federally Funded Research on Irritable Bowel Syndrome The U.S. Government supports a variety of research studies relating to irritable bowel syndrome. These studies are tracked by the Office of Extramural Research at the National
28
Irritable Bowel Syndrome
Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to irritable bowel syndrome. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore irritable bowel syndrome. The following is typical of the type of information found when searching the CRISP database for irritable bowel syndrome: •
Project Title: A CASE CONTROL STUDY OF INTERSTITIAL CYSTITIS Principal Investigator & Institution: Warren, John W.; Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2003; Project Start 18-SEP-2003; Project End 31-AUG-2007 Summary: (provided by applicant): Interstitial cystitis (IC) is a chronic bladder disease manifested by severe bladder pain and urinary frequency and urgency. Using criteria established by the NIDDK, the diagnosis can be made by objective visible findings at cystoscopy. However, IC remains a disease of unknown etiology, inconvenient diagnosis, and unclear natural history. Women comprise 90% of IC cases for unknown reasons. Patients report less life satisfaction than those with end stage renal disease. Identification of risk factors is a proven method for providing clues to pathogenesis of a disease, yet a properly designed study of IC with incident cases, appropriate controls, and attention to disease onset date has never boon performed. Herein we propose such a study comprising national samples of incident IC cases and age and gender matched controls with rigorous attention to onset dates of symptoms. By telephone interview and medical record review, we will identify risk factors for IC and reveal non-bladder syndromes associated with IC. In this group of recent onset cases where a convenient diagnostic test would be most useful, we will test the utility of antiproliferative factor, a urinary factor discovered by Susan Keay of our group. We propose then to follow this well-investigated cohort of IC cases to initiate a natural history study of the disease. This project will allow us to test several hypotheses: 1. That certain features that precede onset of IC symptoms, e.g., bacterial cystitis, distinguish IC cases from controls matched for age and gender, and may be risk factors for the disease. 2) That patients with IC have higher prevalences of certain non-bladder syndromes, e.g., irritable bowel syndrome, than do matched controls. 3) That urine APF, HB-EGF, and/or EGF are sensitive and specific diagnostic markers for IC in patients with symptoms of <=12 months. 4) That patients with IC have remissions and that certain clinical features, e.g., bacterial cystitis at disease onset, are prognostic factors for remissions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
•
Project Title: A SYNDROMEN
NOVEL
DIAGNOSTIC
TEST
FOR
IRRITABLE
29
BOWEL
Principal Investigator & Institution: Wagner, David A.; Metabolic Solutions, Inc. 460 Amherst St Nashua, Nh 03063 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-MAR-2004 Summary: (provided by applicant): Irritable Bowel Syndrome (IBS) is a life altering disorder of the intestines that effects approximately 20 percent of the general population. There is no single diagnostic test for positive confirmation of IBS. Physicians arrive at an lBS diagnosis following a protocol that uses standard endoscopic tests to exclude structural or biochemical abnormalities, a physical examination and a symptom questionnaire. This inefficient process leads to an enormous use of healthcare resources estimated at 3.5 million office visits and 2.2 million prescriptions at a direct and indirect cost of $29 billion annually. Our objective is to develop an easy to use, low cost breath test to diagnosis lBS. The test developed by Metabolic Solutions (MSI) is based on the principle that lBS patients malabsorb fructose. In preliminary studies MSI has demonstrated a novel technology using a carbon 13 tracer and unlabeled fructose to identify individuals with lBS by whether or not they can absorb the administered fructose. This is the first test to assay fructose malabsorption directly from the small intestine and correlate it to the diagnosis of LBS. The proposed test will significantly reduce national health care expenditures because proper diagnosis will lead to fewer office visits, more prudent use of drugs and better general health and well-being for a large number of Americans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A NURSING STUDY OF GUT FUNCTION IN MENSTRUATING WOMEN Principal Investigator & Institution: Heitkemper, Margaret M.; Professor & Director; Biobehavioral Nursing and Health Systems; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 15-SEP-1984; Project End 29-FEB-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A TWIN STUDY OF CHRONIC FATIGUE SYNDROME IN SWEDEN Principal Investigator & Institution: Pedersen, Nancy L.; Karolinska Institute Tomtebodavagen 11F Stockholm, Timing: Fiscal Year 2001; Project Start 15-AUG-2001; Project End 31-JUL-2004 Summary: Despite considerable research, fundamental questions about CFS remain at best partially answered. These questions include its definition, validity, the degree to which it results from genetic versus environmental factors, the nature of the substantial comorbidity observed with other conditions, and the basis of the female preponderance. The overarching aim of this project is to shed light on a number of basic questions about CFS via a large, population-based classical twin study. First, we will collect data on approximately 32,000 adults aged 42-65 years (13,000 complete twin pairs) who are members of the population- based Swedish Twin Registry for persistent fatigue, several overlapping conditions (fibromyalgia, irritable bowel syndrome, tension headache, allergy/eczema, generalized anxiety disorder, and major depression), and a detailed medical history. Second, the medical records of all twins who appear to have CFS-like illness and a subset of those with "CFS-explained" will be requested via an efficient
30
Irritable Bowel Syndrome
national retrieval system. Following expert review, these individuals will be classified in regard to the CDC CFS criteria. Obtaining these unique data will allow us to address a set of critical questions regarding CFS. First, we will estimate the prevalence of CFS and its common comorbidities (fibromyalgia, irritable bowel syndrome, tension headache, allergy/eczema, generalized anxiety disorder, and major depression) in one of the largest samples yet studied. Second, we will use a variety of multivariate techniques to derive an empirical typology of prolonged fatigue and to assess how this typology compares to the CFS definition. Third, we will quantify the genetic and environmental sources of variation for CFS and its comorbid conditions. Fourth, critically, we will examine the influence of gender on these sources of variation. Finally, we will analyze the patterns of comorbidity between CFS and fibromyalgia, irritable bowel syndrome, tension headache, allergy/eczema, generalized anxiety disorder, and major depression using multivariate twin analyses and thereby to estimate the extent of overlap between the shared and unique genetic and environmental sources of variation. In concert with other twin studies being conducted by the investigators and their collaborators, we hope to hasten progress in understanding the etiology of CFS by parallel studies in multiple populations. The current proposal has several unique aims and represents a costeffective means to extend this work in an epidemiological sample that is arguably the best twin registry in the world. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS Principal Investigator & Institution: Camilleri, Michael L.; Professor of Medicine and Physiology; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001 Summary: Our hypotheses are that alpha-2 adrenergic mechanisms modulate colonic sensation in health and in patients with irritable bowel syndrome associated with increased frequency of bowel movements and urgency; and that lower doses of the alpha-2 agonist, clonidine, are required to reduce colonic sensation in IBS compared to health; these antinociceptive effects are achieved without altering colonic compliance or motor function in patients with irritable bowel syndrome. The specific aims of the study are to study the alpha-2 adrenergic modulation of colonic compliance, tone and sensation in healthy human volunteers; to study the alpha-2 adrenergic modulation of gastrointestinal and colonic transit time in healthy human volunteers; and to study the alpha-2 adrenergic modulation of colonic transit, tone, compliance, and sensation in patients with well-characterized autonomic function who have irritable bowel syndrome associated with increased frequency of bowel movements and/or urgency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AUTONOMIC CONTROL OF BODY WEIGHT AND FEEDING Principal Investigator & Institution: Powley, Terry L.; Distinguished Professor; Psychological Sciences; Purdue University West Lafayette West Lafayette, in 479072040 Timing: Fiscal Year 2002; Project Start 01-JAN-1980; Project End 30-NOV-2006 Summary: The proposed project continues a programmatic investigation of the neural mechanisms of feeding and body weight regulation. The long- range goal of the project is a comprehensive functional neuroanatomy of energy homeostasis. For the immediate future, the proposed experiments concentrate on a series of structure-function analyses of the vagus nerve. Extensive evidence has established that the vagus, the Xth cranial
Studies
31
nerve, is critically involved in controlling ingestion and body energy regulation. Presently, however, continued progress in analyzing vagal mechanisms involved in ingestive behavior and physiology is seriously limited by a lack of fundamental structural information about the vagal projections to the gastrointestinal tract. Hence, the immediate goal of the project is the completion of a series of promising analyses that are characterizing the morphological types, regional topographies and functions of vagal projections linking the brain and GI tract. The first aim is to complete a series of experiments on vagal afferent, or sensory, endings in the alimentary canal. This aim includes characterizing structurally and then classifying afferent terminals in the mucosa and submucosa of the GI tract. It also includes developing topographic maps of the concentrations of these chemo-, osmo-, thermo- and mechano- receptors throughout the GI tract. The second aim is to characterize the patterns and timetables of regeneration of each of the different types of vagal projections to the GI tract. These experiments will also correlate the newly identified patterns of structural plasticity with recovery of function. The third aim is to extend our structure-function analyses by screening mutant mice with selective afferent vagal ablations for potential alterations in feeding behavior. Inventories of the different vagal endings, surveys of their terminal distributions, and characterizations of the plasticity in these vagal projections produced by damage or mutation will yield information needed to design, guide and interpret both experimental and surgical manipulations of the autonomic nervous system and GI tract. The program outlined also will extend our understanding of major neural mechanisms implicated in metabolic and digestive diseases including obesity, eating disorders, anorexia, disorders of swallowing, diabetes, vagal dysfunction, autonomic neuropathies, visceral pain, irritable bowel syndrome, and peptic ulcers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOMECHANICS OF ESOPHAGEAL WALL AND VISCERAL SENSATION Principal Investigator & Institution: Mittal, Ravinder K.; Professor of Medicine; Veterans Medical Research Fdn/San Diego Foundation of San Diego San Diego, Ca 92161 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 30-JUN-2005 Summary: (provided by applicant): The biomechanical properties of the esophagus have relevance to its motor and sensory function. These properties have been studied in the animals and humans by several investigators using various techniques. However, there are limitations with each of these techniques. We have developed a novel system of balloon ultrasonography that measures esophageal pressure, radius and wall thickness simultaneously, in vivo, in humans. Our technique, therefore, allows accurate measurement of the wall stress, strain and elastic modulus (wall rigidity) on a continuous time basis. Our preliminary data show that in normal subjects there is a close temporal correlation between increase in intraluminal pressure and esophageal wall thickness, which allows the esophagus to maintain a low wall stress. Patients with motility disorders of the esophagus have a thicker esophageal muscularis propria compared to normal subjects. We hypothesize that difference in the biomechanical properties of the esophageal wall between normal subjects and patients is the reason for impaired esophageal transport and dysphagia in patients with motility disorders of the esophagus. The current understanding is that hypersensitivity of the esophagus is the cause of esophageal pain. Patients with presumed esophageal pain respond to distension of the esophagus at lower balloon volumes than normal subjects. The site of esophageal hypersensitivity may be at either the peripheral (esophageal wall) or at the central level (CNS). The latter is currently the favored site. The differences in the
32
Irritable Bowel Syndrome
biomechanical properties of the esophageal wall in patients and normal subjects may result in different wall stress and strain in response to the same volume of distension. We hypothesize that differences in the biomechanical properties of the esophagus may be the reason for a hypersensitive esophagus. The specific aims of our studies are: 1: In vitro validation of the novel technique of balloon-ultrasonography. 2: To determine biomechanical properties of the esophagus in normal human subjects using balloon ultrasonography and to determine the relationship between esophageal pain and its biomechanical properties. 3: To define the abnormalities of muscularis propria thickness in patients with primary motility disorders of the esophagus. 4: To determine the biomechanical properties of the esophageal wall in patients with a normal and thick muscularis propria and its relationship to esophageal hypersensitivity. 5: To study biomechanics of the esophageal wall in patients with esophageal dysphagia. We believe that our observations have important implications in understanding the mechanisms of esophageal motor and sensory function in healthy and diseased states. Furthermore, the principles discussed in the esophagus may be applicable to the understanding of visceral hypersensitivity seen in irritable bowel syndrome and other functional disorders of the GI tract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALGESIA
BRAIN
IMAGING
AND
PAIN:
ANALYSIS
OF
PLACEBO
Principal Investigator & Institution: Robinson, Michael; Clinical & Health Psychology; University of Florida Gainesville, Fl 32611 Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 31-DEC-2006 Summary: (provided by applicant): This project is designed to investigate the neural mechanisms of placebo analgesia. An innovative placebo protocol that assesses the placebo response to both visceral and cutaneous pain stimulation will be employed. Functional Magnetic Resonance Imaging (fMRI) will enable the characterization of brain mechanisms involved in placebo analgesia in a clinical population which experiences visceral pain as part of their clinical syndrome. This project will capitalize on previous work with Irritable Bowel Syndrome (IBS) patients where differential brain activation was demonstrated to visceral and cutaneous pain stimuli. In this same population a powerful and reliable placebo response to specific expectancy response sets has been demonstrated. The proposed project will combine these protocols to obtain brain images of IBS subject during natural history, placebo, and active agent (rectal lidocaine) conditions. It is anticipated that results will show that the placebo response will selectively activate specific brain regions. Neural activity (as measured by rCBF) will be greater in natural history conditions as compared to placebo conditions in the following brain regions: - lateral and/or medial thalamus, somatosensory areas 1 and 2, insular cortex, anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), and prefrontal cortex. Furthermore, placebo mechanisms that operate primarily through attenuation of nociceptive signals at lower nervous system levels (spinal cord) will be evidenced by decreased thalamic, somatosensory, ACC, and PCC activation. Previous research indicates that expectancy and desire for pain relief will significantly predict the pain reduction from placebo. It is anticipated that these measures will also be associated with the above described brain activation patterns. By comparing the placebo conditions to the rectal lidocaine condition, brain and central nervous system related mechanisms versus peripheral (receptor site) related mechanisms will be differentiated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
33
Project Title: BRAIN/PELVIC VISCERA INTERACTIONS IN PSYCHIATRIC DISEASE Principal Investigator & Institution: Valentino, Rita J.; Professor; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, Pa 19104 Timing: Fiscal Year 2001; Project Start 05-SEP-1998; Project End 31-AUG-2003 Summary: A striking feature of mood and anxiety disorders is their frequent coexistence with functional bowel disorders, such as irritable bowel syndrome. Conversely, psychiatric symptoms are prevalent in subjects diagnosed with functional bowel disorders, which occur in 10-20% of adults. These clinical observations implicate neural substrates linking the brain and gastrointestinal tract in pathology that is prevalent in the adult population. In the current application, a specific circuit linking the forebrain and gastrointestinal tract is proposed. It is proposed that Barrington's nucleus, via divergent projections to the brain noradrenergic nucleus, locus coeruleus (LC) and autonomic parasympathetic nuclei, is in a position to co-regulate brain noradrenergic activity and autonomic parasympathetic activity and thereby coordinate forebrain activity with gastrointestinal function. The proposed aims will provide anatomic and functional evidence for this hypothesis: The specific aims are: (1) Identify regions of the gastrointestinal tract that are linked to the LC via Barrington's nucleus. Transsynaptic tracing (using pseudorabies virus) from the colon, cecum and bladder will be combined with retrograde tract tracing from the LC to determine whether Barrington's LCprojecting neurons also project to preganglionic neurons innervating these organs; (2) Characterize the physiological impact of Barrington's sacral spinal-projections on colon function. Barrington's nucleus has been studied only with regard to its role in micturition. Its projections to the sacral parasympathetic nucleus suggest that it also regulates distal colon function. This hypothesis will be tested by characterizing the effects of selective chemical stimulation of Barrington's nucleus on colonic intraluminal pressure: (3) Determine the role of Barrington's LC-projections in arousal elicited by colon or bladder distension. Colon and bladder distension increase LC discharge and produce arousal as indicated by forebrain electroencephalographic (EEG) activation. The hypothesis that forebrain arousal elicited by colon or bladder distension is mediated by Barrington's projections to the LC will be determined using micro infusion of drugs to selectively inactivate the LC or Barrington's nucleus. Together, these AIMS will begin to elucidate the anatomy and functions of a novel circuit that it is in a position to coordinate forebrain and gastrointestinal activity; a circuit that could play a role in the prevalent disorders that are characterized by a coexistence of psychiatric and gastrointestinal symptoms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE Principal Investigator & Institution: Sandler, Robert S.; Professor of Medicine; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2001; Project Start 01-DEC-1994; Project End 30-NOV-2004 Summary: (Taken from the application) Members of the Center for Gastrointestinal Biology and Disease (CGIBD) are basic and clinical scientists from diverse disciplines dedicated to advancing our understanding of gastrointestinal biology, physiology and epidemiology with a special emphasis on inflammatory bowel diseases. Research on mechanisms responsible for gastrointestinal diseases can be grouped into four major categories: inflammation, fibrogenesis, proliferation and epidemiology/clinical research.
34
Irritable Bowel Syndrome
The goal of the center is to promote and enhance multidisciplinary digestive disease research. The center achieves this goal through: 1) core facilities that provide training, technical support, laboratory animals, assays, imaging and purified cell populations; 2) a pilot feasibility program that offers startup funds to junior investigators, or to established digestive disease research. The center achieves this goal through: 1) core facilities that provide training, technical support, laboratory animals, assays, imaging and purified cell populations; 2) a pilot feasibility program that offers startup funds to junior investigators, or to established investigators who wish to pursue a new research direction; 3) a scientific enrichment program consisting of seminars, symposia and workshops to improve the intellectual climate for digestive disease research and to promote cooperation, collaboration and communication among involved personnel; 4) a professional development and training program that fosters the development of junior faculty. To support the research of members, the center proposes the following cores: 1) Biostatistics and Data Management; 2) Immunotechnologies 3) Advanced Cell Technologies and Tissue Engineering (cell culture and multiparametric cell sorting); 4) Molecular Imaging (confocal microscopy, in-situ hybridization, histology); 5) Gene Delivery; and 6) Gnotobiotic Animal. Gastrointestinal diseases and their complications have a significant health and economic impact. Research by members of this center has led to fundamental breakthroughs in our understanding of mechanisms responsible for inflammatory bowel diseases, cirrhosis, irritable bowel syndrome, and colon cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CENTRAL HYPERSENSITIVITY
MECHANISMS
MODULATING
VISCERAL
Principal Investigator & Institution: Greenwood-Van Meerveld, Beverly; Scientific Director; Oklahoma Foundation for Digestive Res Digestive Research Oklahoma City, Ok 73104 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 28-FEB-2003 Summary: Irritable bowel syndrome (IBS) symptoms are due in part to alterations in visceral sensation. IBS symptoms are frequently exacerbated by stress and anxiety, which suggests a link between cognitive and peripheral autonomic activity. The amygdala has been implicated as a key limbic structure involved in anxiety and activation of the hypothalamic-pituitary-adrenocortical axis. It has been demonstrated that administration of glucocorticoids in the area of the amygdala increases anxiety in rats. Furthermore, rats genetically predisposed to heightened levels of anxiety display a hypersensitive response to colonic distention. The PI hypothesizes that manipulation of amygdala function by glucocorticoids induces colonic hypersensitivity through modulation of spinal neuronal activity. The PI proposes to modulate anxiety by manipulating amygdala function directly with corticosterone and specific glucocorticoid antagonists to determine mechanisms by which the CNS regulates visceral sensitivity. Visceromotor reflexes in response to colorectal distention will be used to determine visceral hypersensitivity in rats with normal and "hypersensitive" colons. It is proposed that chronic stress resulting in elevated glucocorticoid levels could, through the amygdala, modulate the function of critical spinal neurons involved in the colonic stimuli. To further explore the mechanisms involved the PI will modulate amygdala function with glucocorticoids and its effect on spinal cord neuronal activity. Recordings will be made from rat lumbosacral spinal nerves in response to colonic distention following treatment with corticosterone or specific antagonists delivered to the amygdala. This R21 proposal will develop collaborations among scientists in GI neurophysiology, pharmacology, and neuroendocrinology.
Studies
35
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOTILITY
CHOLECYSTOKININ--ROLE
IN
POSTPRANDIAL
GASTRIC
Principal Investigator & Institution: Raybould, Helen E.; Associate Professor; Clinical Research Center; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 95616 Timing: Fiscal Year 2001; Project Start 01-AUG-1989; Project End 31-AUG-2004 Summary: Nutrients in the intestinal lumen initiate changes in motor function of the gastrointestinal tract. Intestinal lipid acts via a cholecystokinin A receptor- (CC.-AR) and a vagal afferent-dependent pathway. The hypothesis to be tested is that intestinal lipidinduced inhibition of gastric motility is dependent on absorption of lipid by enterocytes, formation and release of chylomicrons and apolipoprotein A-IV (apoA-IV), release of CCK. by apo A-IV and CCK acting on CCK-ARs on intestinal afferent nerve terminals. To test this hypothesis, studies are proposed to determine that: (1) inhibition of gastric emptying by lipid in the intestinal lumen depends on chylomicron formation and release of apo A-IV; (2) release of CCK in response to lipid is dependent on chylomicron formation and release of ap A-IV; (3) activation of vagal afferents in response to intestinal lipid is dependent on release of apo A-IV and CCK-AR activation and (4) to demonstrate the expression of CCK-AR on neuronal elements in the stomach and duodenum and their functional regulation by CCK. The role of chylomicron formation in lipid- induced inhibition of gastric emptying or motility and release of CCK will be determined in rats using the surfactant pluronic L81. Postabsorptive chylomicron products in mesenteric lymph will be given intra-arterially to demonstrate their effectiveness to inhibit gastric motility and act via a CCK-AR- and vagal capsaicindependent pathway. The role of apo A-IV in inhibition of gastric motility and CCK release in response to lipid will be determined by in vivo immunoneutralization, removal of apo A-IV from chylous lymph by immunoprecipitation, and by exogenous administration of apo A-I. Lipid-induced inhibition of gastric emptying and release of CCK will be measured in apo A-IV over-expressing and apo A-IV knockout mice. CCK secretion from STC-1;cells will be measured in vitro to determine that apo A-IV acts direct on endocrine cells. Intestinal vagal afferent fiber discharge will be measured in response to intestinal perfusion of lipid and exogenous administration of apo A- IV acts directly on endocrine cells. Intestinal vagal afferent fiber discharge will be measured in response to intestinal perfusion of lipid and exogenous administration of apo A-IV and determine that both of these responses are CCK-AR- dependent using the CCK-AR antagonist devazepide. A direct effect of Cck on vagal afferents innervating the gastroduodenum will be determined by measuring calcium fluxes in response to CCK in nodose neurons in vitro. The cellular sites of expression and origins of Cck-ARs will be determined in immunohistochemical studies using antisera raised to different regions of the rat CCK-AR in tissue from intact, extrinsically denervated or capsaicin treated rats The co- localization of CCK-AR with other enteric neuropeptides, and with neuronal and endocrine CCK will be determined in double labeling experiments. The functional regulation of Cck- Ars in the stomach and duodenum will by investigated using exogenous and endogenous CCK and devazepide. These studies address sensory transduction in the gastrointestinal tract which is important in the regulation of normal digestive function. There is evidence that sensory function of the intestine is altered in pathological conditions such as inflammatory bowel disease, irritable bowel syndrome and obesity. A greater understanding of these sensory mechanisms will help in understanding the pathophysiology of these diseases.
36
Irritable Bowel Syndrome
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COGNITIVE APPROACHES TO MODIFYING HUMAN PAIN PERCEPTION Principal Investigator & Institution: Bushnell, M. Catherine.; Professor; Mc Gill University James Admin. Bldg., Room 429 Montreal, Pq H3a 2T5 Timing: Fiscal Year 2002; Project Start 10-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant): The vast majority of analgesic research has focused on pharmacological agents, addressing particularly the peripheral and spinal cord mechanisms of opioid and anti-inflammatory therapy. It is now recognized, however, that a variety of modulatory mechanisms exists in the nervous system, and more importantly, that many of these endogenous pathways can be accessed through cognitive manipulations. The proposed research investigates a number of cognitive factors that modulate pain perception, examines their interrelationships, and explores possible cerebral mechanisms underlying their action. Study 1 will test the hypothesis that emotional context influences pain perception independent of attentional factors. Psychophysical studies in normal human subjects will employ cross-modality attention tasks, hedonically charged olfactory stimuli (to modify emotional context), and noxious heat as a painful stimulus. Functional magnetic resonance imaging (fMRl) will subsequently examine cerebral activation associated with these cognitively activated pain-modulatory systems. Study 2 will test the general hypothesis that cognitive modulation of pain perception is more pronounced for visceral than for cutaneous stimuli, as suggested by clinical evidence indicating a strong influence of emotional state on chronic visceral pain, such as the pain of irritable bowel syndrome or non-cardiac chest pain. This study will address the issue experimentally, using psychophysical and fMRl testing to compare directly the influence of emotional context and/or attentional state on sensory and affective aspects of visceral and cutaneous pain perception in normal human subjects. Finally, based on recent suggestions of gender dissimilarities in endogenous pain-modulatory systems, we will examine, in the above studies, sexrelated differences in the modulatory influences of emotional context and attention on both the sensory and affective dimensions of pain perception. The influence of a patient's cognitive state on pain has been largely ignored in western medicine. Results of the proposed studies may help educate both physicians and patients about cognitive effects on pain and guide future development of cognitive strategies for pain control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COGNITIVE THERAPY FOR IBS--OUTCOME, PROCESS & PREDICTION Principal Investigator & Institution: Blanchard, Edward B.; Distinguished Professor; Psychology; State University of New York at Albany 1400 Washington Ave Albany, Ny 12222 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2003 Summary: (adapted from investigator's abstract): Irritable Bowel Syndrome (IBS) is a widespread, chronic, disorder of the lower gastrointestinal tract which seems relatively refractory to standard medical care. Recent research from our laboratory strongly suggests that cognitive therapy (CT) is highly effective (70-80 percent clinically improved) in the short-term (out to 3 months post-treatment). The current application seeks to replicate and extend our previous small-scale studies by conducting a controlled clinical trial of CT vs. a self-help support group as an attention placebo
Studies
37
control and symptoms monitoring wait list of 240 chronic IBS patients and follow up the treated patients for at least 12 months. To complete the project in a timely fashion a second site, University of Buffalo Medical Scholl, will be added to run half of the sample. Within this overall project 5 studies will be conducted: (a) examination of relations between stress, especially minor stressful events, and IBS symptoms; (b) controlled comparison of brief (10 sessions) CT administered in small groups to (SG) and to (sic) symptom monitoring. The latter will subsequently be treated to increase the sample sizes for studies c, d, and e; (c) identification of the processes of change within the CT treatment of IBS by examining, at various levels of analysis, the relations between changes in cognitive variables and changes in GI symptoms; (d) prospective one-year follow-up of the effect of CT and SG on IBS; (e) prediction algorithm for the results of the CT treatment of IBS from variables derived from the careful pretreatment assessment of participants; we will determine prediction schemes of end of treatment and a 3-month follow-up as well as what variables predict maintenance of symptom relief over the 12 month follow-up. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROLLED FIBROMYALGIA
FAMILY
STUDY
IN
PATIENTS
WITH
Principal Investigator & Institution: Arnold, Lesley M.; Associate Professor; Psychiatry; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2003 Summary: Fibromyalgia, a chronic musculoskeletal pain disorder of unknown etiology, is a significant public health problem. Evidence from studies of phenomenology, comorbidity, family history, and pharmacologic treatment response suggest that fibromyalgia may be associated with major mood disorder, and possibly to a proposed group of conditions known as affective spectrum disorders. Prior psychiatric research has demonstrated that major mood disorder is highly familial. Family history studies provide a method by which to assess how medical disorders co-aggregate in families and, therefore may share a common risk factor or pathophysiologic mechanism. To date, few studies have explored the morbid risk of major mood disorder (and other proposed affective spectrum disorders) in probands with fibromyalgia and their first- degree relatives. All of these studies have used the family history method, which entails interviewing probands regarding their knowledge of psychiatric illness in relatives. Although most of these studies have provided important preliminary data suggesting an association between fibromyalgia and major mood disorder, this method has been demonstrated to be less sensitive in detecting illness in relatives than direct interview (the family interview method). In order to provide further evidence of a relationship between fibromyalgia and major mood disorder, we propose to study the prevalence of psychiatric and rheumatologic disorders in probands with fibromyalgia and their firstdegree relatives as compared to probands with rheumatoid arthritis and their relatives using the family interview method. In addition to assessing the degree of co-aggregation of these disorders within families, we will also study the occurrence of other conditions within the proposed group of affective spectrum disorders in relation to fibromyalgia, and the association between the severity of fibromyalgia symptoms and the presence of major mood disorder within families. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
38
Irritable Bowel Syndrome
•
Project Title: CORE--HUMAN STUDIES Principal Investigator & Institution: Jensen, Dennis M.; Professor of Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: (Adapted from the application) The mission of the Human Studies Core is to provide shared resources, personnel, services, education, and consultation to CURE investigators, trainees, and their collaborators for the study of patients with selected digestive diseases. The primary goal of this core is to facilitate collaboration, education about, and performance of GI clinical trials, human physiological studies, and health service studies in digestive diseases. The traditional focus of the core has been the investigation of peptic diseases and upper GI physiology, including secretion, motility, and hormonal regulation. This focus has been broadened to include the study of other important gastrointestinal illnesses such as complicated ulcer disease, gastroesophageal reflux disease (GERD), Barrett's epithelium, GI hemorrhage, non-ulcer dyspepsia, Helicobacter pylori infection, pre-cancer conditions (gastritis, polyposis, and ulcerative colitis), and inflammatory bowel disease. An overriding theme of the core is the study of the physiology of visceral pain which may be associated with all of these disorders. The importance of this area in GI diseases is highlighted by the impact of GI symptoms on quality of life and demand for health care services. With this in mind, the core has greatly expanded the study of neuroenteric diseases such as irritable bowel syndrome (IBS), non-ulcer dyspepsia, and non-cardiac chest pain. The specific goals of this core are to provide CURE investigators, trainees, and their collaborators with access to: (1) a quality clinical research unit for performance of GI clinical research at a low cost, (2) utilization of fully equipped endoscopy units for GI clinical and physiologic research studies, (3) laboratory services for GI secretory tests, GI motility and pH testing, and H. pylori assessments (ELISA, C-14 breath testing, and histopathology), (4) teaching of clinical research techniques and consultation about study design, data management, statistical analysis, and routine outcomes, (5) tissue and clinical data banks of patients with selected GI diseases (the largest data bases are for GI hemorrhage and functional GI disease), (6) consultation about conducting health services research including design of studies, cost assessments, quality of life instruments, effectiveness studies, and modeling cost-effectiveness studies, (7) specialized equipment for GI studies (such as equipment for ablating Barrett's epithelium or endoscopic ultrasound instruments), (8) psychophysiology and GI motility laboratories for the study of neuroenteric diseases, and (9) utilization of a brain imaging unit for the study of neuroenteric diseases. The instruments and personnel required for these services and functions are expensive, so that sharing them among various investigators in a core is cost effective and promotes collaboration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENHANCING THE PLACEBO EFFECT IN IRRITABLE BOWEL SYNDROMEN Principal Investigator & Institution: Kaptchuk, Ted J.; Director of Complementary Specialties; Medicine; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-DEC-2006 Summary: (provided by applicant): This grant continues our ongoing research on how placebo effects can be enhanced and provides crucial data on the placebo effect's
Studies
39
scientific validity and clinical significance. Our model uses Irritable Bowel Syndrome (IBS) to study the placebo effects elicited by different patient-practitioner contexts. In phase one, 260 patients will be randomized to a 3 week three arm RCT comparing: 1. sham needle treatment (a validated sham acupuncture placebo device) given in the context of a patient-practitioner interaction 'augmented' with positive cognitive, emotional and symbolic interactions, 2. identical sham given within a 'limited' contextual interaction, 3. a no treatment control. The primary question tested is whether the 'nonspecific' effects across the two sham device arms and the no treatment arm behave monotonically in a manner analogous to 'dose dependence' i.e. is 'augmented' arm > 'limited arm' > wait-list natural history. This trial also allows us to answer whether 1. the placebo effect in IBS can be enhanced, i.e., does an 'augmented' placebo intervention elicit a greater placebo effect than a 'limited' placebo intervention and 2. whether the 'limited' placebo intervention elicits a greater placebo effect than natural history arm with any 'non-specific' effects attendant to being in a no-treatment control. To maintain ethical norms, phase two will continue the same context, but sham acupuncture will seamlessly be switched to verum acupuncture to explore acupuncture's efficacy in IBS. In addition, a second parallel qualitative study will follow 27 additional patients (whose outcome data will be excluded from the larger study's analysis) through the same three arms; the study will use interviews to explore the relationships between patients' interpretations and understandings (what anthropologists call 'meaning') of IBS, and their responses to placebo and verum treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL BOWEL DISORDERS IN CHINESE MEDICINE Principal Investigator & Institution: Berman, Brian M.; Director; Family Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2003; Project Start 22-SEP-2003; Project End 31-MAR-2005 Summary: (provided by applicant): This application is for a Planning Grant for International Centers for Research on Complementary and Alternative Medicine (PICRC) in response to RFA AT-03-002. The goal of planning phase activities is to begin creation of the Functional Bowel Disorders and Traditional Chinese Medicine Research Group, with the participation of consortium members of three universities, The University of Maryland Center for Integrative Medicine, the Chinese University of Hong Kong, and the University of Illinois at Chicago Program for Collaborative Research in the Pharmaceutical Sciences. The consortium will develop a grant application for an International Center for Research on Complementary and Alternative Medicine (ICRC) to be submitted during the two-year planning phase, which will request funding to support three pilot projects related to irritable bowel syndrome and three cores: a Pharmacologic Core, a Data Management, Analysis, and Coordination Core, and an Administrative Core. The projects to be proposed will include 1) a rat model irritable bowel syndrome treatment trial using acupuncture and herbs, 2) a human pathophysiology pilot study on the effect of TCM on cerebral cortical activation and visceral sensation to rectal distension in IBS patients and non-IBS volunteers, and 3) Phase I and II clinical trials of TCM treatment in diarrhea-type IBS patients. Pilot studies in the animal model, standardization and authentication of the herbal preparation, and the techniques of human rectal distension in the functional MRI environment will be conducted in the planning phase to facilitate the projects to be proposed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
40
Irritable Bowel Syndrome
•
Project Title: GDNF IN THE ENTERIC NERVOUS SYSTEM Principal Investigator & Institution: Xia, Yun; Anesthesiology; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): This is a proposal for a KO8 Mentored Clinical Scientist Development Award for a physician scientist who holds an M.D. and Ph.D. in Physiology. The applicant aims to acquire the skills and conceptual knowledge necessary for conducting research on the nervous system of the digestive tract. This requires advanced training in electrophysiological methods, fluorescent immunohistochemistry and molecular biology to be obtained during the 5-year tenure of the Award. A lifelong career as a clinician scientist in an academic medical center is the applicant's goal. The proposed research is in the new and rapidly developing field of neurogastroenterology. The focus in this proposal on the enteric nervous system as a "brain-in-the-gut" addresses an important aspect of neurogastroenterology that is related to functional gastrointestinal disorders. Functional gastrointestinal disorders are believed to reflect neuropathic changes in the enteric nervous system that may be manifest as the irritable bowel syndrome (IBS), nonulcer dyspepsia or non-cardiac chest pain. The research is directed to understanding the role of glial derived neurotropic factor (GDNF) in the enteric nervous system. GDNF came to scientific and clinical life as a promising treatment to reverse neuronal degenerative changes in the brain that lead to Parkinson's disease. GDNF is a protective factor for neurons in the brain and peripheral nervous system. Mutations in the GDNF gene leads to Hirschsprung's disease in animals and humans. Parkinsonian patients in recombinant GDNF therapy trials experienced IBS-like diarrhea and cramping abdominal pain. Human trials showed evidence of a prokinetic action on gastrointestinal transit. The general scientific aim of the proposed work is to understand how GDNF works in the "brain-in-the-gut" to alter motility and secretory functions. The investigative work is based on results of pilot/feasibility studies that show significant actions of applied GDNF on both neuronal excitability and neurotransmission. Experimental protocols are designed to: 1) determine the action of GDNF on electrical and synaptic behavior of neurons in the enteric nervous system; 2) identify the morphological types of enteric neurons on which GDNF acts; 3) determine the localization and distribution of GDNF receptors in the enteric nervous system; 4) identify subtype/s of GDNF receptors that mediate its action on enteric neurons; 5) investigate factors that influence gene expression for the GDNF receptors in enteric neurons. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GRADUAL EXPOSURE TREATMENT FOR IRRITABLE BOWEL SYNDROMEN Principal Investigator & Institution: Decola, Joseph P.; Psychology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 01-APR-2001 Summary: The most commonly used non-medical treatment for Irritable Bowel Syndrome (IBS) is a combination of traditional stress management techniques and nonspecific cognitive therapy methods. This general approach is used to treat patients with divergent target symptoms (i.e., constipation and diarrhea). A limitation of this approach is that the treatment is not derived from a clear theoretical model that identifies a specific process underlying the disorder or treatment. The present study is based on a strong theoretical model that offers specific predictions and treatment
Studies
41
methods. The model assumes that hypervigilance and hypersensitivity to internal sensations in the gut are the critical perceptual mechanisms underlying IBS. These perceptual filters are the result of learning and conditioning processes and can be reversed with a cognitive-behavioral treatment that incorporates gradual exposure to internal sensations. Subject recruitment will be limited to IBS patients with diarrhea as the predominant symptom and the treatment will be implemented with a multiple baseline across subject design. The treatment will consist of several phases: education about the role of learning in the development of IBS symptoms; relaxation training; cognitive restructuring for overestimation and catastrophization errors; exposure to the feared internal sensations; and exposure to avoided situations. The goal of this treatment is to reverse the hypersensitivity and hyperviligance through gradual exposure to these stimuli. The broad objective of this research is to enhance the treatment for IBS and to test the predictions of this theoretical model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERGENERATIONAL TRANSMISSION OF ILLNESS BEHAVIOR Principal Investigator & Institution: Levy, Rona L.; Professor; None; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-MAR-2003 Summary: U.S. health care costs may reach $2 trillion by the year 2000. Over- utilization is one of the major reasons given for rising health care costs. Illness behavior patterns, including health care utilization and disability days, run in families, and parental modeling and reinforcement have been proposed as likely mechanisms to explain family aggregation patterns. However, studies of parental reinforcement of illness behavior have been limited by retrospective reports from adults about their childhood experiences. The first aim of this study is to assess the way parents respond to their children's somatic complaints and to assess the relationship of parental reinforcement and modeling to various measures of illness behavior in their children. The long term goal is the development of an intervention model for prevention or reducing inappropriate illness behavior. A second aim is to determine whether the effects of modeling and reinforcement are independent of the psychosocial variables of family stress, competence, and parent and child psychological symptoms in determining child illness behavior. The proposed study will focus on gastrointestinal illness behavior in the children of adults with irritable bowel syndrome (IBS). Subjects will consist of children aged 8-16 years whose mothers have sought care for IBS from a defined managed care (HMO) population, control children whose mothers have sought care for asthma. All families will be randomly selected from the same population. For the IBS and non-IBS controls, questionnaire, interview and diary data will be obtained from parents and children on illness behavior, reinforcement, psychological symptoms, stress coping, and beliefs about illness, and school attendance data will be obtained from the schools. For all subjects, data will be collected from the HMO database on number, cost, type, and diagnosis for all parent and child health care visits. Data from the HMO and schools will be obtained prospectively for two years after entering the study and retrospectively for the two years prior to entering the study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SYMPTOMS
INTESTINAL
GAS
DYNAMICS
AND
FUNCTIONAL
GUT
Principal Investigator & Institution: Azpiroz, Fernando; Vall D'hebron Foundation Pg Vall D'hebron, 119-129 Barcelona,
42
Irritable Bowel Syndrome
Timing: Fiscal Year 2001; Project Start 01-MAY-2000; Project End 30-APR-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS AND MODULATION OF VISCERAL PAIN Principal Investigator & Institution: Gebhart, Gerald F.; Professor and Chair; Pharmacology; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 01-JUL-1983; Project End 30-JUN-2005 Summary: (adapted from applicant's abstract): Visceral pain, particularly visceral hyperalgesia such as is associated with the functional bowel disorders like irritable bowel syndrome, is poorly understood. Because functional bowel disorders are characterized by increased sensitivity to gastrointestinal stimulation, pain and discomfort, they represent a visceral hyperalgesia. Increasing interest over the past decade or more has contributed significant knowledge about visceral pain mechanisms. The current application proposes to build on this base of knowledge to develop and characterize models of visceral hyperalgesia that relate closely to clinical conditions typified by irritable bowel syndrome. Specifically, this proposal will focus on examination and characterization of peripheral contributions to the development and maintenance of visceral hyperalgesia. The first aim will be to develop appropriate models of irritable bowel syndrome and contrast those models with a model of colonic inflammation/colitis. It is hypothesized that changes in the excitability of visceral sensory fibers contribute significantly to development of visceral hyperalgesia and the second aim of this proposal will be in vivo electrophysiological examination of pelvic nerve afferent fiber excitability. Because increases in excitability of pelvic nerve sensory fibers must arise from changes in the function of ion channels or receptors in their cell bodies and terminals, the third aim of this proposal is to study the excitability of identified colon sensory neurons. These aims are a logical extension of the current project and will continue important investigations into the mechanisms of visceral hyperalgesia. The proposed experiments comprise a quantitative study of visceral hyperalgesia, pelvic nerve sensory afferent fibers and colon sensory neurons that will lead to better understanding of the mechanisms responsible for visceral hyperalgesia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF CHRONIC VISCERAL HYPERALGESIA Principal Investigator & Institution: Al-Chaer, Elie D.; Professor; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2001; Project Start 05-APR-2001; Project End 31-MAR-2005 Summary: Visceral hyperalgesia is a hallmark of the irritable bowel syndrome (IBS), an extremely common disorder, affecting up to 15 percent of the US population with a major socioeconomic impact. Our understanding of the hyperalgesia in functional pain syndromes such as lBS lags behind our knowledge of the mechanisms of other types of visceral pain that are mechanically-induced or caused by inflammatory reactions mainly because of the lack of a valid animal model. Recently, it was shown that functional abdominal pain can be modeled in animals. Colon irritation (CI) in neonatal but not adult rats, can cause a long lasting visceral hyperalgesia that persists long after the initial injury has resolved. In this study, the central hypothesis is that persistent colonic hyperalgesia, residual to neonatal colon irritation, is associated with central neural sensitization maintained by an interactive exchange of information between the spinal cord and thalamus. HYPOTHESIS 1: There exists a postnatal window of time when
Studies
43
minimal colon irritation can induce permanent changes in the nervous system that leads to chronic visceral hyperalgesia. SPECIFIC AIM] will define this window of time in postnatal development using noxious mechanical distension or chemical irritation of the colon to cause chronic visceral hyperalgesia. HYPOTHESIS 2: The persistent visceral hyperalgesia residual to neonatal CI is maintained by central plastic changes in neuronal sensitivity. SPECIFIC AIM 2 will demonstrate with immunocytochemistry and electrophysiology, that the chronic visceral hyperalgesia is associated with neuronal sensitization in the spinal cord and the thalamus. HYPOTHESIS 3: The sensitization is maintained in part by neuronal mechanisms involving glutamatergic and peptidergic processes. SPECIFIC AIM 3 will determine if blockade of glutamate or neurokinin receptors by specific antagonists will reduce the central sensitization. HYPOTHESIS 4: The central sensitization is maintained by an intact dorsal column (DC) participating in a feed-forward dynamic exchange of information between the dorsal horn of the spinal cord and the thalamus. SPECIFIC AIM 4 will demonstrate, using electrophysiology and behavior studies, that the sensitization is mediated by an intact DC-thalamus communication that maintains thalamic sensitization and amplifies spinal neuronal sensitivity via descending pathways. The long-term objective of the proposed study is to define the neurophysiological correlates of chronic visceral hyperalgesia and hence to identify novel therapeutic targets for the relief of pain in patients with functional bowel disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANOTRANSDUCTION IN INTESTINAL SMOOTH MUSCLE CELLS Principal Investigator & Institution: Farrugia, Gianrico; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001; Project Start 01-SEP-1997; Project End 31-DEC-2002 Summary: Mechano-gated ion channels provide a mechanism for cells to respond directly to changes in their environment and are involved in several key cellular functions including cell division, regulation of volume, muscle tone and muscle.hypertrophy. Neurons, cardiac, and vascular smooth muscle cells have mechano-gated ion channels. However, the presence and significance of mechano-gated ion channels in gastrointestinal smooth muscle is unknown. The objective of this proposal is to establish the physiological importance of mechano-gated ion channels in single human and canine jejunal circular smooth muscle cells. The Preliminary data obtained by the PI suggest that membrane stretch, increase in cell volume, and cytoskeletal manipulation modulate the whole cell current in human and canine jejunal circular smooth muscle cells. Based on these preliminary data the working hypothesis of this proposal is that mechano-gated ion channels are present on smooth muscle cells and that activation of the channels results in changes in ionic flux and membrane potential, ultimately resulting in changes in intestinal contractility. There are three specific aims: (1) to determine if a change in shape or size of human and canine jejunal circular smooth muscle cells activates mechano-gated channels; (2) to determine which ion channel or channels underlies the increase in whole cell current evoked by a change in cell size or shape; and (3), to determine if regulation of mechano-gated ion channel open probability is dependent on the cellular cytoskeleton. The development of a dissociation technique for obtaining healthy human small intestinal smooth muscle cells by the PI will enable the use of patch clamp recordings and immunofluorescent techniques to address the three specific aims. The demonstration of mechano-gated ion channels in gastrointestinal smooth muscle will provide a novel pathway by which small intestinal
44
Irritable Bowel Syndrome
smooth muscle cells can directly and appropriately respond to changes in their environment. Activation of mechano-gated ion channels may be of physiological significance in the smooth muscle response to changes in intraluminal pressure in normal digestion, and of pathophysiological significance in inflammatory or obstructive diseases such as Crohn's disease and strictures and in irritable bowel syndrome where mechano-gated ion channels may be overexpressed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MEDIAL PAIN INPUTS TO MONKEY ANTERIOR CINGULATE CORTEX Principal Investigator & Institution: Vogt, Brent A.; Neuroscience and Physiology; Upstate Medical University Research Administration Syracuse, Ny 13210 Timing: Fiscal Year 2004; Project Start 01-DEC-2003; Project End 30-NOV-2008 Summary: (provided by applicant): Anterior cingulate cortex is the most frequently activated cortex in human pain studies and is comprised of perigenual and midcingulate regions. Nociceptive information passes through the midline and intralaminar thalamic nuclei, however, links between the spinothalamic tract and spinoreticulothalamic system to the midline nuclei has never been made directly to cingulate cortex. A case of irritable bowel syndrome with severe visceral pain shows alleviation of symptoms with psychotherapy and reduced midcingulate and increased anterior insular activity. Two hypotheses guide these studies: Functions of perigenual areas 32, 25, 24a-c and midcingulate areas 32' and 24a'-d are driven by different midline thalamic inputs and these nuclei conduct parallel circuits for nociception and stress. Each animal will receive horseradish peroxidase either in the spinal cord or dorsocaudal medullary reticular nucleus, and three fluorescent dextran amine retrograde tracers in contralateral cingulate and/or insular areas followed by reactions for 4 antibodies. Specific Aim #1 will evaluate the immunoarchitecture of the midline and dorsocaudal medullary nuclei with a neuron-specific antibody and antibodies for neurofilaments and calbindin. #2 will determine the projections of the midline nuclei to perigenual, midcingulate, and insular cortices with multiple fluorescent tracers that have the same uptake, transport, and signal properties. #3 will evaluate the topography of inputs to the midline nuclei with anterograde horseradish peroxidase following cervical spinal cord injections. #4 will assess the topography of inputs to the midline nuclei with horseradish peroxidase in the dorsocaudal medullary nucleus. #5 will evaluate overlap of dopamine-13 hydroxylase in each of the midline nuclei with inputs from spinothalamic and medullary nuclei to determine the overlap of nociceptive and stress circuits in the thalamus. These studies will provide the first evidence for differential projections of the midline thalamus to limbic cortex and the extent of spinothalamic, medullary, and locus coeruleus overlap in the medial thalamus and modulatation of sensory, affective, and motor domains of pain processing in anterior cingulate and insular cortices. The mechanisms of medial pain system processing will be identified and this will help interpret human imaging studies and assist in developing objective cdteria and therapies for treating the psychiatric consequences of chronic pain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MEDICAL HISTORY, MEDICATIONS, AND PANCREATIC CANCER RISK Principal Investigator & Institution: Mandelson, Margaret T.; Associate Investigator; Center for Health Studies Seattle, Wa 98101
Studies
45
Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): Risk factors for pancreatic cancer are not well established. The goal of this pilot study is to investigate the relation between medical history, medication use and pancreatic cancer in a case-control study based on medical record abstraction and electronic laboratory and pharmacy data. Our specific aims are: 1. To investigate the relation between medical conditions and pancreatic cancer risk, focusing on: a. Diabetes mellitus, including disease duration, therapy, and glycemic control. b. Pancreatic inflammation, including acute and chronic pancreatitis. c. History of peptic ulcer disease and/or infection with Helicobacter pylori (H. pylori). d. History of cholecystectomy and/or cholelithiasis. 2. To investigate the relation between the use of medications and pancreatic cancer, focusing on nonsteroidal anti-inflammatory drugs, cholesterol lowering agents including HMG-CoA reductase inhibitors and acid suppressive medications including histamine receptor antagonists and proton pump inhibitors. As a secondary specific aim we propose to examine additional medical conditions and medications in order to generate hypotheses for future studies of the epidemiology and prevention of pancreatic cancer. These include evaluation of medical conditions such as irritable bowel syndrome, allergies and asthma as well as medications including immunosuppressive medications and angiotensin converting enzyme inhibitors. To meet these specific aims we propose to conduct a case-control study of pancreatic cancer comprised of 250 newly diagnosed cases and 1,000 controls in the defined population of Group Health Cooperative, a large health maintenance organization. Data on prior medical conditions and medications will be collected through abstraction of traditional and computerized medical records, including electronic laboratory and pharmacy data. Study strengths include the availability of uniformly collected, long-term medical and pharmacy data and the availability of data on important covariates, including smoking. The proposed study will provide a unique opportunity to investigate the role of medical conditions and medications in pancreatic tumorigenesis and to generate new insights into the mechanisms that result in pancreatic cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER TRIAL OF FUNCTIONAL BOWEL DISORDERS Principal Investigator & Institution: Drossman, Douglas Arnold.; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-AUG-2003 Summary: The primary aim of this study is to compare the efficacies of clinical treatments for the group of chronic, painful functional bowel disorders (FBD) that predominantly affect women. Secondary aims include 1) determination of demographic, psychosocial, physiologic and symptomatic predictors of clinical improvement and 2) analysis of significant relationships among physiologic markers of FBD, psychosocial status, symptoms and treatment effects. The Principal Investigator and his colleagues propose to compare cognitive-behavioral psychological treatment with antidepressant drug therapy (desipramine) and education/attention placebo in over 300 women. Interrelationships between psychological and physiological factors on the development, clinical expression and treatment of FBD have long been recognized, but this is the first large-scale study designed both to isolate therapeutic effects, and to investigate interactions among physiologic measures, psychologic and sociodemographic factors, severity of symptoms, and therapeutic improvement including quality of life. In the proposed plan of research, at least 300 female patients (aged 18- 65) with FBD (irritable bowel syndrome, painful constipation and/or functional abdominal pain) will be
46
Irritable Bowel Syndrome
enrolled in clinics at UNC-Chapel Hill and Toronto, Canada. A severity index will determine recruitment into the group of moderate FBD (200 patients) and severe FBD (100 patients). Each group will be randomized into the three treatment arms (cognitivebehavioral treatment, desipramine, and education/attention placebo), treated over a 12week period, and followed for one year. Outcome measures will include symptoms (standardized abdominal pain, stool form, and frequency) using diary cards, daily functional status (Sickness Impact Profile), depression (HAM-D), and psychological distress (SCL-90), physiological measures (enhanced rectal motility and visceralsensation), and health care use. Multivariate statistical methods with a hierarchical design will be applied to the data to assure maintenance of statistical power over multiple tests of overlapping groups. The results of this study may significantly improve an understanding of this complicated syndrome that lowers the quality of life and economic productivity of large numbers of women. The clinical impact of the study, in providing physicians with scientific evidence of the efficacy of treatments of FBD that are commonly used in practice, may be significant. This study may provide clinicians with predictors of success among types of FBD patients and types of therapy that will improve symptoms and quality of life and reduce the health care costs associated with this common syndrome, while improving patient-physician satisfaction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROCHEMICAL MECHANISMS OF VISCERAL PAIN Principal Investigator & Institution: Traub, Richard J.; Associate Professor; Oral & Craniofacial Biol Scis; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2003; Project Start 01-AUG-1999; Project End 31-MAY-2007 Summary: (provided by applicant): Irritable Bowel Syndrome (IBS) is characterized by abdominal pain in the absence of pathology. Epidemiological studies further show IBS is reported most often in menstruating women compared to post-menopausal women or men suggesting gonadal hormones could be a contributing factor. It was recently hypothesized that the pain of IBS could result from sensitization of visceral afferent fibers or hyperexcitability of dorsal horn neurons. Recent data suggests a role for spinal NMDA receptors in processing noxious and innocuous visceral stimuli and NMDA receptors in the brain are modulated by estrogen. The long-term goal of this application is to examine the effects of estrogen on spinal NMDA receptor-mediated processing of noxious and innocuous colorectal stimuli. We hypothesize that estrogen increases activity at spinal NMDA receptors in the absence and presence of colonic inflammation leading to colorectal allodynia and hyperalgesia. This modulation may result from alterations in NMDA receptor subunit composition or second messenger mediated phosphorylation. Using our model of colorectal distention (CRD), we will test these hypotheses by examining the effects of estrogen replacement in ovariectomized rats on visceral sensory processing in the spinal cord in the absence and presence of colonic inflammation, in the following specific aims: 1) Determine the effects of estrogen on responses to transient innocuous, noxious and inflammatory colorectal stimuli. Behavioral, immunocytochemical and electrophysiological studies will test the hypothesis that estrogen facilitates responses to CRD in the absence and presence of colonic inflammation. 2) Characterize the effects of estrogen on subpopulations of visceroceptive projection neurons using retrograde tract tracing and immunocytochemical localization of Fos expression. This will test the hypothesis that estrogen alters the percentage and segmental distribution of supraspinal projection neurons that respond to CRD in the absence and presence of colonic inflammation. 3) Determine if NMDA receptor-mediated modulation of viscerosensory processing is
Studies
47
affected by ovariectomy and estrogen replacement. This will test the hypothesis that the modulation of responses to CRD by estrogen is due to altering activity at NMDA receptors. 4) Determine the mechanism(s) through which estrogen modulates CRDevoked NMDA receptor activity in the absence and presence of colonic inflammation. This will test the hypothesis that estrogen alters NMDA receptor subunit composition and/or modulates second messenger-mediated phosphorylation of tile NMDA receptor. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROIMMUNE MECHANISMS OF VISCERAL HYPERALGESIA Principal Investigator & Institution: Pezzone, Michael A.; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2001; Project Start 15-APR-1999; Project End 31-JAN-2004 Summary: The applicant for this Mentored Clinical Scientist Development Award is currently completing a Fellowship in Gastroenterology and Hepatology at the University of Pittsburgh Medical Center. During his training to obtain combined M.D. and Ph.D. degrees under the mentorship of Bruce Rabin, M.D., Ph.D., the candidate investigated extensively the neural and neuroendocrine mechanisms of stressor-induced immune alterations int he rat, focusing specifically on stress-activated CNS pathways that may modulate lymphocyte function. In these studies, the candidate identified stress-activated neurons in the rat CNS by using c-FOS expression as a marker of neuronal stimulation following acute footshock and conditioned stress. To further his career in academic medicine and to further develop his expertise in neuro-immune interactions and stress, the candidate has designed this research proposal to assess the roles of stress and intestinal inflammation in the development of visceral hyperalgesia in the gut. This model of colonic inflammation (trinitrobenzenesulfonic acid in ethanol) appears to be propagated by cells of the immune system and is subsequently modulated by stress. Understanding the pathophysiologic roles of these factors in the sensitization of gastrointestinal afferents will help further provide important information regarding the etiology and clinical course (including relapse) of painful bowel disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Methods encompassing intestinal electrophysiology, neuropharmacology, histology, and mast cell growth factors will be used to evaluate, in a hapten- induced model of colonic inflammation, the chemical dialog between afferent nerves and inflammatory/immune cells is likely to contribute to the sensitization of gastrointestinal afferents in pathological conditions such as IBS and IBD. This dialog may be modulated by activity in autonomic pathways to the gut and/or by chemicals released from the pituitary gland during stress. Combining these new skills with those previously acquired, the applicant will be well-suited to study a variety of gastrointestinal disease states in addition to characterization of the neuroimmune mechanisms of visceral hyperalgesia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEURONAL CONTROL OF INTESTINAL MOTILITY IN MUTANT MICE Principal Investigator & Institution: Heuckeroth, Robert O.; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 20-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): The proposed studies will systematically examine the cells that control intestinal motility in a panel of mutant mice created by NIH funded mouse mutagenesis projects. This will include anatomic evaluation of the enteric
48
Irritable Bowel Syndrome
nervous system, the Interstitial Cells of Cajal (intestinal pacemaker cells), and sympathetic innervation to the gut. In addition, the principal investigator will use a recently described imaging technique (diolistic labeling) to examine intestinal smooth muscle, and perform functional motility analysis in mutant mice. The long-term objective of these experiments is to identify novel mutations that affect intestinal motility. These studies are important because defects in intestinal innervation and motility cause significant morbidity and mortality. Medical problems associated with abnormal intestinal motility include Hirschsprung's disease, intestinal pseudoobstruction, and irritable bowel syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NK CELL ACTIVITY AND IBS ACROSS THE MENSTRUAL CYCLE Principal Investigator & Institution: Motzer, Sandra A.; Assistant Professor; Biobehavioral Nursing and Health Systems; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2003 Summary: The purpose of this study is to compare natural killer (NK) cell percentage and activity across the menstrual cycle in women with and without irritable bowel syndrome (IBS). NK cells are unique amongst immune cells because their percentage and activity vary in response to many emotional, cognitive and physiological stressor (e.g., anxiety, depression, perceived lack of personal control, bereavement, and exercise). Cognitive/emotional stressors are often experienced by persons with chronic health disturbances. Further, NK function many be amenable to change with interventions targeting distress in normal persons, ill persons, or their caregivers. This study will compare a sample of women with a chronic health disturbance Further, NK function may be amenable to change with interventions targeting distress in normal persons, ill persons, or their caregivers. This study will compare a sample of women with a chronic health disturbance, IBS, with control women without chronic gastrointestinal (GI) symptoms. Differences in physiological arousal and immune function will be examined within the context of menstrual cycle phase. This study is innovative in that it is designed to examine the relationship between stress-related psychological and physiological variables and immune function within the context of menstrual cycle phase in 2 groups of women, one symptomatic without an identified underlying inflammatory component but with evidence of physiological arousal (HPA axis and SNS activation) and another as control. Prior research by others has documented elevated stress hormone levels in women with IBS. Preliminary data suggest innate immune function differs in women with and without symptomatic IBS. Specific aims are to: 1) describe the levels of specific immune function markers across menstrual cycle phases, and test for cycle phase and group difference sin normally menstruating women with and without IBS; 2) extend and affirm the work of others by describing levels of stress and ovarian hormones, and self-report distress across 3 menstrual cycle phases, and by testing for cycle phase and group differences in these variables; and 3) examine the relationship of immune function to measures of physiological arousal, physical and psychological distress, and ovarian hormones during each menstrual cycle phase. Descriptive and correlational statistical and repeated measures ANOVA will be used in data analysis. If a relationship exists between chronic distress and NK cell function, there would be important clinical implications for identifying women at risk for experiencing chronic distress, and for developing and testing interventions targeting distress reduction in vulnerable populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
49
Project Title: NON-ADDICTING CANNABINOID MEDICATIONS Principal Investigator & Institution: Malan, Thomas P.; Anesthesiology; University of Arizona P O Box 3308 Tucson, Az 857223308 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-MAY-2006 Summary: (provided by applicant): As a physician, I see many patients with medical conditions for which adequate therapy is not available. CB2 cannabinoid receptorselective agonist medications may prove useful in treating some of these disease states. One is moderate-to-severe pain, where the use of opioid medications, the most effective therapy, is often limited due to concerns over addiction. In addition, opioids prescribed as analgesics are subject to diversion and abuse. We have shown that CB2 receptorselective agonists produce strong antinociceptive effects in animal models, suggesting that they may be useful as analgesic medications for humans. Unlike cannabinoids with agonist activity at CB1 receptors, CB2 receptor-selective agonists are predicted not to produce the rewarding properties associated with drug abuse, since CB2 receptors are not found in the CNS. By reducing the need for opioids, CB2 receptor-selective medications would diminish the problem of addiction with its severe individual and social costs. CB2 receptor-selective agonists, however, are likely to have important medical applications beyond analgesia. In this proposal, we hypothesize that CB2 receptor-selective agonists will be useful in the treatment of the prevalent and challenging problems of urinary incontinence; irritable bowel syndrome, inflammatory bowel disease and visceral hypersensitivity; and opioid resistant neuropathic pain. Our goal is to combine state-of-the-art chemistry and biology to develop CB2 receptorselective agonists as medications. Aim one will test the hypothesis that CB2 receptorselective agonists will have therapeutically desirable properties beyond analgesic effects. We will explore the activity of CB2 receptor-selective agonists in experimental models relevant to urinary incontinence; inflammatory bowel disease and other conditions associated with sensitization or increased activity of C-fibers. We will also test the hypothesis that CB2 receptor-selective agonists will not produce a withdrawal syndrome or provide reward. Aim two will use a lead optimization strategy to improve the medicinal properties of AM1241, our structural lead compound. This will be accomplished by a structure-activity relationship study involving the systematic manipulation of each of the molecule's pharmacophoric groups using drug design principles. Novel compounds will be evaluated for their affinity at and selectivity for CB2 cannabinoid receptors in vitro and for desired properties in vivo. The successful completion of these aims will provide physicians a therapeutic option that may provide relief for patients with difficult medical conditions and decrease the use of opioids, minimizing opportunities for abuse. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NORADRENERGIC DYSFUNCTION--A MODEL OF FIBROMYALGIA PAIN Principal Investigator & Institution: Jasmin, Luc; Neurological Surgery; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2003 Summary: The goal of this project is to develop a rat model of fibromyalgia pain which could provide the basis for future research into this complex disease. The difficulty in finding an etiology for this painful condition is in part because fibromyalgia is not a discrete or unique disease, but patients also a display number of different symptoms in addition to the widespread tenderness, including fatigue, sleep disturbances, headaches,
50
Irritable Bowel Syndrome
gastrointestinal symptoms, etc. As such, fibromyalgia overlaps conditions such as Chronic Fatigue Syndrome, Irritable Bowel Syndrome, tension and migraine headaches. These conditions share several features, including a female predominance, initiation or exacerbation in response to several different types of "stressors", and response to similar types of pharmacologic and non-pharmacologic modalities (e.g. tricyclic drugs, aerobic exercise). A dysfunction of the noradrenergic system, the basis for the proposed model, presents a unifying explanation for many seemingly disparate findings in fibromyalgia by accounting for the neuroendocrine and autonomic abnormalities, in addition to the chronic pain. Our guiding hypothesis is that in fibromyalgia, chronically decreased noradrenergic input to the spinal cord facilitates substance P release and subsequent hyperalgesia (decreased threshold for pain). This hypothesis is based on both clinical evidence of decreased noradrenaline and increased substance P in the spinal cord of fibromyalgia patients, as well as evidence from basic research demonstrating that acute decreases in spinal noradrenaline allow for greater release of substance P and sustained hyperalgesic effects of this neurotransmitter. These alterations in turn result in greater expression and redistribution of the substance P receptor in the spinal cord, contributing to the chronicity of the hyperalgesia. In the female rat, we will apply a novel technique of selective immunolesion of brainstem noradrenergic input to nociceptive areas of the spinal cord. The first aim will test the hypothesis that lowered nociceptive thresholds in rats with decreased spinal noradrenaline depend on substance P neurotransmission. This hypothesis will be tested by determining the contribution of spinal SP neurotransmission in alterations of nociceptive behavioral and neuronal responses to noxious and innocuous stimuli. The second aim will test the hypothesis that chronically decreased spinal noradrenaline chronically increases basal levels, and facilitates evoked release of substance P, by measuring levels of substance P in the CSF, primary afferent neurons, and spinal cord, both basal and following noxious and innocuous stimulation. In the third aim, we will test the hypothesis that decreased spinal noradrenaline facilitates stimulus-induced increased expression and redistribution of the substance P receptor (NK1 receptor) in the spinal cord by measuring basal and noxious stimulus-induced alterations in the expression of this receptor. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL DRUG DISCOVERY TOOLS FOR DEPRESSION AND ANXIETY Principal Investigator & Institution: Nanda, Steven A.; Promoter Neurosciences, Llc 505 S Rosa Rd, Ste 52 Madison, Wi 53719 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JAN-2004 Summary: (provided by applicant): Stress is a significant factor that can precipitate, exacerbate, and maintain psychopathology. The corticotropin-releasing factor (CRF) system has been implicated in mediating the stress response and linking it to psychopathology. Over-activity of the CRF system is implicated in depression, anxiety, and perhaps other stress-related disorders such as irritable bowel syndrome. Abundant preclinical evidence indicates that treatments targeting this system offer a promising approach for treating certain neuropsychiatric, as well as, other stress-related physical illnesses. Promoter Neuroscience (PNS) has developed intellectual property related to the promoter sequences of the CRF family of genes and is developing screening tools for drug discovery. PNS has demonstrated the feasibility of using cell cultures transiently transfected with CRF system promoter reporter constructs as high throughput screening tools. The proposed studies will further develop PNS's proprietary technologies and
Studies
51
help accelerate the discovery of compounds capable of altering expression of the CRF system. To improve this technology and to make a drug-screening tool relevant to humans, we will transfer our technology to human cortical neuronal cultures, which are derived from a brain region that naturally expresses CRF receptors and has been implicated in mediating the psychopathology. One set of cells will be transfected with constructs containing the human CRF receptor 2a (CRF2a) promoter driving expression of the Lucifer's reporter gene. Separate cortical neuronal cultures will be stably transfected with constructs containing the luciferase reporter gene under control of the human CRF receptor 1 (CRF1) promoter. Studies will characterize the basal levels of expression from the stably transfected cultures. To begin to explore potential new therapeutic approaches, expression from the stably transfected cultures will be monitored following treatment with compounds known to activate several different intracellular pathways. Activation of these intracellular pathways will lead to stimulation of transcription factors that bind to putative cis-regulatory elements identified within the CRF1 and CRF2a promoter regions. The stably transfected human cortical neuronal cultures will provide models relevant to human brain function that will provide PNS with the potential to discover new drugs that regulate CRF receptor expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ORWH: SCOR ON SEX AND GENDER FACTORS AFFECTING WOMEN'S * Principal Investigator & Institution: Greenspan, Joel D.; Associate Professor; Basic Dental Sciences; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): This multidisciplinary SCOR is devoted to the study of the mechanisms of chronic or persistent pain with specialized focus on 1) sex-related factors that influence pain, and 2) painful clinical conditions that demonstrate a high prevalence in women. The Center's research program is diverse, and ranges from molecular studies to systems physiology studies to clinical studies. Our working model is that research on pain has clearly shown that a person's sex is an important factor in determining their perception of, and response to, painful stimulation and pathological pain. Several physiological and psychological mechanisms have been proposed to account for these sex differences, yet many hypotheses remain to be adequately tested. This SCOR would direct its efforts to evaluating physiological models of sex-related pain differences, including the influence of gonadal hormones. Additionally, this Center would evaluate pathophysiological models of chronic pain conditions that are more prevalent in women, focusing on temporomandibular joint disorders (TMD) and the visceral pain associated with conditions such as irritable bowel syndrome (113S). This Center would facilitate the transfer of basic scientific knowledge to the study of persistent pain in humans, and ultimately to the development of new methods of diagnosing and treating these conditions in the general population. One clinical and two basic science projects constitute the scientific basis of the application. The two principal objectives of this SCOR are: 1) To elucidate the underlying mechanisms associated with sex differences in persistent pain of deep muscle and visceral origin. Human and animal studies will explore hypothesized physiological mechanisms of sex differences in pain, including opioid receptor expression, peripheral nociceptor sensitivity, CNS sensitization, and CNS ascending/descending modulation, as well as the influence of gonadal steroids on these mechanisms. All three projects address this objective. 2) To explore the neural basis of temporomandibular disorder (TMD) pain, with special
52
Irritable Bowel Syndrome
emphasis upon sex-related hypotheses. TMD is the major persistent orofacial pain condition of deep tissue origin. It shows a large prevalence in women of childbearing age. The pathophysiology of TMD is poorly understood, but several hypotheses based on sex-related factors have been proposed. Two of the proposed projects (#1and #3) direct efforts explicitly to evaluate such hypotheses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: P2: SEX DIFFERENCES IN THE COLONIC RESPONSES TO STRESS: ROLE OF CRF PATHWAYS Principal Investigator & Institution: Tache, Yvette F.; Professor; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: Stress is implicated as the causative or complicating factor of symptoms of several diseases including altered bowel habits and visceral hyperalgesia in Irritable Bowel Syndrome (IBS) patients. Our previous work as well as other studies show that the activation of corticotropin-releasing factor (CRY) receptors mediates various stressors-induced alterations of gut motor function and that CRF1 receptor is mostly involved in the colonic response. Recent evidence also suggests a role of this pathway in stress-relatcd colonic hypersensitivity to colorectal distention. Despite the greater prevalence of stress-related IBS symptoms in women, most of the experimental knowledge of the effects and mechanisms of stress on gut motor alterations and visceral hyperalgesia derives from studies performed in male rodents. The overall goal of the proposal is to characterize the neuroanatomical and biochemical substrata underlying for sex-related differences in stress-induced colonic responses (motility and visceral pain) in rats. Based on presence of estrogen responsive elements on the CRF gene and its modulation by estrogen in the hypothalamus, we will test the hypothesis that estrogeninduced modulation of CRF signaling pathways contributes to the enhanced colonic responses of female rodents to stress. In the specific aim 1, we will build on our data preliminary data and characterizes sex-related differences in stress-induced colonic motor activation and visceral hyperalgesia using psychological and visceral stressors in model of IBS. We will assess with the newly developed CRF1 and CRF2 selective receptor antagonists the role of activation of CRF receptors in stress-related colonic responses in female rats and modulation by sex hormones. In specific aim 2, we will define the sex-related differential activation of brain, spinal and enteric circuitry induced by stress, particularly at neuronal sites involved in autonomic and pain modulation and known to express estrogen receptors using Fos expression as a marker of neuronal activation. Double labeling will be used to identify the presence of estrogen receptors and identified CRF and/or oxytocin and noradrenergic neurons. Specific Aim 3 will determine the modulation of CRF and CRF1 gene transcription by estrogen at specific sites involved in the colonic responses to stress. The regulation of rat and human CRF and CRF1 receptor promoter activity by estrogens will be further investigated in naive and transfected cells. These studies using functional, neuroanatomical, neurochemical and molecular approaches in rodent model will provide new insight on the interactions between estrogens and CRF pathways as it relates to the visceral response to stress and the underlying mechanisms at the levels of gene regulation and will have relevance to the pathophysiology of stress-related exacerbation of IBS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: P3: SEX DIFFERENCES IMMUNOLOGIC RESPONSES IN IBS
IN
NEUROENDOCRINE
53
AND
Principal Investigator & Institution: Chang, Lin; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: Studies support a prominent role of stress in irritable bowel syndrome (IBS). The principal branches of the general stress response are the hypothalamic-pituitaryadrenal (HPA)axis and the sympathetic nervous system (SNS). The overall hypothesis of this Project is that females and males differ in their HPA axis responsiveness and SNS activation, particularly under stress conditions, and that these differences will help explain the greater vulnerability of females to develop chronic stress-related conditions such as IBS. Furthermore, these sex-related differences in the HPA and SNS are reflected in differences in colonic mucosal immune modulation which in turn relates to the higher prevalence of colonic visceral hypersensitivity in female IBS patients. We will study four subject groups: female IBS patients, male IBS patients, female controls and male controls. In Aim 1, we will test the hypothesis that under basal conditions, males have greater HPA (ACTH, cortisol) and general SNS (cardiosympathetic and sympathoadrenal) activity but females may have greater SNS activity to the pelvic organs. Specifically, we will compare HPA responsiveness in males and females using HPA axis challenge tests, biomathematical modeling analysis to characterize the diurnal rhythm of ACTH and cortisol, and estimate chronically enhanced SNS output to the colon by measuring tissue NE levels and alpha 2-receptor density in colonic biopsies. In Aim 2, we will test the hypothesis that under stress conditions, males show greater general measures of plasma HPA (ACTH, cortisol) and SNS activity (cardiosympathetic, catecholamines and skin conductance) responses to a visceral stressor (flexible sigmoidoscopy) and a psychological stressor (Trier social stress test) compared to females. In Aim 3, we :will test the hypothesis that symptomatic IBS patients have: altered plasma and mucosal cytokine production which differ in females and males and are related to sex-related differences in visceral pain perception. We will measure plasma and colonic mucosal cytokine markers, and perceptual responses to rectal balloon distension to determine if visceral sensitivity is associated with mucosal and plasma immune markers. The combination of experimental approaches should improve our understanding of the sex-related differences in stress response mechanisms underlying functional pain syndromes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: P4: SEX DIFFERENCES IN CRF, NORADRENERGIC FUNCTION AND OXYTOCIN IN CATS WITH IC Principal Investigator & Institution: Buffington, Charles A.; Professor; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: The long-term goal is to exploit a naturally occurring bladder disease in domestic cats (Feline Interstitial Cystitis - FIC) to gain a better understanding of a painful bladder disorder in humans called interstitial cystitis (IC), and by extension other pelvic pain syndromes. This is because many patients with IC also have IBS and other neurovisceral disorders that predominantly affect women, and appear to be exacerbated by stress. The studies proposed here are designed to further investigate the causes of these neurological alterations in controlled studies of cats diagnosed with IC and healthy cats. The studies are needed to elucidate the significance of the underlying
54
Irritable Bowel Syndrome
neurological abnormalities present in human patients with IC. They also are intended to guide the choice of subsequent studies toward the primary systems involved in IC, with the eventual goal of identifying rational treatments of IC in human beings. The overall objective of this proposal is to test the hypothesis that interactions between CRF, sex hormones and the alpha-2 adrenoceptor (alpha2-AR) play a role in the sex difference in stress-responsiveness of cats with FIC. The rationale for the proposal is based on 1) clinical evidence that females are more prone to develop IC than males (intact males in cats), 2) the gap in knowledge in factors that may account for such sex differences due to the paucity of experimental data in this field, 3) evidence from our recent studies pointing to a role of alpha2-AR dysfunction in cats with IC, and 4) existing evidence that urothelial and alpha2-AR function can be modulated by testosterone, estrogen, and oxytocin. By studying a natural occurring animal model of IC which shares many features with a rat model of IBS, and with the respective human patient populations, we will be able to assess the role of sex hormones on the expression of these diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POPULATION BASED TWIN STUDY OF CHRONIC FATIGUE SYNDROMEN Principal Investigator & Institution: Sullivan, Patrick F.; Associate Professor; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2001 Summary: Despite considerable research, fundamental questions about CFS-like illness remain at best partially answered. These questions include its definition, validity, the degree to which it results from genetic versus environmental factors, and the nature of the substantial comorbidity observed with other conditions. The overarching aim of this Project is to shed light on a number of basic questions about CFS via a large populationbased classical twin study. First, we will screen approximately 13,000 same-sex twin pairs who are members of the Mid-Atlantic Twin Registry for the lifetime presence of CFS-like illness (and several overlapping conditions such as fibromyalgia and major depression). Second, all twins who screen positive and a subset of twins who screen negative will be directly and blindly interviewed. The interviews will collect information about CFS symptoms, psychiatric disorders, stress life events, and medical history, and medical history. We will obtain additional standardized medical data via the subject's physician(s). Third, all screening, direct interview and medical data will be independently reviewed by three of the study investigators to determine the certainty than an individual meets criteria for "presumptive CFS" plus approximations of the Centers for Disease Control, British, and Australian CFS case definitions. Obtaining these unique data will allow us to address a set of critical questions regarding CFS-like illness. First, using the direct interview data will allow us to address a set of critical questions regarding CFS-like illness. First, using the direct interview data, we will use multivariate techniques to derive and empirical typology of prolonged fatigue and to assess how this typology compares to the major CFS case definitions to answer the question: "Is there a point of rarity that distinguishes the common symptom of fatigue from case definitions of CFS"? Next, we will quantify the role of genetic predisposition and environmental sources of variation from different definitions of CFS-like illness. This will allow us to address 2 important questions. Because the degree to which a complex and idiopathic condition is heritable is an important validator, we can address the question: "Do these definitions yield similar or different estimates of heritability?" In addition, examining the extent to which liability to CFS- like illness is due to additive genetic, shared environmental, and individual-specific environmental precipitating
Studies
55
effects will yield glimpses into the fundamental nature of CFS. Finally, using multivariate twin analyses, we address the question: "To what extent to the genetic and environmental sources of variation of these other conditions overlap with CFS?" Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRESYNAPTIC MECHANISMS IN THE INTESTINE Principal Investigator & Institution: Galligan, James J.; Professor; Pharmacology and Toxicology; Michigan State University 301 Administration Bldg East Lansing, Mi 48824 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 30-JUN-2004 Summary: Presynaptic mechanisms are an important means for neurotransmitters, hormones, paracrine substances and drugs to modulate the activity of myenteric nerves and gut motility. Despite the clear importance of presynaptic mechanisms in regulating neurotransmission in the myenteric plexus, little is known about the details of these mechanisms. The proposed studies are designed to characterize these mechanisms. Electrophysiological methods will be used to study excitatory synaptic transmission between myenteric neurons in acutely isolated preparations of guinea pig intestine and between guinea pig myenteric neurons maintained under tissue culture conditions. These studies will investigate the contributions of acetylcholine (ACh) acting at nicotinic cholinergic receptors and ATP acting at P2X purine receptors, to fast excitatory synaptic potentials (fEPSPs) during long trains of stimulation. As nicotinic receptors desensitize quickly, it is anticipated that ACh will be the predominate transmitter early while ATP will predominate later in the train of activity. Presynaptic mechanisms controlling the release of these two important transmitters will also be investigated. These studies will focus on channels which provide the calcium needed for transmitter release and the presynaptic receptors which facilitate their release. The facilitatory effects of 5-HT4 receptor activation on fEPSPs mediated by ACh and ATP will be investigated. In addition, these studies will investigate the contribution of 5-HT3 and 5-HT4 receptors to excitation of enteric sensory nerve terminals. The role of presynaptic nicotinic acetylcholine receptors (nAChRs) in controlling the release of the slow synaptic transmitters, substance P/neurokinin A will also be investigated. These latter studies will attempt to establish that there are presynaptic nAChRs on the terminals of sensory neurons and that ACh released from sensory neurons facilitates SP/NKA release and enhances slow excitatory synaptic transmission. There are many disorders of gut motility which have their basis either directly or indirectly in alterations in enteric neurotransmission. These disorders include gastroesophageal reflux disease, the irritable bowel syndrome and chronic intestinal pseudo-obstruction. It is anticipated that these studies will provide new insights into mechanisms of synaptic transmission in the gut which could lead to the development of new and effect drug treatments for motility disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PSYCHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROMEN Principal Investigator & Institution: Whitehead, William E.; Professor of Medicine; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2001; Project Start 01-JUL-1993; Project End 30-NOV-2002 Summary: The irritable bowel syndrome (IBS), which is characterized by abdominal pain and altered bowel habits, is the most common gastrointestinal disorder, affecting 9.4 percent of the population. Fifty to 60 percent of IBS patients report pain at
56
Irritable Bowel Syndrome
abnormally low volumes of rectal distention, suggesting that visceral hyperalgesia may be the mechanism for IBS. A cognitive behavioral model is presented which accounts for increased pain sensitivity in IBS by two hypotheses: (1) Two cognitive traits--selective attention on gastrointestinal sensations and attribution of disease significance to these sensations--are the mechanisms by which stress and other factors influence pain perception. (2) Childhood social learning in the form of increased attention for somatic complaints and modeling of sick role behavior by parents, is the most important determinant of selective attention and disease attribution. The differential recall of previously memorized words, depending on their content, will be used to develop a test for selective attention. Words describing gastrointestinal sensations plus control words describing respiratory sensations and neutral words will be tested for a prior probability of recall by healthy subjects. Then IBS patients, patients with lactose malabsorption (an enzyme deficiency producing chronic gastrointestinal symptoms similar to IBS), patients with asthma, and healthy controls will memorize these words, and 15 minutes later will be tested for recall. Other techniques for assessing selective attention which will be compared to the recall task are the Stroop Color Test and recognition of words in the above categories presented briefly by a tachistoscope. The test of disease attribution will be developed by presenting the same gastrointestinal and respiratory sensations and asking subjects to rate whether they could be symptoms of disease. After developing valid and reliable measures, new samples of IBS patients, lactose intolerant patients, and controls will complete these tests of reinforcement and modeling of gastrointestinalrelated sick role behavior and tests of rectal distention pain thresholds. A subsequent study will determine whether experimental stress increases pain sensitivity and progressive muscle relaxation decreases pain sensitivity in IBS patients, and whether these psychological influences on perceptions are associated with changes in selective attention to gastrointestinal sensations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECURRENT ABDOMINAL PAIN IN CHILDREN Principal Investigator & Institution: Shulman, Robert; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 30-APR-2007 Summary: (provided by applicant) Ten to 17 percent of children between the ages of 4 and 16 years meet the criteria for recurrent abdominal pain (RAP) a condition that accounts for at least 5 percent of all pediatric office visits and often leads to significant disability (e.g., school absence). From 30-60 percent of children with RAP will go on to experience similar pain as adults leading to the suggestion that RAP and irritable bowel syndrome (IBS) may be the same syndrome at different developmental stages. Similar to IBS, 20-68 percent of children reporting abdominal pain also experience alterations in bowel patterns (constipation and/or diarrhea). Although the cause(s) of RAP (as well as IBS) are unknown, factors contributing to the symptom experience, including health care seeking, are likely to include both physiological and psychosocial. The relationships among physiologic abnormalities, psychological makeup, and parental responses/behaviors in RAP are largely unexplored (undefined). To study the contributions of these sets of factors and their potential interplay, we propose to compare three groups of children: those with RAP who are referred to tertiary medical attention (RAP-GI); who have RAP but do not seek medical attention beyond their pediatrician (RAP-Ped); and those who do not have RAP symptoms (Controls). Our Specific Aims are to describe and compare among these children (ages 7-10): 1) GI symptoms (abdominal pain and bowel patterns) and functional disability (pain
Studies
57
interfering with activity, school absences) using retrospective and prospective symptom measures; 2) autonomic nervous system function (spectral and non-spectral analysis of heart rate variability and urine catecholamines); 3) child and parent pain coping skills, parent modeling and reinforcement of illness behavior; and 4) psychological distress (anxiety, depression, and somatization). Children will be recruited from pediatric practices in Houston. This proposed interdisciplinary study will be the first in children to examine concurrently both physiologic and psychosocial factors related to RAP, and its functional consequences, and to compare these to a sample of children with RAP who do not seek tertiary medical attention. Because so many children with RAP are identified as having IBS when they reach adulthood, this study may provide insight into the developmental progression of this disorder. These data could be used to develop guidelines for use by health care providers to intervene early with children who have this common complaint in order to prevent health care seeking behavior with its attendant financial and emotional cost. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF IMMUNOSUPPRESSIVE MOLECULES IN IBD Principal Investigator & Institution: Jobin, Christian; Assistant Professor; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2003; Project Start 30-SEP-1993; Project End 30-JUN-2008 Summary: (provided by applicant): A single layer of intestinal epithelial cells (IEC) protects the host from the toxic luminal environment. These cells are in close proximity with lamina propria immune cells and likely communicate with each other by direct contact and/or secretion of soluble mediators. Interestingly, the mucosa of the distal ileum and colon is constantly exposed to a complex microbial flora, yet no pathological inflammation occurs in normal hosts. This suggests that IEC gene expression must be tightly regulated to avoid overreaction to ubiquitous luminal bacterial products, yet be able to transiently respond to environmental pathogens. Although the repertoire of proinflammatory molecules synthesized by IEC has been identified, little is known about how these cells regulate coordinated expression and suppression of these genes. In addition, the intracellular signaling pathways associated with IEC gene expression are still poorly understood. Finally, the kinetics and distribution of NF-kappaB-activated cells during the course of an intestinal inflammatory process is currently unclear, much less during treatment intervention. We have shown that the NF-kappaB pathway regulates expression of a number of proinflammatory cytokines and adhesion molecules in IEC. Interestingly, native IEC and most transformed colonic cell lines show a unique IkappaBa phosphorylation and degradation process that distinguishes these cells from other cell lineages. Our hypothesis is that normal lEC have a unique NF-kappaB signaling pathway which buffers their cellular responses to the aggressive luminal environment. This hypothesis will be tested by addressing the following SPECIFIC AIMS: 1) Dissect the unique IkappaB/NF-kappaB signal transduction in transformed and native IEC following stimulation with environmentally relevant cytokines and commensal bacteria and explore mechanisms of suppression of this pathway by TGFbeta 2) Determine the physiological role of NF-kappaB in acute and chronic intestinal inflammation and tissue repair by using kappaB-green fluorescence protein transgenic mice with experimental colitis in combination with selective inhibition of the NF-kappaB pathway. Our ultimate goal is to prevent the onset and relapse of inflammatory bowel diseases (IBD) by manipulating key regulatory signaling proteins involved in central inflammatory pathways.
58
Irritable Bowel Syndrome
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RISK FACTORS FOR ENDOMETRIOSIS Principal Investigator & Institution: Hunter, David J.; Director; Epidemiology; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 03-AUG-2001; Project End 31-JUL-2003 Summary: (provided by applicant): Endometriosis, the third leading cause of gynecologic hospitalization in the United States, remains one of the most enigmatic gynecologic pathologies. Endometriosis is defined as the presence of endometrial tissue outside of the uterine cavity. These implants respond to the hormonal cues of the menstrual cycle and "bleed" as they would in the uterus. The consequence is the development of adhesions, scarring, and painful inflammation. Signs and symptoms include dysmenorrhea, dyspareunia, infertility, dysuria, and irritable bowel syndrome.The effects of the disease can be physically and mentally debilitating with frequent misdiagnoses and poor treatment options. Its prevalence among U.S. women has been estimated to be approximately 10%, [the] time from onset of symptoms to laparoscopically confirmed diagnosis is estimated to average between 6 and 11 years. To date, the etiology of endometriosis remains unknown and few epidemiologic studies exist. Using data on 2,690 laparoscopically confirmed incident cases of endometriosis collected from the Nurses' Health Study II, an ongoing, prospective cohort study that began in 1989, the applicant proposes a study to assess the following hypotheses: a) Women with menstrual characteristics of younger age at menarche, longer time to menstrual regularity, or shorter menstrual cycle length are at higher risk of endometriosis. b) Women with a low waist-to-hip ratio are a higher risk of endometriosis. c) Women with a higher body mass index at age 18 are at lower risk of endometriosis. d)Women who were born with a greater birthweight are at higher risk of endometriosis. All analyses will control for other known and suggested risk factors for endometriosis such as oral contraceptive use and cigarette smoking. The applicant will have more than 90% power to evaluate the above hypotheses. These analyses will be the first prospective data with adequate power to evaluate this important and understudied cause of morbidity among premenopausal women. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SELECTIVE CRF ANTAGONISTS FOR BOWEL DISORDERS Principal Investigator & Institution: Grigoriadis, Dimitri E.; Neurocrine Biosciences, Inc. 10555 Science Center Dr San Diego, Ca 921211100 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 01-MAY-2003 Summary: (Applicant's abstract): Corticotropin releasing factor (CRF) controls the anterior pituitary secretion of adrenocorticotropin and other propiomelanocortin products. CRF also coordinates the endocrine, behavioral and autonomic responses to stress. The long-term objectives of this proposal are to establish that selective corticotrophin releasing factor receptor subtype 1 (CRF1) antagonists will have therapeutic implications in irritable bowel syndrome (IBS) characterized by altered bowel movement and visceral hypersensitivity. The specific aims will be: 1) to demonstrate specific tissue localization of CRF1 receptors in the colon; 2) to identify and synthesize centrally acting vs. peripherally acting high affinity CRF1 receptor nonpeptide antagonists; and 3) to examine both centrally acting and peripherally acting CRF1 antagonists in models of stress-related colonic motor stimulation and visceral hypersensitivity in rodents for potential utility in IBS. This will be achieved using novel
Studies
59
tools including C-terminal CRF1 receptor antibodies, selective CRF1 receptor antagonists and experimental models to assess distal colonic motor function and visceromotor response to colorectal distension. Based on the co-morbidity between anxiety/depression and IBS and stress-related onset or enhanced IBS symptomatology, these pre-clinical studies will provide the key information needed to pursue a novel therapeutic approach for IBS using Neurocrine CRF1 receptor antagonists and to further develop this therapeutic approach in Phase II studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEX DIFFERENCES IN VISCERAL PAIN: INFLUENCE OF GONADAL STEROIDS Principal Investigator & Institution: Murhpy, Anne Z.; Univ of Maryland, Baltimore Baltimore, Md Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: Irritable bowel syndrome (IBS), a common gastrointestinal disorder characterized by abdominal pain and a change in bowel habits, will affect up to 20% of the general population. Epidemiological studies have established that females are 2-5x more likely to suffer from IBS in comparison to males. A defining characteristic of IBS is severe gastrointestinal pain. Surprisingly, while an extensive body of research has been conducted examining the neural mechanisms underlying visceral pain, these studies have been conducted exclusively in males. Thus, it is not known how visceroceptive information is processed within the CNS of females. Similarly, the impact of gonadal steroids on visceral pain is also not known. Behavioral studies in Aim 1 will characterize the sex differences and influence of gonadal steroids on visceral pain. Our preliminary data indicate that there are profound sex differences in the visceral motor reflex, an indicator of visceral pain following noxious colorectal distention. Our data further show that the sexually dimorphic response to noxious visceral stimulation is estrogen dependent. Anatomical studies proposed in Aim 2 will test the hypothesis that sex differences in the organization and activation of the spinoparabrachial circuit provide the anatomical substrate for the dimorphic response to noxious visceral stimulation. Studies using acute somatic stimuli have reported that morphine produces a significantly greater degree of analgesia in males versus females, and our preliminary studies indicate that morphine alleviation of visceral pain is also sexually dimorphic. Studies proposed in Aim 3 will test the hypothesis that morphine produces a significantly greater degree of analgesia in males in comparison to females in a model of visceral pain. Immunocytochemical and molecular studies proposed in Aim 4 will test the hypothesis that opioid receptor expression within the lumbosacral spinal cord is sexually dimorphic. The influence of gonadal steroids on opioid receptor expression will also be examined. Together, these studies will begin to elucidate the neural mechanisms underlying sex differences in visceral pain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SLOWING OF TRANSIT - THE THIRD ENTERIC FUNCTION OF 5HT Principal Investigator & Institution: Lin, Henry C.; Director Gastrointestinal Motility Progr; Cedars-Sinai Medical Center Box 48750, 8700 Beverly Blvd Los Angeles, Ca 90048 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): In order to optimize nutrition, the movement of a meal through the small intestine must be precisely controlled to ensure that there is
60
Irritable Bowel Syndrome
adequate time to complete the time-demanding steps of digestion and absorption. Abdominal pain, nausea, bloating, diarrhea and malnutrition are the consequences of impaired control of intestinal transit. After a fat-containing meal, inhibitory feedback mechanisms are activated by the proximal and distal small intestine as the jejunal and ileal brake, respectively. In contrast to this focus of the postprandial gut to slow transit, much of the research efforts over the past 100 years have been directed at the peristaltic reflex, which is responsible for the acceleration of intestinal transit and are known to be mediated by 5-HT. Currently, two roles of enteric 5-HT have been established: the triggering of the peristaltic and mucosal secretory reflexes via intrinsic primary afferent neurons and gut-to-CNS and gut-to-pancreas communications via extrinsic sensory nerves. We have recently found a third role of enteric 5-HT. Specifically, 5-HT is also involved in the slowing of transit by fat via a 5-HT3 pathway that is dependent on 5-HT transmission via myenteric neurons. In this proposal, we will test our overall hypothesis that slowing of intestinal transit by fat depends on primary afferent nerves, betaadrenergic pathway and 5-HT transmission via myenteric neurons, which in turn activates opioid neurons, that slow transit. We will test the hypotheses using pharmacologic and physiologic approaches. The results of these studies will help us to refine our hypotheses so that we can test the neuroanatomic components of this pathway using immunohistochemistry. We have developed a collaboration with 2 leading neuroscientists who will provide this project with additional expertise in immunohistochemistry. In addition, to test the role of a novel beta-adrenergic system in the slowing of intestinal transit by fat, we have developed a multi-disciplinary team approach by including a cardiologist experienced in the 13- adrenergic system. The PI has a track record of success in bench-to-bedside translational research in the area of nutrient control of intestinal transit. His experience includes the discovery of a novel, nutrient-based strategy to slow intestinal transit. This application will bring this new treatment back to basic research so that we can understand the neural pathways that underpin the slowing response to fat. The hypotheses to be tested in this project will expand our understanding of a new role for enteric 5-HT which may explain conditions such as irritable bowel syndrome and provide better understanding of the effects of drugs that are directed at 5-HT pathways. In addition, by investigating the mediators of the control of intestinal transit, we will gain knowledge that can be used to control the movement of a meal through the small intestine and, in turn, reduce symptoms and improve nutrition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPATIAL AND TEMPORAL CHARACTERISTICS OF CENTRAL PAIN SE Principal Investigator & Institution: Mauderli, Andre P.; Prosthodontics; University of Florida Gainesville, Fl 32611 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 31-MAY-2007 Summary: (provided by the applicant): Prolonged pain appears to have the potential to modulate its own intensity through positive and negative feedback (central sensitization by pain, pain inhibition by pain). If the feedback is positive, the result is a vicious pain cycle and a progressive increase in pain sensitivity. Increased pain sensitivity means that a given stimulus is perceived as more painful (hyperalgesia), or - in more extreme cases - that a previously non-painful stimulus becomes painful (allodynia). The vicious cycle may lead to sensitization beyond the topographical boundaries of the original pain, and thus it may render remote body regions more pain-prone. The result may be a snowball effect of progressive expansion of the painful area. There is evidence suggesting that the
Studies
61
vicious cycle may be a pathophysiological factor in certain chronic pain diseases, including fibromyalgia syndrome (FMS), myofascial pain syndrome (MPS), and irritable bowel syndrome (IBS). This research is guided by 4 questions: 1) Does the intensity and duration of a persistent pain have an effect on how pain sensitivity changes over time? 2) Does the sensitizing effect of pain signals reach beyond the topographical location of the original pain focus? 3) Is it possible to interrupt the vicious pain cycle and allow the sensitized state to return to normal by temporarily silencing the local pain focus that presumably started the cycle? 4) Does the maintenance of the sensitized state depend on central NMDA receptor function, molecular constituents known to play a role in temporal integration of pain stimuli and other memory systems? The subjects in this study will be asked to rate pain intensities by setting the slider on an electronic visual analog scale. Novel methodology will be used for probing the temporal and spatial response properties of central pain modulation with experimental pain with prolonged series of thermal pulses. The effect of silencing clinical pain foci with transdermally delivered local anesthetics on thermallyinduced sensitization will be studied. The importance of NMDA receptor systems in the maintenance of a sensitized state will be assessed by measuring pain sensitization properties before and after pharmacologically blocking them. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE FUNCTION RELATIONSHIP OF MUSCARINIC TOXIN MT-7 Principal Investigator & Institution: Baksi, Krishna; Universidad Central Del Caribe Bayamon, Pr 009606032 Timing: Fiscal Year 2002; Project Start 01-AUG-1994; Project End 31-DEC-2005 Summary: Muscarinic acetylcholine receptors (mAChRs) are coupled to G-proteins and activate different second messengers and ion channels. Currently, there are five subtypes of mAChRs (M1 to M5) which are differentially distributed throughout the body. mAChRs are involved in a variety of disorders such as irritable bowel syndrome, asthma, glaucoma, cardiac arrhythmia, Parkinson's disease (PD), and Alzheimer's disease (AD). To date, the study of functions and characterization of subtypes of mAChRs are hampered due to lack of highly selective agonists and antagonists. Several toxins which recognize the mAChRs have been purified and sequenced from the venom of mamba snakes of the genus Dendroaspis. The sequences of the toxins are homologous, but their mode of action and selectivity for mAChR subtypes are different. For example, MT-7 is specific only for M1 receptors, whereas MT-3 toxin shows high affinity for M4 receptors, and low affinity for M1 receptors. The structure- activity relationship of MT-7 toxin, therefore, needed to establish the essential amino acid residues responsible for its binding to the M1 receptor to display its functions clearly. Biologically active recombinant MT-7 (rMT-7) toxin is available for such studies. The hypothesis of this proposal is that the functional site of MT-7 toxin requires multiple amino acid residues studies. The hypothesis of this proposal is that the functional site of MT-7 toxin requires multiple amino acid residues which are present in all the three loops of the toxin for its subtype specificity as well as for its action as antagonist. I, therefore propose to study the interaction of MT-7 toxin to M1 receptor, and the Specific Aims of my proposal are. SPECIFIC AIM 1: Production of MT7/MT3 chimeras and MT7M analogues. SPECIFIC AIM 2: Structure function relationship. SPECIFIC AIM 3: The mode of interaction of MT7/MT3chimeras/MT-7 analogues with M1 receptors. The completion of this study will lead us to establish the critical amino acid residues responsible for MT-7 toxin's binding to its receptor, and will also establish the specific
62
Irritable Bowel Syndrome
amino acid residues responsible for MT-7 toxin's subtype specificity. The results will help to design therapeutic agents for different disorders involving mAChRs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE EFFICACY OF REIKI IN THE TREATMENT OF FIBROMYALGIA Principal Investigator & Institution: Assefi, Nassim P.; Women's Health Specialist; Medicine; University of Washington Seattle, Wa 98195 Timing: Fiscal Year 2002; Project Start 15-APR-2002; Project End 28-FEB-2004 Summary: (provided by applicant): Fibromyalgia (FM), one of the most common rheumatologic diagnoses, is a condition of unknown etiology characterized by widespread muscle pain and stiffness, accompanied by a variety of other symptoms including sleep disturbance, headaches, irritable bowel syndrome, and psychological distress. Treatment is generally unsatisfactory and most randomized, controlled treatment trials have been unable to demonstrate a sustained effective intervention. Thus, it is not surprising that the vast majority of FM patients have tried complementary and alternative medicine (CAM) therapies. Reiki is a form of energy medicine in which practitioners reportedly access universal life energy to heal patients, either by direct contact at specific hand positions or from a distance. A vast body of anecdotal literature as well as 2 randomized controlled trials suggest that Reiki may be an effective treatment for FM, appearing to relieve pain and improve psychological well being. In addition, it appears to have no adverse effects and can eventually be self-administered, making it a low-risk, low-cost, potentially patient-empowering intervention. This study will investigate the efficacy of Reiki in the treatment of FM. 100 Reiki-naive FM patients will be recruited from a chronic fatigue referral clinic, and will undergo an 8-week, biweekly (16 treatments) trial. Patients will be randomized into 2 Reiki groups (directcontact and distant Reiki) and 2 control (sham and placebo) groups. The sham Reiki practitioners will be professional actors who resemble the true Reiki practitioners but have no experience with health care or healing arts and are taught to mimic the Reiki Masters' verbal and physical interactions with the patients, while distracting whatever healing intention they may possess by doing mental arithmetic. The specific aims of this study are: 1) to evaluate the short and long-term efficacy and safety of an 8-week placebo-controlled randomized trial of both direct-contact and distant Reiki in the treatment of FM; 2) establish carefully constructed control groups for their feasibility and scientific usefulness for future trials of Reiki and other types of energy medicine; and 3) to collect pilot data for larger trials on the mechanism, safety, and duration of clinical and subjective effects of Reiki. Patients will be assessed at enrollment, 4 and 8 weeks during treatment and 12 weeks post-treatment. Our primary outcomes will be patient global assessment, subjective pain and mean number of tender points. Secondary outcomes will include pain threshold, sleep, fatigue, and psychological indicators. This pilot study could potentially impact the clinical care of the estimated 6 million Americans with FM, and shape the design of future larger, randomized, placebocontrolled trials of Reiki and other energy therapies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TREATMENT OF FEAR AND PAIN IN IRRITABLE BOWEL SYNDROMEN Principal Investigator & Institution: Naliboff, Bruce D.; Clinical Professor; Brentwood Biomedical Research Institute Bldg. 114, Room 218 Los Angeles, Ca 90073 Timing: Fiscal Year 2002; Project Start 06-SEP-2002; Project End 31-MAY-2007
Studies
63
Summary: (provided by applicant) Irritable Bowel Syndrome (IBS) is the most common of the functional gastrointestinal disorders with primary symptoms of chronic abdominal pain or discomfort associated with altered bowel habits. IBS is characterized by stress-related symptom exacerbations and a high co-morbidity with affective disorders, in particular, anxiety. The current proposal is based on a disease model of IBS that emphasizes enhanced responsiveness and conditioning of stress and fear circuits in the central nervous system, and associated hypervigilance, stress-induced hyperalgesia, and altered autonomic responses to visceral sensation. Based on this model and the highly successful exposure treatments now used for anxiety disorders, we have designed and successfully piloted a unique cognitive behavioral treatment (CBT) for IBS. Traditional CBT treatments focus on decreasing general stress responses and increasing coping skills for life stress, and have shown only modest efficacy in IBS. We hypothesize that IBS symptoms can be more effectively treated by specifically changing responses to visceral sensations through decreasing interoceptive conditioned responses, and directing attention away from visceral stimuli. If our hypotheses are correct, we expect to see greater symptom improvements as well as normalization of altered physiological responses following this new CBT approach. We propose to address the following specific aims: 1) Do subjective outcomes differ between the two cognitive behavioral interventions with and without interoceptive exposure and directed attention, and an attention control treatment? 2) Are differential treatment responses accompanied by changes in perceptual and autonomic responses to visceral stimuli? And 3) Are differential treatment responses accompanied by normalization of altered regional brain activation in response to visceral stimuli? In separate studies we will compare CBT with interoceptive exposure and directed attention to tradition CBT (and a control condition) on outcome measures of symptom reduction, beliefs, visceral sensitivity (pain, discomfort, and fear responses to balloon distension), and central responses to visceral stimulation using functional magnetic resonance imaging (fMRI). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: WOMEN'S HEALTH AND FUNCTIONAL VISCERAL DISORDERS CENTER Principal Investigator & Institution: Mayer, Emeran A.; Microbiology and Immunology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The Women's Health and Functional Visceral Disorders Center is composed of a cohesive group of clinical investigators and basic scientists with strong independent grant-supported research programs in the interactions between the nervous system and the viscera, with special emphasis on stress neurobiology, sex differences and chronic functional disorders. The main focus of the Center is the identification of sex-related factors that play a role in the development, clinical manifestation and treatment response of two common visceral pain syndromes, e.g. Irritable Bowel Syndrome (IBS) and Interstitial Cystitis (IC). Both disorders are common, occur more commonly in females, appear to show sex differences in treatment responses and cause significant morbidity and impairment in quality of life. The Center has two clinical and two basic science Projects, which closely interdigitate and overlap in terms of thematic, experimental approach and hypotheses. Thus, while the clinical Projects study sex differences in central stress circuit activation and peripheral outputs of these circuits in human patients with IBS and IC, the two basic Projects study animal models of both disorders. State of the art technology ranging from molecular biological
64
Irritable Bowel Syndrome
approaches to functional brain imaging techniques will be used to address the following specific aims in the four Projects: 1. Sex Differences in Central Stress Circuit Responsiveness in IBS and IC patients 2. Sex differences in the colonic responses to stress: Role of CRF pathways 3. Sex differences in neuroendocrine and immunologic responses in IBS 4. Sex differences in CRF, noradrenergic function and oxytocin in cats with IC. To facilitate the research, the Center has an Administrative Core and a Scientific Core (Neuroendocrine Measures) and will take advantage of existing NIH-funded core and service facilities on campus, including the CURE: Digestive Diseases Research Center, the UCLA Brain Mapping Center and the GCRC. The Center provides an optimal environment for cooperation and collaboration among its investigators, who already have had a major impact on the field individually. Thus, the synergy expected from the Center promises to have an even larger impact upon expanded research into a highly prevalent, but inadequately treated area of women's health. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “irritable bowel syndrome” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for irritable bowel syndrome in the PubMed Central database: •
Do published guidelines for evaluation of Irritable Bowel Syndrome reflect practice? by Yawn BP, Lydick E, Locke GR, Wollan PC, Bertram SL, Kurland MJ.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59674
•
Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. by Rodriguez LA, Ruigomez A.; 1999 Feb 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27756
•
Irritable bowel syndrome: Could it be celiac disease? by Hoey J.; 2002 Feb 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99362
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print. 6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text
Studies
65
The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with irritable bowel syndrome, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “irritable bowel syndrome” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for irritable bowel syndrome (hyperlinks lead to article summaries): •
A population study on irritable bowel syndrome and mental health. Author(s): Osterberg E, Blomquist L, Krakau I, Weinryb RM, Asberg M, Hultcrantz R. Source: Scandinavian Journal of Gastroenterology. 2000 March; 35(3): 264-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10766319&dopt=Abstract
•
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Author(s): Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. Source: Alimentary Pharmacology & Therapeutics. 2003 April 1; 17(7): 895-904. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12656692&dopt=Abstract
•
A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Author(s): Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. Source: The American Journal of Gastroenterology. 2003 October; 98(10): 2209-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14572570&dopt=Abstract
•
A systematic review of tegaserod for the treatment of irritable bowel syndrome. Author(s): Bergmann K. Source: Journal of Clinical Pharmacy and Therapeutics. 2003 April; 28(2): 151-3; Author Reply 153. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12713613&dopt=Abstract
•
Abnormalities of left colonic motility in ambulant nonconstipated patients with irritable bowel syndrome. Author(s): Clemens CH, Samsom M, Van Berge Henegouwen GP, Smout AJ. Source: Digestive Diseases and Sciences. 2003 January; 48(1): 74-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645793&dopt=Abstract
journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
66
Irritable Bowel Syndrome
•
Abuse, dissociation, and somatization in irritable bowel syndrome: towards an explanatory model. Author(s): Salmon P, Skaife K, Rhodes J. Source: Journal of Behavioral Medicine. 2003 February; 26(1): 1-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690943&dopt=Abstract
•
Alosetron approved for treatment of irritable bowel syndrome. Author(s): Miller JL. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2000 March 15; 57(6): 519. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10754758&dopt=Abstract
•
Alosetron in irritable bowel syndrome. Author(s): McColl KE. Source: Lancet. 2000 July 8; 356(9224): 164-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10963271&dopt=Abstract
•
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Author(s): Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG. Source: Alimentary Pharmacology & Therapeutics. 1999 November; 13(11): 1419-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10571597&dopt=Abstract
•
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Author(s): Houghton LA, Foster JM, Whorwell PJ. Source: Alimentary Pharmacology & Therapeutics. 2000 June; 14(6): 775-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10848662&dopt=Abstract
•
Alosetron: a new therapy for irritable bowel syndrome. Author(s): Kupecz D. Source: The Nurse Practitioner. 2000 July; 25(7): 95-6, 98-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10916831&dopt=Abstract
•
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Author(s): Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Source: The American Journal of Gastroenterology. 2000 May; 95(5): 1231-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10811333&dopt=Abstract
Studies
67
•
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Author(s): Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A. Source: Gut. 2003 May; 52(5): 671-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12692051&dopt=Abstract
•
Anal pressure waves in patients with irritable bowel syndrome. Author(s): Bouchoucha M, Choufa T, Faye A, Berger A, Arsac M. Source: Diseases of the Colon and Rectum. 1999 November; 42(11): 1487-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10566540&dopt=Abstract
•
Anisocoria associated with the medical treatment of irritable bowel syndrome. Author(s): Nussdorf JD, Berman EL. Source: Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society. 2000 June; 20(2): 100-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10870922&dopt=Abstract
•
Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Author(s): Jarrett ME, Burr RL, Cain KC, Hertig V, Weisman P, Heitkemper MM. Source: Digestive Diseases and Sciences. 2003 February; 48(2): 386-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12643620&dopt=Abstract
•
Are probiotics useful in irritable bowel syndrome? Author(s): Faber SM. Source: Journal of Clinical Gastroenterology. 2003 July; 37(1): 93-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12811225&dopt=Abstract
•
Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. Author(s): Cooke C, Carr I, Abrams K, Mayberry J. Source: Arquivos De Gastroenterologia. 2000 January-March; 37(1): 20-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10962623&dopt=Abstract
•
Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome. Author(s): Clemens CH, Samsom M, Roelofs JM, van Berge Henegouwen GP, Smout AJ. Source: The American Journal of Gastroenterology. 2003 August; 98(8): 1838-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12907341&dopt=Abstract
68
Irritable Bowel Syndrome
•
Autonomic nervous system reactivity in irritable bowel syndrome. Author(s): Punyabati O, Deepak KK, Sharma MP, Dwivedi SN. Source: Indian J Gastroenterol. 2000 July-September; 19(3): 122-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10918719&dopt=Abstract
•
Bacterial supplementation in the irritable bowel syndrome. A randomised doubleblind placebo-controlled crossover study. Author(s): O'Sullivan MA, O'Morain CA. Source: Dig Liver Dis. 2000 May; 32(4): 294-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11515626&dopt=Abstract
•
Basic pathophysiologic mechanisms in irritable bowel syndrome. Author(s): Mayer EA, Naliboff BD, Chang L. Source: Digestive Diseases (Basel, Switzerland). 2001; 19(3): 212-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11752839&dopt=Abstract
•
Behavioral and physiological sleep characteristics in women with irritable bowel syndrome. Author(s): Elsenbruch S, Thompson JJ, Hamish MJ, Exton MS, Orr WC. Source: The American Journal of Gastroenterology. 2002 September; 97(9): 2306-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12358249&dopt=Abstract
•
Behavioral treatment of irritable bowel syndrome: a 1-year follow-up study. Author(s): Schwarz SP, Blanchard EB, Neff DF. Source: Biofeedback Self Regul. 1986 September; 11(3): 189-98. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3300787&dopt=Abstract
•
Behaviorally treated irritable bowel syndrome patients: a four-year follow-up. Author(s): Schwarz SP, Taylor AE, Scharff L, Blanchard EB. Source: Behaviour Research and Therapy. 1990; 28(4): 331-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2222390&dopt=Abstract
•
Behavioural psychotherapy in the treatment of irritable bowel syndrome. Author(s): Corney RH, Stanton R, Newell R, Clare A, Fairclough P. Source: Journal of Psychosomatic Research. 1991; 35(4-5): 461-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1920177&dopt=Abstract
•
Bladder dysfunction and irritable bowel syndrome. Author(s): Terruzzi V, Magatti F, Quadri G, Tenore C, Minoli G, Belloni C. Source: The American Journal of Gastroenterology. 1992 September; 87(9): 1231-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1519598&dopt=Abstract
Studies
69
•
Bladder smooth muscle dysfunction in patients with irritable bowel syndrome. Author(s): Whorwell PJ, Lupton EW, Erduran D, Wilson K. Source: Gut. 1986 September; 27(9): 1014-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3758813&dopt=Abstract
•
Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Author(s): Sivri A, Cindas A, Dincer F, Sivri B. Source: Clinical Rheumatology. 1996 May; 15(3): 283-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8793261&dopt=Abstract
•
Bowel sound biofeedback as a treatment for irritable bowel syndrome. Author(s): Radnitz CL, Blanchard EB. Source: Biofeedback Self Regul. 1988 June; 13(2): 169-79. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3207766&dopt=Abstract
•
Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Author(s): McEvoy R. Source: The Medical Journal of Australia. 1989 July 17; 151(2): 112. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2783226&dopt=Abstract
•
Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Author(s): Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D. Source: The Medical Journal of Australia. 1989 May 15; 150(10): 604. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2783214&dopt=Abstract
•
Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Author(s): Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Naliboff B, Vogt B, FitzGerald L, Mandelkern MA. Source: The American Journal of Gastroenterology. 2003 June; 98(6): 1354-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12818281&dopt=Abstract
•
Brain-gut interaction in irritable bowel syndrome. Author(s): Harris ML, Aziz Q. Source: Hosp Med. 2003 May; 64(5): 264-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789734&dopt=Abstract
70
Irritable Bowel Syndrome
•
Brain-gut interaction in irritable bowel syndrome: new findings of a multicomponent disease model. Author(s): Schmulson MJ. Source: Isr Med Assoc J. 2001 February; 3(2): 104-10. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11347592&dopt=Abstract
•
Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. Author(s): Fukudo S, Nomura T, Muranaka M, Taguchi F. Source: Journal of Clinical Gastroenterology. 1993 September; 17(2): 133-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8031340&dopt=Abstract
•
Bran and irritable bowel syndrome: time for reappraisal. Author(s): Francis CY, Whorwell PJ. Source: Lancet. 1994 July 2; 344(8914): 39-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7912305&dopt=Abstract
•
Bran supplementation in the treatment of irritable bowel syndrome. Author(s): Snook J, Shepherd HA. Source: Alimentary Pharmacology & Therapeutics. 1994 October; 8(5): 511-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7865643&dopt=Abstract
•
British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Author(s): Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, Hungin P, Kumar D, Libby G, Spiller R, Read N, Silk D, Whorwell P. Source: Gut. 2000 November; 47 Suppl 2: Ii1-19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11053260&dopt=Abstract
•
Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Author(s): Badia X, Mearin F, Balboa A, Baro E, Caldwell E, Cucala M, Diaz-Rubio M, Fueyo A, Ponce J, Roset M, Talley NJ. Source: Pharmacoeconomics. 2002; 20(11): 749-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201794&dopt=Abstract
•
Celiac sprue as a possible cause of symptoms in presumed irritable bowel syndrome. Author(s): Hasler WL. Source: Gastroenterology. 2002 June; 122(7): 2086-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078669&dopt=Abstract
Studies
71
•
Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Author(s): Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, Fournet J, Segebarth C. Source: The American Journal of Gastroenterology. 2002 March; 97(3): 654-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11926209&dopt=Abstract
•
Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Author(s): Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD. Source: Pain. 2003 May; 103(1-2): 99-110. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749964&dopt=Abstract
•
Cerebral response to electric stimulation of the colon and abdominal skin in healthy subjects and patients with irritable bowel syndrome. Author(s): Rossel P, Pedersen P, Niddam D, Arendt-Nielsen L, Chen AC, Drewes AM. Source: Scandinavian Journal of Gastroenterology. 2001 December; 36(12): 1259-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11761014&dopt=Abstract
•
Charcoal tablets in the treatment of patients with irritable bowel syndrome. Author(s): Hubner WD, Moser EH. Source: Adv Ther. 2002 September-October; 19(5): 245-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539884&dopt=Abstract
•
Childhood recurrent abdominal pain and subsequent adult irritable bowel syndrome. Author(s): Hyams JS, Hyman PE, Rasquin-Weber A. Source: Journal of Developmental and Behavioral Pediatrics : Jdbp. 1999 October; 20(5): 318-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10533988&dopt=Abstract
•
Chili pepper and rectal hyperalgesia in irritable bowel syndrome. Author(s): Schmulson MJ, Valdovinos MA, Milke P. Source: The American Journal of Gastroenterology. 2003 May; 98(5): 1214-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809862&dopt=Abstract
•
Chronic pelvic pain and irritable bowel syndrome. Author(s): Gupta JK, More S, Clark TJ. Source: Hosp Med. 2003 May; 64(5): 275-80. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789736&dopt=Abstract
72
Irritable Bowel Syndrome
•
Clinical assessment of irritable bowel syndrome. Author(s): Lembo TJ, Fink RN. Source: Journal of Clinical Gastroenterology. 2002 July; 35(1 Suppl): S31-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184137&dopt=Abstract
•
Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Author(s): Camilleri M, Heading RC, Thompson WG. Source: Alimentary Pharmacology & Therapeutics. 2002 August; 16(8): 1407-30. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12182741&dopt=Abstract
•
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Author(s): Corazziari E, Bytzer P, Delvaux M, Holtmann G, Malagelada JR, Morris J, Muller-Lissner S, Spiller RC, Tack J, Whorwell PJ. Source: Alimentary Pharmacology & Therapeutics. 2003 September 15; 18(6): 569-80. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12969083&dopt=Abstract
•
Coeliac disease presenting with symptoms of irritable bowel syndrome. Author(s): Shahbazkhani B, Forootan M, Merat S, Akbari MR, Nasserimoghadam S, Vahedi H, Malekzadeh R. Source: Alimentary Pharmacology & Therapeutics. 2003 July 15; 18(2): 231-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869084&dopt=Abstract
•
Cognitive function in people with chronic illness: inflammatory bowel disease and irritable bowel syndrome. Author(s): Attree EA, Dancey CP, Keeling D, Wilson C. Source: Applied Neuropsychology. 2003; 10(2): 96-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12788684&dopt=Abstract
•
Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study. Author(s): Boyce P, Gilchrist J, Talley NJ, Rose D. Source: The Australian and New Zealand Journal of Psychiatry. 2000 April; 34(2): 300-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10789535&dopt=Abstract
•
Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Author(s): Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Source: American Journal of Therapeutics. 2003 January-February; 10(1): 61-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522523&dopt=Abstract
Studies
73
•
Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Author(s): Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Source: Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 2002 June; 14(3): 241-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12061908&dopt=Abstract
•
Contemporary thoughts on the treatment of irritable bowel syndrome. Author(s): Giaquinta D. Source: Manag Care Interface. 2002 August; 15(8): 19-20, 22. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12229060&dopt=Abstract
•
Correlation of serotonin and monoamine oxidase levels with anxiety level in diarrhea-predominant irritable bowel syndrome. Author(s): Singh RK, Pandey HP, Singh RH. Source: Indian J Gastroenterol. 2003 May-June; 22(3): 88-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839379&dopt=Abstract
•
Current concepts of the irritable bowel syndrome. Author(s): Quigley EM. Source: Scandinavian Journal of Gastroenterology. Supplement. 2003; (237): 1-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12797672&dopt=Abstract
•
Current insights into the pathophysiology of irritable bowel syndrome. Author(s): Schwetz I, Bradesi S, Mayer EA. Source: Current Gastroenterology Reports. 2003 August; 5(4): 331-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12864964&dopt=Abstract
•
Dealing with irritable bowel syndrome. Author(s): Abbas Z. Source: J Pak Med Assoc. 1999 March; 49(3): 78-81 Concl. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10531788&dopt=Abstract
•
Defining and diagnosing irritable bowel syndrome. Author(s): Schuster MM. Source: Am J Manag Care. 2001 July; 7(8 Suppl): S246-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11474909&dopt=Abstract
74
Irritable Bowel Syndrome
•
Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Author(s): Garcia Rodriguez LA, Ruigomez A, Wallander MA, Johansson S, Olbe L. Source: Scandinavian Journal of Gastroenterology. 2000 March; 35(3): 306-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10766326&dopt=Abstract
•
Diagnosing irritable bowel syndrome. Author(s): van Zanten SV. Source: Reviews in Gastroenterological Disorders. 2003; 3 Suppl 2: S12-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12775998&dopt=Abstract
•
Diagnosing the patient with abdominal pain and altered bowel habits: is it irritable bowel syndrome? Author(s): Holten KB, Wetherington A, Bankston L. Source: American Family Physician. 2003 May 15; 67(10): 2157-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12776965&dopt=Abstract
•
Diagnosis of irritable bowel syndrome. Author(s): Olden KW. Source: Gastroenterology. 2002 May; 122(6): 1701-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12016433&dopt=Abstract
•
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Author(s): Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR. Source: Clinical Chemistry. 2003 June; 49(6 Pt 1): 861-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765980&dopt=Abstract
•
Diet in the irritable bowel syndrome. Author(s): Floch MH, Narayan R. Source: Journal of Clinical Gastroenterology. 2002 July; 35(1 Suppl): S45-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184139&dopt=Abstract
•
Diet triggers symptoms in women with irritable bowel syndrome. The patient's perspective. Author(s): Jarrett M, Visser R, Heitkemper M. Source: Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates. 2001 September-October; 24(5): 246-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847996&dopt=Abstract
Studies
75
•
Direct clinical evidence for spinal hyperalgesia in a patient with irritable bowel syndrome. Author(s): Malcolm A, Phillips SF, Kellow JE, Cousins MJ. Source: The American Journal of Gastroenterology. 2001 August; 96(8): 2427-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11513185&dopt=Abstract
•
Distal colonic motor activity in four subgroups of patients with irritable bowel syndrome. Author(s): Cole SJ, Duncan HD, Claydon AH, Austin D, Bowling TE, Silk DB. Source: Digestive Diseases and Sciences. 2002 February; 47(2): 345-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11858232&dopt=Abstract
•
Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Author(s): Dunlop SP, Jenkins D, Spiller RC. Source: The American Journal of Gastroenterology. 2003 July; 98(7): 1578-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12873581&dopt=Abstract
•
Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Author(s): Ragnarsson G, Bodemar G. Source: Scandinavian Journal of Gastroenterology. 1999 October; 34(10): 993-1000. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10563669&dopt=Abstract
•
Do published guidelines for evaluation of irritable bowel syndrome reflect practice? Author(s): Yawn BP, Lydick E, Locke GR, Wollan PC, Bertram SL, Kurland MJ. Source: Bmc Gastroenterology [electronic Resource]. 2001; 1(1): 11. Epub 2001 October 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11701092&dopt=Abstract
•
Does a physically active lifestyle improve symptoms in women with irritable bowel syndrome? Author(s): Lustyk MK, Jarrett ME, Bennett JC, Heitkemper MM. Source: Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates. 2001 May-June; 24(3): 129-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847862&dopt=Abstract
•
Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Author(s): Masand PS, Gupta S, Schwartz TL, Kaplan D, Virk S, Hameed A, Lockwood K. Source: Psychosomatics. 2002 November-December; 43(6): 451-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12444227&dopt=Abstract
76
Irritable Bowel Syndrome
•
Does irritable bowel syndrome really exist? Reactions to the proposed motility-based classification system. Author(s): Whitehead WE. Source: Gastroenterology. 2003 March; 124(3): 598. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12612895&dopt=Abstract
•
Drug therapy options for patients with irritable bowel syndrome. Author(s): Talley NJ. Source: Am J Manag Care. 2001 July; 7(8 Suppl): S261-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11474911&dopt=Abstract
•
Dyspepsia, irritable bowel syndrome, and constipation: review and what's new. Author(s): Camilleri M. Source: Reviews in Gastroenterological Disorders. 2001; 1(1): 2-17. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12120117&dopt=Abstract
•
Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Author(s): Stanghellini V, Tosetti C, Barbara G, De Giorgio R, Cogliandro L, Cogliandro R, Corinaldesi R. Source: The American Journal of Gastroenterology. 2002 November; 97(11): 2738-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12425541&dopt=Abstract
•
Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Author(s): Camilleri M, Williams DE. Source: Pharmacoeconomics. 2000 April; 17(4): 331-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10947488&dopt=Abstract
•
Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Author(s): Clemens CH, Samsom M, Van Berge Henegouwen GP, Fabri M, Smout AJ. Source: Alimentary Pharmacology & Therapeutics. 2002 May; 16(5): 993-1002. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11966509&dopt=Abstract
•
Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Author(s): Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Source: Digestive Diseases and Sciences. 2002 November; 47(11): 2615-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452404&dopt=Abstract
Studies
77
•
Effect of red chillies on small bowel and colonic transit and rectal sensitivity in men with irritable bowel syndrome. Author(s): Agarwal MK, Bhatia SJ, Desai SA, Bhure U, Melgiri S. Source: Indian J Gastroenterol. 2002 September-October; 21(5): 179-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416746&dopt=Abstract
•
Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Author(s): Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Source: Alimentary Pharmacology & Therapeutics. 2000 July; 14(7): 869-78. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10886042&dopt=Abstract
•
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Author(s): Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Source: Lancet. 2000 March 25; 355(9209): 1035-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10744088&dopt=Abstract
•
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Author(s): Cremonini F, Delgado-Aros S, Camilleri M. Source: Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. 2003 February; 15(1): 79-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588472&dopt=Abstract
•
Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Author(s): Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Source: Hepatogastroenterology. 2002 January-February; 49(43): 193-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11941952&dopt=Abstract
•
Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. Author(s): Berman SM, Naliboff BD, Chang L, Fitzgerald L, Antolin T, Camplone A, Mayer EA. Source: The American Journal of Gastroenterology. 2002 November; 97(11): 2791-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12425550&dopt=Abstract
•
Epidemiology of irritable bowel syndrome in Chinese. Author(s): Lau EM, Chan FK, Ziea ET, Chan CS, Wu JC, Sung JJ. Source: Digestive Diseases and Sciences. 2002 November; 47(11): 2621-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452405&dopt=Abstract
78
Irritable Bowel Syndrome
•
Epidemiology of irritable bowel syndrome in Croatia. Author(s): Baretic M, Bilic A, Jurcic D, Mihanovic M, Sunic-Omejc M, Dorosulic Z, Restek-Petrovic B. Source: Coll Antropol. 2002 December; 26 Suppl: 85-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674839&dopt=Abstract
•
Evaluation of drug treatment in irritable bowel syndrome. Author(s): Talley NJ. Source: British Journal of Clinical Pharmacology. 2003 October; 56(4): 362-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12968980&dopt=Abstract
•
Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Author(s): Sen S, Dear KL, King TS, Elia M, Hunter JO. Source: European Journal of Gastroenterology & Hepatology. 2002 July; 14(7): 753-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12169984&dopt=Abstract
•
Evidence for autonomic dysregulation in the irritable bowel syndrome. Author(s): Gupta V, Sheffield D, Verne GN. Source: Digestive Diseases and Sciences. 2002 August; 47(8): 1716-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184520&dopt=Abstract
•
Evidence-based position statement on the management of irritable bowel syndrome in North America. Author(s): American College of Gastroenterology Functional Gastrointestinal Disorders Task Froce. Source: The American Journal of Gastroenterology. 2002 November; 97(11 Suppl): S1-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12425585&dopt=Abstract
•
Evolution of visceral sensitivity in patients with irritable bowel syndrome. Author(s): Poitras P, Riberdy Poitras M, Plourde V, Boivin M, Verrier P. Source: Digestive Diseases and Sciences. 2002 April; 47(4): 914-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11991628&dopt=Abstract
•
Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. Author(s): Fukudo S, Kanazawa M, Kano M, Sagami Y, Endo Y, Utsumi A, Nomura T, Hongo M. Source: Journal of Gastroenterology. 2002 November; 37 Suppl 14: 145-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12572883&dopt=Abstract
Studies
79
•
Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Author(s): Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Source: European Journal of Gastroenterology & Hepatology. 2002 December; 14(12): 1331-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12468954&dopt=Abstract
•
Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. Author(s): Svedberg P, Johansson S, Wallander MA, Hamelin B, Pedersen NL. Source: Alimentary Pharmacology & Therapeutics. 2002 May; 16(5): 975-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11966507&dopt=Abstract
•
Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Author(s): Zimmerman J. Source: Digestive Diseases and Sciences. 2003 April; 48(4): 743-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12741465&dopt=Abstract
•
FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky. Author(s): Horwitz BJ. Source: Health News. 2002 October; 8(10): 1-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12416480&dopt=Abstract
•
Features of eating disorders in patients with irritable bowel syndrome. Author(s): Tang TN, Toner BB, Stuckless N, Dion KL, Kaplan AS, Ali A. Source: Journal of Psychosomatic Research. 1998 August; 45(2): 171-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9753389&dopt=Abstract
•
Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. Author(s): Treem WR, Ahsan N, Kastoff G, Hyams JS. Source: Journal of Pediatric Gastroenterology and Nutrition. 1996 October; 23(3): 280-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8890079&dopt=Abstract
•
Fiber supplements for irritable bowel syndrome: do they really make a difference? Author(s): Wald A. Source: The American Journal of Gastroenterology. 1990 December; 85(12): 1652-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2174644&dopt=Abstract
80
Irritable Bowel Syndrome
•
Fibromyalgia in patients with irritable bowel syndrome. An association with the severity of the intestinal disorder. Author(s): Lubrano E, Iovino P, Tremolaterra F, Parsons WJ, Ciacci C, Mazzacca G. Source: International Journal of Colorectal Disease. 2001 August; 16(4): 211-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11515679&dopt=Abstract
•
Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Author(s): Sperber AD, Atzmon Y, Neumann L, Weisberg I, Shalit Y, Abu-Shakrah M, Fich A, Buskila D. Source: The American Journal of Gastroenterology. 1999 December; 94(12): 3541-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10606316&dopt=Abstract
•
Food allergy and irritable bowel syndrome. Author(s): Mullin GE. Source: Jama : the Journal of the American Medical Association. 1991 April 3; 265(13): 1736. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2002578&dopt=Abstract
•
Food allergy and the irritable bowel syndrome. Author(s): Zwetchkenbaum JF, Burakoff R. Source: The American Journal of Gastroenterology. 1988 September; 83(9): 901-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3046334&dopt=Abstract
•
Food hypersensitivity and irritable bowel syndrome. Author(s): Zar S, Kumar D, Benson MJ. Source: Alimentary Pharmacology & Therapeutics. 2001 April; 15(4): 439-49. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11284772&dopt=Abstract
•
Food hypersensitivity and the irritable bowel syndrome. Author(s): Schmidt M, Floch MH. Source: The American Journal of Gastroenterology. 1992 January; 87(1): 18-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1728118&dopt=Abstract
•
Food intolerance and the irritable bowel syndrome. Author(s): Nanda R, James R, Smith H, Dudley CR, Jewell DP. Source: Gut. 1989 August; 30(8): 1099-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2767507&dopt=Abstract
Studies
81
•
Food intolerance, atopy, and irritable bowel syndrome. Author(s): Smith MA, Youngs GR, Finn R. Source: Lancet. 1985 November 9; 2(8463): 1064. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2865536&dopt=Abstract
•
Food-related gastrointestinal symptoms in the irritable bowel syndrome. Author(s): Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Bjornsson ES. Source: Digestion. 2001; 63(2): 108-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11244249&dopt=Abstract
•
Fructose malabsorption and the irritable bowel syndrome. Author(s): Born P, Vierling T, Barina W. Source: Gastroenterology. 1991 November; 101(5): 1454. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1796960&dopt=Abstract
•
Fructose-sorbitol malabsorption and symptom provocation in irritable bowel syndrome: relationship to enteric hypersensitivity and dysmotility. Author(s): Evans PR, Piesse C, Bak YT, Kellow JE. Source: Scandinavian Journal of Gastroenterology. 1998 November; 33(11): 1158-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9867093&dopt=Abstract
•
Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Author(s): Tornblom H, Lindberg G, Nyberg B, Veress B. Source: Gastroenterology. 2002 December; 123(6): 1972-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12454854&dopt=Abstract
•
Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. Author(s): Yuan YZ, Tao RJ, Xu B, Sun J, Chen KM, Miao F, Zhang ZW, Xu JY. Source: World Journal of Gastroenterology : Wjg. 2003 June; 9(6): 1356-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12800256&dopt=Abstract
•
Functional diagnostic work-up in patients with irritable bowel syndrome. Author(s): Klauser AG, Voderholzer WA, Schindlbeck NE, Muller-Lissner SA. Source: Zeitschrift Fur Gastroenterologie. 1996 May; 34(5): 273-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8686358&dopt=Abstract
82
Irritable Bowel Syndrome
•
Functional disability in adolescents and young adults with symptoms of irritable bowel syndrome: the role of academic, social, and athletic competence. Author(s): Claar RL, Walker LS, Smith CA. Source: Journal of Pediatric Psychology. 1999 June; 24(3): 271-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10379142&dopt=Abstract
•
Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Author(s): Holtmann G, Goebell H, Talley NJ. Source: The American Journal of Gastroenterology. 1997 June; 92(6): 954-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9177509&dopt=Abstract
•
Gallbladder contraction in patients with irritable bowel syndrome. Author(s): Braverman DZ. Source: Isr J Med Sci. 1987 March; 23(3): 181-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3294738&dopt=Abstract
•
Gallbladder dynamics in patients with irritable bowel syndrome and essential dyspepsia. Author(s): Misra SP, Dwivedi M, Mital M, Misra V. Source: Journal of Clinical Gastroenterology. 1991 February; 13(1): 65-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2007748&dopt=Abstract
•
Gallbladder function in the irritable bowel syndrome. Author(s): Keshavarziam A, Anagnostides A, Chadwick VS, Fitzpatrick ML. Source: Journal of Clinical Gastroenterology. 1987 June; 9(3): 366. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3611697&dopt=Abstract
•
Gastric emptying and dyspeptic symptoms in the irritable bowel syndrome. Author(s): van Wijk HJ, Smout AJ, Akkermans LM, Roelofs JM, ten Thije OJ. Source: Scandinavian Journal of Gastroenterology. 1992; 27(2): 99-102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1561533&dopt=Abstract
•
Gastrointestinal dysfunction in a community sample of subjects with symptoms of irritable bowel syndrome. Author(s): Lanng C, Mortensen D, Friis M, Wallin L, Kay L, Boesby S, Jorgensen T. Source: Digestion. 2003; 67(1-2): 14-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12743435&dopt=Abstract
Studies
83
•
Gastrointestinal motility in patients with irritable bowel syndrome studied by using radiopaque markers. Author(s): Horikawa Y, Mieno H, Inoue M, Kajiyama G. Source: Scandinavian Journal of Gastroenterology. 1999 December; 34(12): 1190-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10636065&dopt=Abstract
•
Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Author(s): Evans PR, Bak YT, Shuter B, Hoschl R, Kellow JE. Source: Digestive Diseases and Sciences. 1997 October; 42(10): 2087-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9365140&dopt=Abstract
•
Gender differences in irritable bowel syndrome. Author(s): Chang L, Heitkemper MM. Source: Gastroenterology. 2002 November; 123(5): 1686-701. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12404243&dopt=Abstract
•
Gender differences in irritable bowel syndrome. Author(s): Chial HJ, Camilleri M. Source: J Gend Specif Med. 2002 May-June; 5(3): 37-45. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078061&dopt=Abstract
•
Gender differences in Manning criteria in the irritable bowel syndrome. Author(s): Smith RC, Greenbaum DS, Vancouver JB, Henry RC, Reinhart MA, Greenbaum RB, Dean HA, Mayle JE. Source: Gastroenterology. 1991 March; 100(3): 591-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1993482&dopt=Abstract
•
Gender differences in psychological distress among patients with irritable bowel syndrome. Author(s): Blanchard EB, Keefer L, Galovski TE, Taylor AE, Turner SM. Source: Journal of Psychosomatic Research. 2001 May; 50(5): 271-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11399285&dopt=Abstract
•
Gender issues in the management of inflammatory bowel disease and irritable bowel syndrome. Author(s): Kane S. Source: Int J Fertil Womens Med. 2002 May-June; 47(3): 136-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081259&dopt=Abstract
84
Irritable Bowel Syndrome
•
Gender role and irritable bowel syndrome: literature review and hypothesis. Author(s): Toner BB, Akman D. Source: The American Journal of Gastroenterology. 2000 January; 95(1): 11-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10638553&dopt=Abstract
•
Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Author(s): Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Source: The American Journal of Gastroenterology. 2001 September; 96(9): 2671-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11569693&dopt=Abstract
•
Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome. Author(s): D'Anchino M, Orlando D, De Feudis L. Source: The Journal of Infection. 2002 October; 45(3): 169-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387773&dopt=Abstract
•
Group treatment of patients with irritable bowel syndrome. Author(s): Lammert M, Ratner M. Source: Social Work in Health Care. 1986 Fall; 12(1): 67-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3603327&dopt=Abstract
•
GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Author(s): Svedlund J, Sjodin I, Dotevall G. Source: Digestive Diseases and Sciences. 1988 February; 33(2): 129-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3123181&dopt=Abstract
•
Gut feelings about irritable bowel syndrome. Author(s): Stahl SM. Source: The Journal of Clinical Psychiatry. 2001 August; 62(8): 590-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11561928&dopt=Abstract
•
Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Author(s): Lea R, Houghton LA, Calvert EL, Larder S, Gonsalkorale WM, Whelan V, Randles J, Cooper P, Cruickshanks P, Miller V, Whorwell PJ. Source: Alimentary Pharmacology & Therapeutics. 2003 March 1; 17(5): 635-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12641511&dopt=Abstract
Studies
85
•
Gynaecological consultation in patients with the irritable bowel syndrome. Author(s): Prior A, Whorwell PJ. Source: Gut. 1989 July; 30(7): 996-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2759494&dopt=Abstract
•
H. pylori infection and visceral hypersensitivity in patients with irritable bowel syndrome. Author(s): Gerards C, Leodolter A, Glasbrenner B, Malfertheiner P. Source: Digestive Diseases (Basel, Switzerland). 2001; 19(2): 170-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11549828&dopt=Abstract
•
Harnessing the patient's powers of recovery: the role of the psychotherapies in the irritable bowel syndrome. Author(s): Read NW. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 473-87. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580923&dopt=Abstract
•
Health care utilization and economic issues in irritable bowel syndrome. Author(s): Gralnek IM. Source: Eur J Surg Suppl. 1998; (583): 73-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10027677&dopt=Abstract
•
Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Author(s): El-Serag HB, Olden K, Bjorkman D. Source: Alimentary Pharmacology & Therapeutics. 2002 June; 16(6): 1171-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030961&dopt=Abstract
•
Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Author(s): Luscombe FA. Source: Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 2000 March; 9(2): 161-76. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10983480&dopt=Abstract
•
Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Author(s): Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Source: Pharmacoeconomics. 2002; 20(7): 455-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12093301&dopt=Abstract
86
Irritable Bowel Syndrome
•
Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Author(s): Creed F, Ratcliffe J, Fernandez L, Tomenson B, Palmer S, Rigby C, Guthrie E, Read N, Thompson D. Source: Annals of Internal Medicine. 2001 May 1; 134(9 Pt 2): 860-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11346322&dopt=Abstract
•
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Author(s): Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Source: Clinical Therapeutics. 2002 April; 24(4): 675-89; Discussion 674. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12017411&dopt=Abstract
•
High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Author(s): Francis CY, Duffy JN, Whorwell PJ, Morris J. Source: Digestive Diseases and Sciences. 1997 February; 42(2): 404-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9052526&dopt=Abstract
•
High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Author(s): Parisi GC, Zilli M, Miani MP, Carrara M, Bottona E, Verdianelli G, Battaglia G, Desideri S, Faedo A, Marzolino C, Tonon A, Ermani M, Leandro G. Source: Digestive Diseases and Sciences. 2002 August; 47(8): 1697-704. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184518&dopt=Abstract
•
How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Author(s): Heaton KW, Ghosh S, Braddon FE. Source: Gut. 1991 January; 32(1): 73-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1991641&dopt=Abstract
•
How effective are antidepressant medications in the treatment of irritable bowel syndrome and nonulcer dyspepsia? Author(s): Pearson RL. Source: The Journal of Family Practice. 2000 May; 49(5): 396. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10836766&dopt=Abstract
Studies
87
•
Hydrogen breath test quantification and clinical correlation of lactose malabsorption in adult irritable bowel syndrome and ulcerative colitis. Author(s): Sciarretta G, Giacobazzi G, Verri A, Zanirato P, Garuti G, Malaguti P. Source: Digestive Diseases and Sciences. 1984 December; 29(12): 1098-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6548690&dopt=Abstract
•
Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery. Author(s): Sanger GJ. Source: Digestive Diseases (Basel, Switzerland). 1999; 17(2): 90-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10545714&dopt=Abstract
•
Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Author(s): Verne GN, Robinson ME, Price DD. Source: Pain. 2001 July; 93(1): 7-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11406333&dopt=Abstract
•
Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Author(s): Palsson OS, Turner MJ, Johnson DA, Burnelt CK, Whitehead WE. Source: Digestive Diseases and Sciences. 2002 November; 47(11): 2605-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12452403&dopt=Abstract
•
Hypnotherapy and refractory irritable bowel syndrome: a single case study. Author(s): Galovski TE, Blanchard EB. Source: Am J Clin Hypn. 2002 July; 45(1): 31-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12116613&dopt=Abstract
•
Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome? Author(s): Forbes A, MacAuley S, Chiotakakou-Faliakou E. Source: International Journal of Colorectal Disease. 2000 November; 15(5-6): 328-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11151439&dopt=Abstract
•
Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Author(s): Gonsalkorale WM, Houghton LA, Whorwell PJ. Source: The American Journal of Gastroenterology. 2002 April; 97(4): 954-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12003432&dopt=Abstract
88
Irritable Bowel Syndrome
•
Hypothalamic digoxin and irritable bowel syndrome. Author(s): Kumar AR, Kurup PA. Source: Indian J Gastroenterol. 2001 September-October; 20(5): 173-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11676326&dopt=Abstract
•
Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Author(s): El-Serag HB. Source: Reviews in Gastroenterological Disorders. 2003; 3 Suppl 2: S3-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12775997&dopt=Abstract
•
Impact of sex and gender on irritable bowel syndrome. Author(s): Heitkemper M, Jarrett M, Bond EF, Chang L. Source: Biological Research for Nursing. 2003 July; 5(1): 56-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12886671&dopt=Abstract
•
Infection as a cause of irritable bowel syndrome. Author(s): Spiller RC. Source: Hosp Med. 2003 May; 64(5): 270-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789735&dopt=Abstract
•
Intestinal reactivity to words with emotional content and brain information processing in irritable bowel syndrome. Author(s): Blomhoff S, Spetalen S, Jacobsen MB, Vatn M, Malt UF. Source: Digestive Diseases and Sciences. 2000 June; 45(6): 1160-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10877232&dopt=Abstract
•
Irritable bowel syndrome and health-related quality of life: a population-based study in Calgary, Alberta. Author(s): Li FX, Patten SB, Hilsden RJ, Sutherland LR. Source: Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 2003 April; 17(4): 259-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12704470&dopt=Abstract
•
Irritable bowel syndrome and mirtazapine. Author(s): Thomas SG. Source: The American Journal of Psychiatry. 2000 August; 157(8): 1341-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10910804&dopt=Abstract
Studies
89
•
Irritable bowel syndrome in a psychiatric patient population. Author(s): North CS, Alpers DH. Source: Comprehensive Psychiatry. 2000 March-April; 41(2): 116-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10741890&dopt=Abstract
•
Irritable bowel syndrome in primary care: the patients' and doctors' views on symptoms, etiology and management. Author(s): Bijkerk CJ, de Wit NJ, Stalman WA, Knottnerus JA, Hoes AW, Muris JW. Source: Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 2003 June; 17(6): 363-8; Quiz 405-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12813601&dopt=Abstract
•
Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Author(s): Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, Mayer EA. Source: Pain. 2000 August; 87(2): 137-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10924807&dopt=Abstract
•
Irritable bowel syndrome. Author(s): Zaman A. Source: Clinical Cornerstone. 2002; 4(4): 22-33. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12739324&dopt=Abstract
•
Irritable bowel syndrome: a management strategy. Author(s): Thompson WG. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 453-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580921&dopt=Abstract
•
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Author(s): Olden KW. Source: Cleve Clin J Med. 2003 June; 70 Suppl 2: S3-7. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12825862&dopt=Abstract
•
Irritable bowel syndrome: are incentives useful for improving survey response rates? Author(s): Patten SB, Li FX, Cook T, Hilsden RJ, Sutherland LR. Source: Journal of Clinical Epidemiology. 2003 March; 56(3): 256-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12725880&dopt=Abstract
90
Irritable Bowel Syndrome
•
Irritable bowel syndrome: definition, diagnosis and epidemiology. Author(s): Talley NJ. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 371-84. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580915&dopt=Abstract
•
Irritable bowel syndrome: epidemiology and diagnosis. Author(s): Ron Y. Source: Isr Med Assoc J. 2003 March; 5(3): 201-2. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12725144&dopt=Abstract
•
Irritable bowel syndrome: evaluation and treatment. Author(s): Somers SC, Lembo A. Source: Gastroenterology Clinics of North America. 2003 June; 32(2): 507-29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858604&dopt=Abstract
•
Irritable bowel syndrome: new pharmaceutical approaches to treatment. Author(s): Farthing MJ. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 461-71. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580922&dopt=Abstract
•
Irritable bowel syndrome: new recommendations for diagnosis and treatment. Author(s): Lacy BE. Source: Archives of Internal Medicine. 2003 June 9; 163(11): 1374-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796080&dopt=Abstract
•
Irritable bowel syndrome: unravelling the mysteries. Author(s): Hunter JO. Source: Hosp Med. 2003 May; 64(5): 262-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789733&dopt=Abstract
•
Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. Author(s): Kalantar JS, Locke GR 3rd, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd. Source: Alimentary Pharmacology & Therapeutics. 2003 June 1; 17(11): 1389-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12786633&dopt=Abstract
Studies
91
•
Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychosocial features. Author(s): Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Source: Gastroenterology. 1996 February; 110(2): 393-404. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8566585&dopt=Abstract
•
Kruis scoring system and Manning's criteria in diagnosis of irritable bowel syndrome: is it better to use combined? Author(s): Dogan UB, Unal S. Source: Acta Gastroenterol Belg. 1996 October-December; 59(4): 225-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9085621&dopt=Abstract
•
Lactose intolerance and irritable bowel syndrome. Author(s): Mascolo R, Saltzman JR. Source: Nutrition Reviews. 1998 October; 56(10): 306-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9810810&dopt=Abstract
•
Lactose intolerance and irritable bowel syndrome. Author(s): Turnbull GK. Source: Nutrition (Burbank, Los Angeles County, Calif.). 2000 July-August; 16(7-8): 6656. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10906590&dopt=Abstract
•
Lactose intolerance in different types of irritable bowel syndrome in north Indians. Author(s): Rana SV, Mandal AK, Kochhar R, Katyal R, Singh K. Source: Trop Gastroenterol. 2001 October-December; 22(4): 202-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11963325&dopt=Abstract
•
Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactosefree diet. Author(s): Vernia P, Ricciardi MR, Frandina C, Bilotta T, Frieri G. Source: Ital J Gastroenterol. 1995 April; 27(3): 117-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7548919&dopt=Abstract
•
Lactose malabsorption, irritable bowel syndrome and self-reported milk intolerance. Author(s): Vernia P, Di Camillo M, Marinaro V. Source: Dig Liver Dis. 2001 April; 33(3): 234-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11407668&dopt=Abstract
92
Irritable Bowel Syndrome
•
Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Author(s): Small PK, Loudon MA, Hau CM, Noor N, Campbell FC. Source: Scandinavian Journal of Gastroenterology. 1997 January; 32(1): 39-47. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9018765&dopt=Abstract
•
Learning needs of Taiwanese nurses caring for patients with irritable bowel syndrome. Author(s): Chen H, McCutcheon H. Source: Nursing & Health Sciences. 2001 December; 3(4): 173-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11906625&dopt=Abstract
•
Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Author(s): Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Source: Gut. 1998 August; 43(2): 256-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10189854&dopt=Abstract
•
Likely impacts of recruitment site and methodology on characteristics of enrolled patient population: irritable bowel syndrome clinical trial design. Author(s): Jones R. Source: The American Journal of Medicine. 1999 November 8; 107(5A): 85S-90S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10588178&dopt=Abstract
•
Lines written on reading another review article about the irritable bowel syndrome. Author(s): Valori R. Source: Lancet. 1993 January 2; 341(8836): 36-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8093280&dopt=Abstract
•
Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Author(s): Simren M, Simms L, D'Souza D, Abrahamsson H, Bjornsson ES. Source: Alimentary Pharmacology & Therapeutics. 2003 January; 17(2): 279-87. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534414&dopt=Abstract
•
Lipid-induced intestinal gas retention in irritable bowel syndrome. Author(s): Serra J, Salvioli B, Azpiroz F, Malagelada JR. Source: Gastroenterology. 2002 September; 123(3): 700-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12198695&dopt=Abstract
Studies
93
•
Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Author(s): Tougas G, Snape WJ Jr, Otten MH, Earnest DL, Langaker KE, Pruitt RE, Pecher E, Nault B, Rojavin MA. Source: Alimentary Pharmacology & Therapeutics. 2002 October; 16(10): 1701-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12269961&dopt=Abstract
•
Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Author(s): Dobrilla G, Imbimbo BP, Piazzi L, Bensi G. Source: Gut. 1990 March; 31(3): 355-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2182401&dopt=Abstract
•
Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome. Author(s): McGahan L. Source: Issues Emerg Health Technol. 2000 October; (11): 1-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11902219&dopt=Abstract
•
Low dominance and high intropunitiveness in ulcerative colitis and irritable bowel syndrome. Author(s): Arapakis G, Lyketsos CG, Gerolymatos K, Richardson SC, Lyketsos GC. Source: Psychotherapy and Psychosomatics. 1986; 46(4): 171-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3628684&dopt=Abstract
•
Management of irritable bowel syndrome. Author(s): Gunn MC, Cavin AA, Mansfield JC. Source: Postgraduate Medical Journal. 2003 March; 79(929): 154-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12697915&dopt=Abstract
•
Management of irritable bowel syndrome. Author(s): Viera AJ, Hoag S, Shaughnessy J. Source: American Family Physician. 2002 November 15; 66(10): 1867-74. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12469960&dopt=Abstract
•
Management of irritable bowel syndrome. Author(s): De Giacomo C. Source: Gastroenterology. 2001 December; 121(6): 1527-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11758547&dopt=Abstract
94
Irritable Bowel Syndrome
•
Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Author(s): Scarpignato C, Pelosini I. Source: Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 1999 March; 13 Suppl A: 50A-65A. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10202210&dopt=Abstract
•
Management of irritable bowel syndrome: start of a new era? Author(s): Silk DB. Source: European Journal of Gastroenterology & Hepatology. 2003 June; 15(6): 679-96. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12840681&dopt=Abstract
•
Management of the irritable bowel syndrome. Author(s): Camilleri M. Source: Gastroenterology. 2001 February; 120(3): 652-68. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11179242&dopt=Abstract
•
Medical and lay views of irritable bowel syndrome. Author(s): Dixon-Woods M, Critchley S. Source: Family Practice. 2000 April; 17(2): 108-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10758070&dopt=Abstract
•
Medical literature implies continuous positive airway pressure might be appropriate treatment for irritable bowel syndrome. Author(s): Herr JR. Source: Chest. 2002 September; 122(3): 1107. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226070&dopt=Abstract
•
Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Author(s): Poynard T, Regimbeau C, Benhamou Y. Source: Alimentary Pharmacology & Therapeutics. 2001 March; 15(3): 355-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11207510&dopt=Abstract
•
Multicenter phase III clinical trial of otilonium bromide in irritable bowel syndrome. Author(s): Kaushik A, Pursnani ML, Kar P. Source: Indian J Gastroenterol. 2002 March-April; 21(2): 85-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11990341&dopt=Abstract
Studies
95
•
Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation. Author(s): Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Source: Alimentary Pharmacology & Therapeutics. 2002 September; 16(9): 1649-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197844&dopt=Abstract
•
Natural killer cell function and psychological distress in women with and without irritable bowel syndrome. Author(s): Motzer SA, Jarrett M, Heitkemper MM, Tsuji J. Source: Biological Research for Nursing. 2002 July; 4(1): 31-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12363280&dopt=Abstract
•
Neuropathophysiology of irritable bowel syndrome. Author(s): Wood JD. Source: Journal of Clinical Gastroenterology. 2002 July; 35(1 Suppl): S11-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184133&dopt=Abstract
•
Neurotransmitter antagonism in management of irritable bowel syndrome. Author(s): Lembo T. Source: Lancet. 2000 March 25; 355(9209): 1030-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10744083&dopt=Abstract
•
New approaches to the medical treatment of irritable bowel syndrome. Author(s): Berrada D, Canenguez K, Lembo T. Source: Current Gastroenterology Reports. 2003 August; 5(4): 337-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12864965&dopt=Abstract
•
New developments in the diagnosis and treatment of irritable bowel syndrome. Author(s): Longstreth GF, Drossman DA. Source: Current Gastroenterology Reports. 2002 October; 4(5): 427-34. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228046&dopt=Abstract
•
New insights into the psychosocial aspects of irritable bowel syndrome. Author(s): Lea R, Whorwell PJ. Source: Current Gastroenterology Reports. 2003 August; 5(4): 343-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12864966&dopt=Abstract
•
Nongastrointestinal disorders in the irritable bowel syndrome. Author(s): Azpiroz F, Dapoigny M, Pace F, Muller-Lissner S, Coremans G, Whorwell P, Stockbrugger RW, Smout A. Source: Digestion. 2000; 62(1): 66-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10899728&dopt=Abstract
96
Irritable Bowel Syndrome
•
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Author(s): Pimentel M, Chow EJ, Lin HC. Source: The American Journal of Gastroenterology. 2003 February; 98(2): 412-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591062&dopt=Abstract
•
Novel therapies in the treatment of irritable bowel syndrome. Author(s): Berrada D, Lembo T. Source: Expert Opinion on Investigational Drugs. 2003 April; 12(4): 635-45. Review. Erratum In: Expert Opin Investig Drugs. 2003 May; 12(5): 907. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12665418&dopt=Abstract
•
Objective evaluation of psychological abnormality in irritable bowel syndrome. Author(s): Chakraborti SK, Dey BK, Ghosh N, Chaudhury AN, Guha Mazumder DN. Source: Indian J Gastroenterol. 1996 April; 15(2): 43-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8935932&dopt=Abstract
•
Octylonium bromide in the treatment of the irritable bowel syndrome: a clinicalfunctional study. Author(s): Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Marzio L, Di Felice F, et al. Source: Hepatogastroenterology. 1992 October; 39(5): 392-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1459516&dopt=Abstract
•
One-year follow-up of newly diagnosed irritable bowel syndrome patients. Author(s): Ruigomez A, Wallander MA, Johansson S, Garcia Rodriguez LA. Source: Alimentary Pharmacology & Therapeutics. 1999 August; 13(8): 1097-102. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10468687&dopt=Abstract
•
Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Author(s): Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G, et al. Source: Scandinavian Journal of Gastroenterology. 1995 June; 30(6): 535-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7569760&dopt=Abstract
•
Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Author(s): Stefanini GF, Prati E, Albini MC, Piccinini G, Capelli S, Castelli E, Mazzetti M, Gasbarrini G. Source: The American Journal of Gastroenterology. 1992 January; 87(1): 55-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1728124&dopt=Abstract
Studies
97
•
Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. Author(s): Czimmer J, Suto G, Kiraly A, Mozsik G. Source: Journal of Physiology, Paris. 2001 January-December; 95(1-6): 153-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11595430&dopt=Abstract
•
Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Author(s): Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R. Source: Alimentary Pharmacology & Therapeutics. 1998 October; 12(10): 1003-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9798806&dopt=Abstract
•
Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Author(s): Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Source: The American Journal of Gastroenterology. 2003 January; 98(1): 122-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12526947&dopt=Abstract
•
Outpatients with irritable bowel syndrome: a comparison of first time and chronic attenders. Author(s): Guthrie EA, Creed FH, Whorwell PJ, Tomenson B. Source: Gut. 1992 March; 33(3): 361-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1568655&dopt=Abstract
•
Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome. Author(s): Louvel D, Delvaux M, Felez A, Fioramonti J, Bueno L, Lazorthes Y, Frexinos J. Source: Gut. 1996 November; 39(5): 741-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9014776&dopt=Abstract
•
Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. Author(s): Rossel P, Drewes AM, Petersen P, Nielsen J, Arendt-Nielsen L. Source: Scandinavian Journal of Gastroenterology. 1999 October; 34(10): 1001-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10563670&dopt=Abstract
•
Patients with irritable bowel syndrome: health status and use of health care services. Author(s): Donker GA, Foets M, Spreeuwenberg P. Source: The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 1999 October; 49(447): 787-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10885081&dopt=Abstract
98
Irritable Bowel Syndrome
•
Perceptual hyperreactivity to auditory stimuli in patients with irritable bowel syndrome. Author(s): Blomhoff S, Jacobsen MB, Spetalen S, Dahm A, Malt UF. Source: Scandinavian Journal of Gastroenterology. 2000 June; 35(6): 583-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10912657&dopt=Abstract
•
Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Author(s): Jailwala J, Imperiale TF, Kroenke K. Source: Annals of Internal Medicine. 2000 July 18; 133(2): 136-47. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10896640&dopt=Abstract
•
Physiological correlates of childhood abuse: chronic hyperarousal in PTSD, depression, and irritable bowel syndrome. Author(s): Kendall-Tackett KA. Source: Child Abuse & Neglect. 2000 June; 24(6): 799-810. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10888019&dopt=Abstract
•
Potential pitfalls in the differential diagnosis of irritable bowel syndrome. Author(s): Smout A, Azpiroz F, Coremans G, Dapoigny M, Collins S, Muller-Lissner S, Pace F, Stockbrugger R, Vatn M, Whorwell P. Source: Digestion. 2000; 61(4): 247-56. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10878451&dopt=Abstract
•
Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Author(s): Vanner SJ, Depew WT, Paterson WG, DaCosta LR, Groll AG, Simon JB, Djurfeldt M. Source: The American Journal of Gastroenterology. 1999 October; 94(10): 2912-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10520844&dopt=Abstract
•
Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome. Author(s): Tuncer C, Cindoruk M, Dursun A, Karakan T. Source: Acta Gastroenterol Belg. 2003 April-June; 66(2): 133-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12891921&dopt=Abstract
•
Productivity loss due to irritable bowel syndrome. Author(s): Gandjour A. Source: Archives of Internal Medicine. 2003 October 13; 163(18): 2249; Author Reply 2249-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14557225&dopt=Abstract
Studies
99
•
Psychopathology in irritable bowel syndrome: support for a psychophysiological model. Author(s): Sykes MA, Blanchard EB, Lackner J, Keefer L, Krasner S. Source: Journal of Behavioral Medicine. 2003 August; 26(4): 361-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12921009&dopt=Abstract
•
Quality of life in irritable bowel syndrome, effect of therapy. Author(s): Chassany O, Bergmann JF. Source: Eur J Surg Suppl. 1998; (583): 81-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10027679&dopt=Abstract
•
Quality of life in irritable bowel syndrome. Author(s): Lea R, Whorwell PJ. Source: Pharmacoeconomics. 2001; 19(6): 643-53. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11456212&dopt=Abstract
•
Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Author(s): Simren M, Abrahamsson H, Svedlund J, Bjornsson ES. Source: Scandinavian Journal of Gastroenterology. 2001 May; 36(5): 545-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11346211&dopt=Abstract
•
Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Author(s): Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Source: Digestive Diseases and Sciences. 1998 February; 43(2): 400-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9512138&dopt=Abstract
•
Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Author(s): Koide A, Yamaguchi T, Odaka T, Koyama H, Tsuyuguchi T, Kitahara H, Ohto M, Saisho H. Source: The American Journal of Gastroenterology. 2000 July; 95(7): 1735-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10925977&dopt=Abstract
•
Randomized, double-blind, placebo-controlled trial of prednisolone in postinfectious irritable bowel syndrome. Author(s): Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, Spiller RC. Source: Alimentary Pharmacology & Therapeutics. 2003 July 1; 18(1): 77-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12848628&dopt=Abstract
100 Irritable Bowel Syndrome
•
Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America. Author(s): Avigan M, Justice R, Mackey AC, Nair N. Source: The American Journal of Gastroenterology. 2003 September; 98(9): 2105-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14499800&dopt=Abstract
•
Rectal tone and brain information processing in irritable bowel syndrome. Author(s): Blomhoff S, Spetalen S, Jacobsen MB, Vatn M, Malt UF. Source: Digestive Diseases and Sciences. 2000 June; 45(6): 1153-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10877231&dopt=Abstract
•
Recurrent abdominal pain in children: forerunner to adult irritable bowel syndrome? Author(s): Jarrett M, Heitkemper M, Czyzewski DI, Shulman R. Source: Journal for Specialists in Pediatric Nursing : Jspn. 2003 July-September; 8(3): 819. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12942886&dopt=Abstract
•
Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Author(s): Ringel Y, Drossman DA, Turkington TG, Bradshaw B, Hawk TC, Bangdiwala S, Coleman RE, Whitehead WE. Source: Digestive Diseases and Sciences. 2003 September; 48(9): 1774-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14561000&dopt=Abstract
•
Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Author(s): Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R. Source: Gastroenterology. 2000 May; 118(5): 842-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10784583&dopt=Abstract
•
Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Author(s): Verne GN, Robinson ME, Vase L, Price DD. Source: Pain. 2003 September; 105(1-2): 223-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14499439&dopt=Abstract
•
Risk factor for irritable bowel syndrome: role of food allergies. Author(s): Addolorato G, Capristo E, Ghittoni G, Ancona C, Gasbarrini G. Source: The American Journal of Gastroenterology. 2000 August; 95(8): 2130-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10950079&dopt=Abstract
Studies
101
•
Risk factors in irritable bowel syndrome. Author(s): Hunt SC. Source: The American Journal of Gastroenterology. 2000 August; 95(8): 2129-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10950078&dopt=Abstract
•
Role of food hypersensitivity in irritable bowel syndrome. Author(s): Zar S, Kumar D, Kumar D. Source: Minerva Med. 2002 October; 93(5): 403-12. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410172&dopt=Abstract
•
Sense of coherence and quality of life in women with and without irritable bowel syndrome. Author(s): Motzer SA, Hertig V, Jarrett M, Heitkemper MM. Source: Nursing Research. 2003 September-October; 52(5): 329-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14501547&dopt=Abstract
•
Sensory dysfunction and the irritable bowel syndrome. Author(s): Houghton LA. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 415-27. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580918&dopt=Abstract
•
Serotonergic modulators in the treatment of irritable bowel syndrome: influence on psychiatric and gastrointestinal symptoms. Author(s): Castle MZ, Silk DB, Libby GW. Source: Alimentary Pharmacology & Therapeutics. 2003 June 1; 17(11): 1425. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12786637&dopt=Abstract
•
Serotonin and its implication for the management of irritable bowel syndrome. Author(s): Gershon MD. Source: Reviews in Gastroenterological Disorders. 2003; 3 Suppl 2: S25-34. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12776000&dopt=Abstract
•
Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome. Author(s): Jarrett M, Heitkemper M, Cain KC, Burr RL, Hertig V. Source: Digestive Diseases and Sciences. 2000 May; 45(5): 952-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10795760&dopt=Abstract
102 Irritable Bowel Syndrome
•
Stimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. Author(s): Fritz E, Hammer J, Schmidt B, Eherer AJ, Hammer HF. Source: The American Journal of Gastroenterology. 2003 October; 98(10): 2253-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14572576&dopt=Abstract
•
Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. Author(s): Muller-Lissner S, Koch G, Talley NJ, Drossman D, Rueegg P, Dunger-Baldauf C, Lefkowitz M. Source: Journal of Clinical Epidemiology. 2003 April; 56(4): 310-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767407&dopt=Abstract
•
Symptoms across the menstrual cycle in women with irritable bowel syndrome. Author(s): Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Source: The American Journal of Gastroenterology. 2003 February; 98(2): 420-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591063&dopt=Abstract
•
Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Author(s): Hasler WL, Schoenfeld P. Source: Alimentary Pharmacology & Therapeutics. 2003 Apr15; 17(8): 997-1005. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12694081&dopt=Abstract
•
Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome--influence on psychiatric and gastrointestinal symptoms. Author(s): Kilkens TO, Honig A, Rozendaal N, Van Nieuwenhoven MA, Brummer RJ. Source: Alimentary Pharmacology & Therapeutics. 2003 January; 17(1): 43-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12492731&dopt=Abstract
•
The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Author(s): Su YC, Wang WM, Wang SY, Lu SN, Chen LT, Wu DC, Chen CY, Jan CM, Horowitz M. Source: The American Journal of Gastroenterology. 2000 August; 95(8): 1900-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10950033&dopt=Abstract
•
The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Author(s): Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. Source: The American Journal of Gastroenterology. 2000 April; 95(4): 981-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10763948&dopt=Abstract
Studies
103
•
The many faces of irritable bowel syndrome. Author(s): Gwee KA. Source: Singapore Med J. 1999 July; 40(7): 441-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10560266&dopt=Abstract
•
The measurement of irritable bowel syndrome (IBS)-related misconceptions in people with IBS. Author(s): Dancey CP, Fox R, Devins GM. Source: Journal of Psychosomatic Research. 1999 September; 47(3): 269-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10576475&dopt=Abstract
•
The problem of gas in irritable bowel syndrome. Author(s): Whorwell PJ. Source: The American Journal of Gastroenterology. 2000 July; 95(7): 1618-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10925958&dopt=Abstract
•
The role of psychosocial factors in irritable bowel syndrome. Author(s): Gaynes BN, Drossman DA. Source: Bailliere's Best Practice & Research. Clinical Gastroenterology. 1999 October; 13(3): 437-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10580920&dopt=Abstract
•
The understanding of their illness amongst people with irritable bowel syndrome: a Q methodological study. Author(s): Stenner PH, Dancey CP, Watts S. Source: Social Science & Medicine (1982). 2000 August; 51(3): 439-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10855930&dopt=Abstract
•
Towards an integrative model of irritable bowel syndrome. Author(s): Naliboff BD, Chang L, Munakata J, Mayer EA. Source: Prog Brain Res. 2000; 122: 413-23. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10737074&dopt=Abstract
•
Treatment of irritable bowel syndrome with loperamide oxide. An open study to determine optimal dosage. Author(s): Ragnarsson G, Bodemar G. Source: Journal of Internal Medicine. 2000 August; 248(2): 165-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10947896&dopt=Abstract
104 Irritable Bowel Syndrome
•
Treatment of irritable bowel syndrome: new modalities for a new millennium. Author(s): Olden KW. Source: The American Journal of Gastroenterology. 2000 April; 95(4): 863-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10763925&dopt=Abstract
•
Understanding irritable bowel syndrome and gastrointestinal motility. Author(s): Lind CD. Source: Mayo Clinic Proceedings. 1992 August; 67(8): 804-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1434922&dopt=Abstract
•
Understanding the irritable bowel syndrome. Author(s): Young GP. Source: Aust Fam Physician. 1987 April; 16(4): 392-6, 399, 404. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3593106&dopt=Abstract
•
University of Miami Division of Clinical Pharmacology therapeutic rounds: irritable bowel syndrome-pathophysiology, diagnosis, and treatment. Author(s): Schwartz D, Stollman N. Source: American Journal of Therapeutics. 2000 August; 7(4): 265-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486161&dopt=Abstract
•
Update in the therapeutic management of irritable bowel syndrome. Author(s): Villanueva A, Dominguez-Munoz JE, Mearin F. Source: Digestive Diseases (Basel, Switzerland). 2001; 19(3): 244-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11752844&dopt=Abstract
•
Update: irritable bowel syndrome. Author(s): Smith JN. Source: Mo Med. 1979 May; 76(5): 262-4, 269. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=440268&dopt=Abstract
•
Upper gastrointestinal and mental symptoms in the irritable bowel syndrome. Author(s): Svedlund J, Sjodin I, Dotevall G, Gillberg R. Source: Scandinavian Journal of Gastroenterology. 1985 June; 20(5): 595-601. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4023624&dopt=Abstract
•
Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome. Author(s): Harding JP, Hamm LR, Ehsanullah RS, Heath AT, Sorrells SC, Haw J, Dukes GE, Wolfe SG, Mangel AW, Northcutt AR. Source: Alimentary Pharmacology & Therapeutics. 1997 December; 11(6): 1073-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9663832&dopt=Abstract
Studies
105
•
Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Author(s): Sperber AD, Carmel S, Atzmon Y, Weisberg I, Shalit Y, Neumann L, Fich A, Friger M, Buskila D. Source: The American Journal of Gastroenterology. 2000 April; 95(4): 995-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10763949&dopt=Abstract
•
Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. Author(s): Milo R. Source: Current Medical Research and Opinion. 1980; 6(9): 577-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6996928&dopt=Abstract
•
Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Author(s): Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Source: The American Journal of Gastroenterology. 2002 November; 97(11): 2803-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12425552&dopt=Abstract
•
V. Stress and irritable bowel syndrome. Author(s): Mayer EA, Naliboff BD, Chang L, Coutinho SV. Source: American Journal of Physiology. Gastrointestinal and Liver Physiology. 2001 April; 280(4): G519-24. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11254476&dopt=Abstract
•
Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Author(s): Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Source: Digestive Diseases and Sciences. 2003 July; 48(7): 1317-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12870789&dopt=Abstract
•
Validity of the Family APGAR in patients with irritable bowel syndrome. Author(s): Gwyther RE, Bentz EJ, Drossman DA, Berolzheimer N. Source: Family Medicine. 1993 January; 25(1): 21-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8454119&dopt=Abstract
•
Verapamil effective in irritable bowel syndrome? Author(s): McLeod J. Source: The Medical Journal of Australia. 1983 August 6; 2(3): 119. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6877141&dopt=Abstract
106 Irritable Bowel Syndrome
•
Verapamil in the treatment of irritable bowel syndrome. Author(s): Byrne S. Source: The Journal of Clinical Psychiatry. 1987 September; 48(9): 388. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3624216&dopt=Abstract
•
Visceral afferent hypersensitivity in irritable bowel syndrome--evaluation by cerebral evoked potential after rectal stimulation. Author(s): Sinhamahapatra P, Saha SP, Chowdhury A, Chakrabarti SK, Ghosh A, Maiti B. Source: The American Journal of Gastroenterology. 2001 July; 96(7): 2150-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11467647&dopt=Abstract
•
Visceral algesia in irritable bowel syndrome, fibromyalgia, and sphincter of oddi dysfunction, type III. Author(s): Chun A, Desautels S, Slivka A, Mitrani C, Starz T, DiLorenzo C, Wald A. Source: Digestive Diseases and Sciences. 1999 March; 44(3): 631-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10080161&dopt=Abstract
•
Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Author(s): Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Source: Digestive Diseases and Sciences. 1995 April; 40(4): 819-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7720476&dopt=Abstract
•
What can be done to control incontinence associated with the irritable bowel syndrome? Author(s): Drossman DA. Source: The American Journal of Gastroenterology. 1989 April; 84(4): 355-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2929552&dopt=Abstract
•
What do patients with irritable bowel syndrome dream about? A comparison with inflammatory bowel disease. Author(s): Lal S, Whorwell PJ. Source: Dig Liver Dis. 2002 July; 34(7): 506-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12236484&dopt=Abstract
•
What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Author(s): Cann PA, Read NW, Holdsworth CD. Source: Gut. 1984 February; 25(2): 168-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6319244&dopt=Abstract
Studies
107
•
What is the relevance of a systematic review of pharmacological management in irritable bowel syndrome to older people? Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Author(s): Camilleri M, Kim DY. Source: Journal of the American Geriatrics Society. 2001 September; 49(9): 1249-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11559387&dopt=Abstract
•
Wheat fibre and irritable bowel syndrome. A controlled trial. Author(s): Manning AP, Heaton KW, Harvey RF. Source: Lancet. 1977 August 27; 2(8035): 417-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=70639&dopt=Abstract
•
Which is the best distension protocol to study rectal sensitivity in the irritable bowel syndrome? Author(s): Rey E, Alvarez Sanchez A, Diaz-Rubio M. Source: Rev Esp Enferm Dig. 2002 April; 94(4): 211-20. English, Spanish. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12185932&dopt=Abstract
•
Who gets irritable bowel syndrome and does seeing a gastroenterologist affect its course? Author(s): Bernstein CN. Source: Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie. 2001 October; 15 Suppl B: 5B-7B. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11694907&dopt=Abstract
•
Whole-bowel transit in patients with the irritable bowel syndrome. Author(s): Hardy JG, Wood E, Clark AG, Reynolds JR. Source: European Journal of Nuclear Medicine. 1986; 11(10): 393-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3699063&dopt=Abstract
•
Women with irritable bowel syndrome: differences in patients' and physicians' perceptions. Author(s): Heitkemper M, Carter E, Ameen V, Olden K, Cheng L. Source: Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates. 2002 September-October; 25(5): 192-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12394395&dopt=Abstract
109
CHAPTER 2. SYNDROME
NUTRITION
AND
IRRITABLE
BOWEL
Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and irritable bowel syndrome.
Finding Nutrition Studies on Irritable Bowel Syndrome The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “irritable bowel syndrome” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
110 Irritable Bowel Syndrome
The following information is typical of that found when using the “Full IBIDS Database” to search for “irritable bowel syndrome” (or a synonym): •
A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Author(s): Department of Gastroenterology, M. Curie Regional Hospital, Szczecin, Poland.
[email protected] Source: Niedzielin, K Kordecki, H Birkenfeld, B Eur-J-Gastroenterol-Hepatol. 2001 October; 13(10): 1143-7 0954-691X
•
A dietary remedy for irritable bowel syndrome. Source: Cerrato, P L RN. 1987 July; 50(7): 65-6 0033-7021
•
A new look at irritable bowel syndrome [IBS]: a neuroenteric disorder. Author(s): Weill Medical College of Cornell University, New York, NY, USA. Source: Frissora, C L Compr-Ther. 2002 Fall; 28(3): 222-31 0098-8243
•
A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Author(s): The Natural Medicine Research Unit, Hadassah University Hospital, Jerusalem, Israel.
[email protected] Source: Sallon, S Ben Arye, E Davidson, R Shapiro, H Ginsberg, G Ligumsky, M Digestion. 2002; 65(3): 161-71 0012-2823
•
A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Author(s): Gastroenterology Research Unit, Unit E7, Box 201 A, Addenbrookes NHS Trust, Hill's Road, CB2 2QQ, Cambridge, UK. Source: Madden, J A Hunter, J O Br-J-Nutr. 2002 September; 88 Suppl 1: S67-72 00071145
•
A single-blind trial of reflexology for irritable bowel syndrome. Author(s): School of Healthcare Studies, University of Leeds.
[email protected] Source: Tovey, Philip Br-J-Gen-Pract. 2002 January; 52(474): 19-23 0960-1643
•
A systematic review of alternative therapies in the irritable bowel syndrome. Author(s): Department of Internal Medicine, Northwestern Memorial Hospital, 251 E Huron, Galter 4-104, Chicago, IL 60611, USA. Source: Spanier, J A Howden, C W Jones, M P Arch-Intern-Med. 2003 February 10; 163(3): 265-74 0003-9926
•
Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms. Author(s): Department of Gastroenterology, University Hospital Nottingham, United Kingdom. Source: Hebden, J M Blackshaw, E D'Amato, M Perkins, A C Spiller, R C Am-JGastroenterol. 2002 September; 97(9): 2315-20 0002-9270
•
Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. Author(s): Gastroenterology Unit, Germans Trias i Pujol Hospital Badalona, Barcelona, Spain. Source: Villagrasa, M Boix, J Humbert, P Quer, J C Ital-J-Gastroenterol. 1991 November; 23(8 Suppl 1): 67-70 0392-0623
Nutrition
111
•
Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome? Author(s): Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation, OH 44195, USA. Source: Shen, B Soffer, E E Cleve-Clin-J-Med. 2003 January; 70(1): 64-5 0891-1150
•
Anisocoria associated with the medical treatment of irritable bowel syndrome. Author(s): Department of Ophthalmology, Ochsner Clinic, New Orleans, Louisiana 70121, USA. Source: Nussdorf, J D Berman, E L J-Neuroophthalmol. 2000 June; 20(2): 100-1 1070-8022
•
Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. Author(s): Department of Gastroenterologist, Leicester General Hospital, U.K. Source: Cooke, C Carr, I Abrams, K Mayberry, J Arq-Gastroenterol. 2000 Jan-March; 37(1): 20-4 0004-2803
•
Bacterial supplementation in the irritable bowel syndrome. A randomised doubleblind placebo-controlled crossover study. Author(s): Department of Gastroenterology, Adelaide & Meath Hospital, Tallaght, Dublin, Ireland. Source: O'Sullivan, M A O'Morain, C A Dig-Liver-Dis. 2000 May; 32(4): 294-301
•
Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Author(s): Gastroenterology Institute, Shaare Zedek Medical Center, Jerusalem, Israel. Source: Goldstein, R Braverman, D Stankiewicz, H Isr-Med-Assoc-J. 2000 August; 2(8): 583-7 1565-1088
•
Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Author(s): Department of Gastroenterology and Infectious Diseases, Universitatsklinikum Benjamin Franklin, Freie Universitat Berlin, D-12200 Berlin, Germany.
[email protected] Source: Wahnschaffe, U Ullrich, R Riecken, E O Schulzke, J D Gastroenterology. 2001 December; 121(6): 1329-38 0016-5085
•
Charcoal tablets in the treatment of patients with irritable bowel syndrome. Author(s): Berolina Drug Development GmbH, Neuenhagen, Germany. Source: Hubner, W D Moser, E H Adv-Ther. 2002 Sep-October; 19(5): 245-52 0741-238X
•
Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Author(s): Mayo Clinic, Rochesster, MN 55905, USA.
[email protected] Source: Camilleri, M Heading, R C Thompson, W G Aliment-Pharmacol-Ther. 2002 August; 16(8): 1407-30 0269-2813
•
Constipation, diarrhea, and irritable bowel syndrome. Author(s): Attending Colon and Rectal Surgeon, Department of Surgery, Wilford Hall Medical Center, San Antonio, Texas, USA. Source: Browning, S M Prim-Care. 1999 March; 26(1): 113-39 0095-4543
•
Contemporary thoughts on the treatment of irritable bowel syndrome. Source: Giaquinta, D Manag-Care-Interface. 2002 August; 15(8): 19-20, 22
•
Current concepts in the management of the irritable bowel syndrome. Author(s): Bowel Disease and Motility Center, Long Beach Memorial Medical Center, CA.
112 Irritable Bowel Syndrome
Source: Snape, W J Rev-Gastroenterol-Mex. 1994 Apr-June; 59(2): 127-32 0375-0906 •
Dealing with irritable bowel syndrome. Author(s): Department of Medicine, Aga Khan University Hospital, Karachi. Source: Abbas, Z J-Pak-Med-Assoc. 1999 March; 49(3): 78-81 concl 0030-9982
•
Diet in the irritable bowel syndrome. Author(s): Gastroenterology & Nutrition Section, Norwalk Hospital, Yale University School of Medicine, Norwalk, Connecticut, USA.
[email protected] Source: Floch, M H Narayan, R J-Clin-Gastroenterol. 2002 July; 35(1 Suppl): S45-52 01920790
•
Diet triggers symptoms in women with irritable bowel syndrome. The patient's perspective. Author(s): Department of Biobehavioral Nursing and Health Systems, University of Washington, Box 357266, Seattle, WA 98195-7266, USA.
[email protected] Source: Jarrett, M Visser, R Heitkemper, M Gastroenterol-Nurs. 2001 Sep-October; 24(5): 246-52 1042-895X
•
Dietary treatment of irritable bowel syndrome: current evidence and guidelines for future practice. Source: Burden, S. J-hum-nutr-diet. Oxford : Blackwell Science Ltd. June 2001. volume 14 (3) page 231-241. 0952-3871
•
Drug therapy options for patients with irritable bowel syndrome. Source: Talley, N J Am-J-Manag-Care. 2001 July; 7(8 Suppl): S261-7 1096-1860
•
Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. Author(s): Gastrointestinal Research Unit, Departments of Gastroenterology and Surgery, University Medical Center Utrecht, The Netherlands. Source: Clemens, C H Samsom, M Van Berge Henegouwen, G P Fabri, M Smout, A J Aliment-Pharmacol-Ther. 2002 May; 16(5): 993-1002 0269-2813
•
Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Author(s): Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK. Source: Sen, S Mullan, M M Parker, T J Woolner, J T Tarry, S A Hunter, J O Dig-Dis-Sci. 2002 November; 47(11): 2615-20 0163-2116
•
Effect of red chillies on small bowel and colonic transit and rectal sensitivity in men with irritable bowel syndrome. Author(s): Department of Gastroenterology, B Y L Nair Hospital and T N Medical College, Mumbai. Source: Agarwal, M K Bhatia, S J Desai, S A Bhure, U Melgiri, S Indian-J-Gastroenterol. 2002 Sep-October; 21(5): 179-82 0254-8860
•
Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Author(s): Dipartimento di Scienze Farmaceutiche, Universita di Bologna, Italy.
[email protected] Source: Brigidi, P Vitali, B Swennen, E Bazzocchi, G Matteuzzi, D Res-Microbiol. 2001 October; 152(8): 735-41 0923-2508
Nutrition
113
•
Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. Author(s): Department of Internal Medicine, Taichung Veterans General Hospital, Taiwan. Source: Liu, J H Chen, G H Yeh, H Z Huang, C K Poon, S K J-Gastroenterol. 1997 December; 32(6): 765-8 0944-1174
•
Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Author(s): Department of Gastroenterology, Addenbrooke's Hospital NHS Trust, Hills Road, Cambridge CB2 2QQ, UK. Source: Sen, S Dear, K L King, T S Elia, M Hunter, J O Eur-J-Gastroenterol-Hepatol. 2002 July; 14(7): 753-6 0954-691X
•
Evidence-based position statement on the management of irritable bowel syndrome in North America. Source: Am-J-Gastroenterol. 2002 November; 97(11 Suppl): S1-5 0002-9270
•
FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky. Author(s): Section of Gastroenterology, Temple University Hospital, Philadelphia, Pennsylvania, USA. Source: Horwitz, B J Health-News. 2002 October; 8(10): 1-2 1081-5880
•
Functional diagnostic work-up in patients with irritable bowel syndrome. Author(s): Department of Gastroenterology, University of Munich, Germany. Source: Klauser, A G Voderholzer, W A Schindlbeck, N E Muller Lissner, S A ZGastroenterol. 1996 May; 34(5): 273-8 0044-2771
•
Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Author(s):
[email protected] Source: Luscombe, F A Qual-Life-Res. 2000 March; 9(2): 161-76 0962-9343
•
High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Author(s): Servizio di Gastroenterologia, Casa di Cura Abano Terme USL 16, Padova, Italy. Source: Parisi, G C Zilli, M Miani, M P Carrara, M Bottona, E Verdianelli, G Battaglia, G Desideri, S Faedo, A Marzolino, C Tonon, A Ermani, M Leandro, G Dig-Dis-Sci. 2002 August; 47(8): 1697-704 0163-2116
•
Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome? Author(s): St Mark's Hospital, Watford Road, Harrow HA1 3UJ, UK.
[email protected] Source: Forbes, A MacAuley, S Chiotakakou Faliakou, E Int-J-Colorectal-Dis. 2000 November; 15(5-6): 328-34 0179-1958
•
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left? Source: Robb Nicholson, C Harv-Womens-Health-Watch. 1998 November; 6(3): 8 1070910X
114 Irritable Bowel Syndrome
•
Impact of irritable bowel syndrome on personal relationships and working practices. Author(s): Department of Gastroenterology & Nutrition, Central Middlesex Hospital, The North West London Hospitals NHS Trust, London, UK. Source: Silk, D B Eur-J-Gastroenterol-Hepatol. 2001 November; 13(11): 1327-32 0954691X
•
Inflammatory bowel disease and irritable bowel syndrome. Author(s): Johns Hopkins University School of Medicine, Baltimore, Maryland. Source: Bayless, T M Harris, M L Med-Clin-North-Am. 1990 January; 74(1): 21-8 00257125
•
Interventions for irritable bowel syndrome: a nursing model. Source: Heitkemper, M Levy, R L Jarrett, M Bond, E F Gastroenterol-Nurs. 1995 NovDecember; 18(6): 224-30 1042-895X
•
Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Author(s): Dept. of Internal Medicine and Gastroenterology, Bellana Hospital, University of Bologna, Italy.
[email protected] Source: Bazzocchi, G Gionchetti, P Almerigi, P F Amadini, C Campieri, M Dig-Liver-Dis. 2002 September; 34 Suppl 2: S48-53 1590-8658
•
Irritable bowel syndrome and Crohn's disease. Source: Jones, VolumeA. Hunter, J.O. Food allergy and intolerance / [edited by] Jonathan Brostoff, Stephen J. Challacombe. London : Bailli'ere Tindall, 1987. page 555569. ISBN: 0702011568
•
Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactosefree diet. Author(s): Cattedra di Gastroenterologia I, Universita La Sapienza, Roma, Italy. Source: Vernia, P Ricciardi, M R Frandina, C Bilotta, T Frieri, G Ital-J-Gastroenterol. 1995 April; 27(3): 117-21 0392-0623
•
Lipid-induced intestinal gas retention in irritable bowel syndrome. Author(s): Digestive System Research Unit, Hospital General Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain. Source: Serra, J Salvioli, B Azpiroz, F Malagelada, J R Gastroenterology. 2002 September; 123(3): 700-6 0016-5085
•
Living with irritable bowel syndrome. Source: Anonymous Nursing. 1999 September; 29(9): 20 0360-4039
•
Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial. Author(s): Department of Gastroenterology, G. B. Pant Hospital, New Delhi, India. Source: Misra, S P Thorat, V K Sachdev, G K Anand, B S Q-J-Med. 1989 October; 73(270): 931-9 0033-5622
•
Management of irritable bowel syndrome. Author(s): Naval Hospital Jacksonville, Jacksonville, Florida, USA.
[email protected] Source: Viera, A J Hoag, S Shaughnessy, J Am-Fam-Physician. 2002 November 15; 66(10): 1867-74 0002-838X
•
Managing irritable bowel syndrome. Source: Alderman, J Adv-Nurse-Pract. 1999 January; 7(1): 40-1, 45-6, 78 1096-6293
Nutrition
115
•
New developments in the diagnosis and treatment of irritable bowel syndrome. Author(s): Department of Gastroenterology, Kaiser Permanente Medical Care Program, 4647 Zion Avenue, San Diego, CA 92120, USA.
[email protected] Source: Longstreth, G F Drossman, D A Curr-Gastroenterol-Repage 2002 October; 4(5): 427-34 1522-8037
•
Nutritional issues in irritable bowel syndrome. Author(s): Division of Gastroenterology, University Hospital, Nottingham, UK. Source: Dunlop, S P Spiller, R C Curr-Opin-Clin-Nutr-Metab-Care. 2001 November; 4(6): 537-40 1363-1950
•
Patient satisfaction with alosetron for the treatment of women with diarrheapredominant irritable bowel syndrome. Author(s): Mayo Clinic Scottsdale, Scottsdale, Arizona, USA. Source: Olden, K DeGarmo, R G Jhingran, P Bagby, B Decker, C Markowitz, M Carter, E Bobbitt, W Dahdul, A DeCastro, E Gringeri, L Johanson, J Levinson, L Mula, G Poleynard, G Stoltz, R R Truesdale, R Young, D Am-J-Gastroenterol. 2002 Dec; 97(12): 3139-46 0002-9270
•
Quality of life in irritable bowel syndrome, effect of therapy. Author(s): Therapeutics Research Unit, Lariboisiere Hospital, Paris, France. Source: Chassany, O Bergmann, J F Eur-J-Surg-Suppl. 1998; (583): 81-6
•
Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome. Author(s): Istituto di Clinica Medica e Gastroenterologia, Universita di Bologna, Italy. Source: Lanfranchi, G A Bazzocchi, G Campieri, M Brignola, C Fois, F Imbimbo, B P EurJ-Clin-Pharmacol. 1988; 33(6): 571-5 0031-6970
•
Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. Author(s): Experimental Medicine and Motility Unit, Ministry of Health, Mexico City General Hospital; Mexico D.F.
[email protected] Source: Awad, R A Cordova, V H Dibildox, M Santiago, R Camacho, S ActaGastroenterol-Latinoam. 1997; 27(4): 247-51 0300-9033
•
Risk of irritable bowel syndrome among asthma patients. Author(s): Centro Espanol de Investigacion Farmacoepidemiologica (CEIFE), Madrid, Spain.
[email protected] Source: Huerta, C Garcia Rodriguez, L A Wallander, M A Johansson, S Pharmacoepidemiol-Drug-Saf. 2002 Jan-February; 11(1): 31-5 1053-8569
•
Role of dietary fibre in irritable bowel syndrome: a clinical study. Source: Sharma, S Saini, R K Goswami, S K Sharma, A Singh, S Indian-J-Med-Sci. 1987 February; 41(2): 29-33 0019-5359
•
Role of food hypersensitivity in irritable bowel syndrome. Author(s): OGEM Department, St. Georges Hospital Medical School, London, UK. Source: Zar, S KuMarch, D Kumar, D Minerva-Med. 2002 October; 93(5): 403-12 00264806
•
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Author(s): Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Foundation, Rochester, Minnesota 55905, USA.
[email protected]
116 Irritable Bowel Syndrome
Source: Camilleri, Michael Atanasova, Elena Carlson, Paula J Ahmad, Umraan Kim, H Jae Viramontes, Blanca E McKinzie, Sanna Urrutia, Raul Gastroenterology. 2002 August; 123(2): 425-32 0016-5085 •
Systematic review on the management of irritable bowel syndrome in North America. Author(s): Albert Einstein College of Medicine, Bronx, NY, USA. Source: Brandt, L J Bjorkman, D Fennerty, M B Locke, G R Olden, K Peterson, W Quigley, E Schoenfeld, P Schuster, M Talley, N Am-J-Gastroenterol. 2002 November; 97(11 Suppl): S7-26 0002-9270
•
Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Author(s): Drug Information Center, College of Pharmacy, Washington State University, Spokane, WA, USA. Source: Baker, D E Rev-Gastroenterol-Disord. 2001; 1(4): 187-98 1533-001X
•
The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Author(s): CURE Digestive Diseases Research Center / Neuroenteric Disease Program, Department of Medicine, University of California School of Medicine, Los Angeles, CA 90073, USA.
[email protected] Source: Mayer, E A Berman, S Derbyshire, S W Suyenobu, B Chang, L Fitzgerald, L Mandelkern, M Hamm, L Vogt, B Naliboff, B D Aliment-Pharmacol-Ther. 2002 July; 16(7): 1357-66 0269-2813
•
The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Author(s): University of Ottawa, Ontario, Canada.
[email protected] Source: Thompson, W G Hungin, A P Neri, M Holtmann, G Sofos, S Delvaux, M Caballero Plasencia, A Eur-J-Gastroenterol-Hepatol. 2001 August; 13(8): 933-9 0954-691X
•
The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. Source: Gilvarry, J Kenny, A Fielding, J F Ir-J-Med-Sci. 1989 October; 158(10): 262 00211265
•
The treatment of functional dyspepsia with red pepper. Author(s): Department of Internal Medicine, University of Bologna, Via Massarenti 48, 40138 Bologna, Italy.
[email protected] Source: Bortolotti, M Coccia, G Grossi, G Miglioli, M Aliment-Pharmacol-Ther. 2002 June; 16(6): 1075-82 0269-2813
•
The treatment of irritable bowel syndrome. Author(s): University of Ottawa, Ottawa, Ontario, Canada.
[email protected] Source: Thompson, W G Aliment-Pharmacol-Ther. 2002 August; 16(8): 1395-406 02692813
•
Therapeutic strategy for the irritable bowel syndrome. Author(s): Cattedra di Gastroenterologia, II Facolta, Universita di Napoli, Italy. Source: Castiglione, F Daniele, B Mazzacca, G Ital-J-Gastroenterol. 1991 November; 23(8 Suppl 1): 53-5 0392-0623
•
Treating irritable bowel syndrome. Author(s): Digestion Health Center, University of Virginia Health Science Center, USA. Source: Bickston, S J Health-News. 1999 January 5; 5(1): 3 1081-5880
Nutrition
117
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
118 Irritable Bowel Syndrome
The following is a specific Web list relating to irritable bowel syndrome; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Food and Diet Barley Source: Healthnotes, Inc.; www.healthnotes.com Fructo-Oligosaccharides (FOS) and Other Oligosaccharides Source: Healthnotes, Inc.; www.healthnotes.com Juices Source: Healthnotes, Inc.; www.healthnotes.com Milk Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/foods_view/0,1523,95,00.html Natural Sweeteners Source: Healthnotes, Inc.; www.healthnotes.com Refined Sweeteners Source: Healthnotes, Inc.; www.healthnotes.com Rhubarb Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Rye Source: Healthnotes, Inc.; www.healthnotes.com Sugar Alcohols Source: Healthnotes, Inc.; www.healthnotes.com Tea Source: Healthnotes, Inc.; www.healthnotes.com Wheat Source: Healthnotes, Inc.; www.healthnotes.com
119
CHAPTER 3. ALTERNATIVE MEDICINE AND IRRITABLE BOWEL SYNDROME Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to irritable bowel syndrome. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to irritable bowel syndrome and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “irritable bowel syndrome” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to irritable bowel syndrome: •
A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Author(s): Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. Source: The American Journal of Gastroenterology. 2003 October; 98(10): 2209-18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14572570&dopt=Abstract
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
120 Irritable Bowel Syndrome
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com®: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMD®Health: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to irritable bowel syndrome; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Allergies and Sensitivities Source: Healthnotes, Inc.; www.healthnotes.com Constipation Source: Healthnotes, Inc.; www.healthnotes.com Diarrhea Source: Healthnotes, Inc.; www.healthnotes.com Fibromyalgia Source: Healthnotes, Inc.; www.healthnotes.com Fibromyalgia Source: Integrative Medicine Communications; www.drkoop.com Irritable Bowel Syndrome Source: Healthnotes, Inc.; www.healthnotes.com Irritable Bowel Syndrome Alternative names: Spastic Colon Source: Prima Communications, Inc.www.personalhealthzone.com Proctitis Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 121
Rectal Inflammation Source: Integrative Medicine Communications; www.drkoop.com Spastic Colon Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Healthnotes, Inc.; www.healthnotes.com •
Alternative Therapy Acupuncture Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,663,00.html Ayurveda Source: Integrative Medicine Communications; www.drkoop.com Ayurveda Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,672,00.html Biofeedback Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,675,00.html Hydrotherapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,705,00.html Hypnotherapy Source: Healthnotes, Inc.; www.healthnotes.com Hypnotherapy Source: Integrative Medicine Communications; www.drkoop.com Hypnotherapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,706,00.html Meditation Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,717,00.html Reflexology Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com
122 Irritable Bowel Syndrome
Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,730,00.html Traditional Chinese Medicine Source: Integrative Medicine Communications; www.drkoop.com Traditional Chinese Medicine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10085,00.html Yoga Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,746,00.html •
Chinese Medicine Guizhi Alternative names: Cassia Twig; Ramulus Cinnamomi Source: Chinese Materia Medica
•
Homeopathy Argentum Nitricum Source: Healthnotes, Inc.; www.healthnotes.com Asafoetida Source: Healthnotes, Inc.; www.healthnotes.com Lilium Tigrinum Source: Healthnotes, Inc.; www.healthnotes.com Lycopodium Source: Healthnotes, Inc.; www.healthnotes.com Nux Vomica Source: Healthnotes, Inc.; www.healthnotes.com Podophyllum Source: Healthnotes, Inc.; www.healthnotes.com Sulphur Source: Healthnotes, Inc.; www.healthnotes.com
•
Herbs and Supplements Acidophilus Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com
Alternative Medicine 123
Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,748,00.html Acidophilus and Other Probiotics Source: Prima Communications, Inc.www.personalhealthzone.com Aloe Alternative names: Aloe vera, Aloe barbadensis, Aloe ferox , Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Aloe Vera Source: Integrative Medicine Communications; www.drkoop.com Bupleurum Alternative names: Bupleurum chinense, Bupleurum falcatum Source: Healthnotes, Inc.; www.healthnotes.com Caraway Alternative names: Carum carvi Source: Healthnotes, Inc.; www.healthnotes.com Chamomile Alternative names: Matricaria recutita Source: Healthnotes, Inc.; www.healthnotes.com Chamomile Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,766,00.html Coleus Forskohlii Source: Prima Communications, Inc.www.personalhealthzone.com Dicyclomine Source: Healthnotes, Inc.; www.healthnotes.com Digestive Enzymes Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10051,00.html Fiber Source: Healthnotes, Inc.; www.healthnotes.com FOS Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10026,00.html Ginger Alternative names: Zingiber officinale Source: Healthnotes, Inc.; www.healthnotes.com
124 Irritable Bowel Syndrome
GLA (Gamma-Linolenic Acid) Source: Prima Communications, Inc.www.personalhealthzone.com Glutamine Source: Integrative Medicine Communications; www.drkoop.com Glutamine Source: Prima Communications, Inc.www.personalhealthzone.com Grapefruit Seed Extract Source: Healthnotes, Inc.; www.healthnotes.com Herbal Digestive Formula Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10104,00.html Hops Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Hyoscyamine Source: Healthnotes, Inc.; www.healthnotes.com Ispaghula Source: Integrative Medicine Communications; www.drkoop.com Kava Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,798,00.html L. Acidophilus Source: Integrative Medicine Communications; www.drkoop.com Lactase Source: Healthnotes, Inc.; www.healthnotes.com Lactobacillus Acidophilus Source: Integrative Medicine Communications; www.drkoop.com Marshmallow Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10042,00.html Mentha X Piperita Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 125
Peppermint Alternative names: Mentha piperita Source: Healthnotes, Inc.; www.healthnotes.com Peppermint Alternative names: Mentha x piperita Source: Integrative Medicine Communications; www.drkoop.com Peppermint Source: Prima Communications, Inc.www.personalhealthzone.com Peppermint Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,812,00.html Plantago Isphagula Source: Integrative Medicine Communications; www.drkoop.com Plantago Psyllium Alternative names: Psyllium, Ispaghula; Plantago psyllium/ovata Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org PMS Herbal Combination Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,947,00.html Psyllium Alternative names: Plantago ovata, Plantago ispaghula Source: Healthnotes, Inc.; www.healthnotes.com Psyllium Alternative names: Ispaghula,Plantago isphagula Source: Integrative Medicine Communications; www.drkoop.com Psyllium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,814,00.html Slippery Elm Source: Prima Communications, Inc.www.personalhealthzone.com St. John's Wort Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,824,00.html Valerian Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca
126 Irritable Bowel Syndrome
Valerian Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10064,00.html Wormwood Alternative names: Artemisia absinthium Source: Healthnotes, Inc.; www.healthnotes.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
127
CHAPTER 4. DISSERTATIONS ON IRRITABLE BOWEL SYNDROME Overview In this chapter, we will give you a bibliography on recent dissertations relating to irritable bowel syndrome. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “irritable bowel syndrome” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on irritable bowel syndrome, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Irritable Bowel Syndrome ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to irritable bowel syndrome. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
A Comparative Psychophysiological Study of Normal Subjects, Psychoneurotic Patients and Patients with Irritable Bowel Syndrome by Latimer, Paul Ross; PhD from McMaster University (Canada), 1980 http://wwwlib.umi.com/dissertations/fullcit/NK50847
•
Autonomic and Endocrine Activity in Irritable Bowel Syndrome Patients with and without Depressive Symptoms by Thompson, Jennifer Jean; PhD from The University of Oklahoma Health Sciences Center, 2003, 197 pages http://wwwlib.umi.com/dissertations/fullcit/3087228
•
Irritable Bowel Syndrome among Women with Chronic Pelvic Pain: Characteristics, Treatment, and Post-operative Outcomes by Williams, Rachel Elizabeth; PhD from The University of North Carolina at Chapel Hill, 2003, 148 pages http://wwwlib.umi.com/dissertations/fullcit/3086650
128 Irritable Bowel Syndrome
•
Stress Management Training for the Irritable Bowel Syndrome by Lynch, Patrick Michael; PhD from Queen's University at Kingston (Canada), 1986 http://wwwlib.umi.com/dissertations/fullcit/NL32193
•
The Impact of Psychological Information on Medical Recommendations for Treating Irritable Bowel Syndrome by Roth, David Alan; PhD from Hofstra University, 2003, 153 pages http://wwwlib.umi.com/dissertations/fullcit/3075169
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
129
CHAPTER 5. CLINICAL TRIALS AND IRRITABLE BOWEL SYNDROME Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning irritable bowel syndrome.
Recent Trials on Irritable Bowel Syndrome The following is a list of recent trials dedicated to irritable bowel syndrome.8 Further information on a trial is available at the Web site indicated. •
Genetics of Fibromyalgia Condition(s): Fibromyalgia; Irritable Bowel Syndrome; Chronic Fatigue Syndrome; Depression Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Purpose - Excerpt: The Fibromyalgia Family Study identifies and collects blood samples from families with two or more members affected with Fibromyalgia Syndrome (FMS). The primary goal of the study is to identify genes that predispose people to FMS and/or symptoms related to FMS; identifying these genes may lead to a better understanding of the disease and more effective treatments. Study Type: Observational Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00071162
•
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Condition(s): Irritable Bowel Syndrome
8
These are listed at www.ClinicalTrials.gov.
130 Irritable Bowel Syndrome
Study Status: This study is currently recruiting patients. Sponsor(s): (Sponsor Name Pending) Purpose - Excerpt: The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00067457 •
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Condition(s): Irritable Bowel Syndrome Study Status: This study is currently recruiting patients. Sponsor(s): (Sponsor Name Pending) Purpose - Excerpt: The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrheapredominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00067561
•
Acupuncture vs. Placebo in Irritable Bowel Syndrome Condition(s): Irritable Bowel Syndrome Study Status: This study is not yet open for patient recruitment. Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) Purpose - Excerpt: Little is known about acupuncture's efficacy for Irritable Bowel Syndrome (IBS). This trial uses a manualized acupuncture treatment format that closely follows clinical practice and allows flexibility in designing individualized treatments. In addition, a second parallel qualitative study will follow a subgroup of patients throughout the trial to explore the relationships between patients' interpretations and understandings (what anthropologists call "meaning") of irritable bowel and their response to treatment. Cortisol levels (an important stress hormone) will also be assessed. Phase(s): Phase I; Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00065403
•
Brain Imaging and Pain in Irritable Bowel Syndrome Condition(s): Irritable Bowel Syndrome
Clinical Trials 131
Study Status: This study is not yet open for patient recruitment. Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Neurological Disorders and Stroke (NINDS) Purpose - Excerpt: This study examines the mechanisms, including brain imaging of placebo analgesia Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00065754 •
Treatment of Functional Bowel Disorders Condition(s): Irritable Bowel Syndrome; Constipation; Abdominal Pain; Functional Colonic Diseases Study Status: This study is completed. Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Purpose - Excerpt: The primary purpose for this study is to compare clinical treatments for patients with functional bowel disorders (irritable bowel syndrome, abdominal pain, painful constipation) in women. We also plan to: 1) determine what clinical features (medical or psychological) determine which patients will improve to these treatments, and 2) understand if there are any physiological features that relate to improvement in symptoms and response to the treatments. We will compare a psychological treatment (cognitive-behavioral therapy - CBT) with education/attention placebo, and an antidepressant drug (desipramine) with a pill placebo. This is the first large-scale study designed to determine the therapeutic effects of these methods, and to also determine interactions among physiologic measures, psychologic and sociodemographic factors, severity of symptoms, and therapeutic improvement including quality of life. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00006157
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “irritable bowel syndrome” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical
132 Irritable Bowel Syndrome
trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
133
CHAPTER 6. PATENTS ON IRRITABLE BOWEL SYNDROME Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “irritable bowel syndrome” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on irritable bowel syndrome, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Irritable Bowel Syndrome By performing a patent search focusing on irritable bowel syndrome, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. 9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
134 Irritable Bowel Syndrome
The following is an example of the type of information that you can expect to obtain from a patent search on irritable bowel syndrome: •
1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders Inventor(s): Bryans; Justin Stephen (Balsham, GB), Capiris; Thomas (Plymouth, MI), Horwell; David Christopher (Cambridge, GB), Kneen; Clare Octavia (Essex, GB), Wustrow; David Juergen (Ann Arbor, MI) Assignee(s): Pfizer, Inc. (Ann Arbor, MI) Patent Number: 6,518,289 Date filed: April 3, 2000 Abstract: Novel amines of formulas (1), (1C), (1F), (1G) and (1H) or a pharmaceutical acceptable salt thereof wherein n is an integer of from 0 to 2; m is an integer of from 0 to 3; R is sulfonamide, amide, phosphonic acid, heterocycle, sulfonic acid, or hydroxamic acid; A' is a bridged ring selected from (1), (2), (3), (4), (5) wherein is the point of attachment; Z.sub.1 to Z.sub.4 are each independently selected from hydrogen and methyl; o is an integer of from 1 to 4; and p is an integer of from 0 to 2. In formula (1) above R cannot be sulfonic acid when m is 2 and n is 1 are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, especially irritable bowel syndrome. Excerpt(s): wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl, or carboxyl are known in U.S. Pat. No. 5,563,175 and various divisionals. These patents are hereby incorporated by reference. The compounds of the instant invention are novel amines and their pharmaceutically acceptable salts useful in a variety of disorders. The disorders include: epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders, especially irritable bowel syndrome. The compounds of the invention are those of formulas 1, 1C, 1F, 1G, and 1H below. Web site: http://www.delphion.com/details?pn=US06518289__
•
Administering osmotic colonic evacuant containing a picosulfate Inventor(s): Borody; Thomas Julius (144 Great North Road, Five Dock NSW 2046, AU), Shortis; Nicolas Peter (144 Great North Road, Five Dock NSW 2046, AU), Shortis; Walter George (144 Great North Road, Five Dock NSW 2046, AU) Assignee(s): none reported Patent Number: 6,103,268 Date filed: November 30, 1998 Abstract: Colonic evacuation, treatment of small bowel bacterial overgrowth or irritable bowel syndrome or treating acute or chronic bacterial bowel infection comprises administering an osmotic colonic evacuant in solid form, preferably a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate or a sulfate based laxative comprising a picosulfate, together with a diluent.
Patents 135
Excerpt(s): The present invention relates to orthostatic lavage solutions or colonic evacuants for cleansing the gastrointestinal tract, or for the treatment of bowel diseases and/or disorders. The advent of colonoscopy brought with it the need for a simplified, routine bowel cleansing protocol or product to achieve a clean colonic mucosa required by the colonoscopist to detect even small lesions in the bowel, e.g., small polyps. Similar requirements exist for colonic surgery. In the early days of colonoscopy, during the late 1970's, numerous protocols for bowel cleansing were designed by individual bowel surgeons and gastroenterologists to satisfy the requirements of their particular practices. Such protocols included the use of fasting in combination with various purgatives such as Epsom salts or osmotic agents plus enemas. Though, when complex protocols were followed strictly they often achieved their effect and resulted in a clean bowel. However, the protocols were invariably complex and required on average three days of cleansing which made them unpleasant and unacceptable. Furthermore, they were often dangerous because they caused marked fluid and electrolyte shifts in body compartments and on rare occasions predisposed to arrythmias, hypertension and in fact demise of the patient. Web site: http://www.delphion.com/details?pn=US06103268__ •
Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation Inventor(s):.ANG.kerblom; Eva (Uppsala, SE), Beierlein; Katarina (Uppsala, SE), Haraldsson; Martin (Taby, SE), Johansson; Rolf (Huddinge, SE), Ringberg; Erik (Uppsala, SE), Sjoberg; Birger (Sollentuna, SE), Weinz; Birgitta (Sollentuna, SE) Assignee(s): Pharmacia & Upjohn AB (Stockholm, SE) Patent Number: 6,124,354 Date filed: April 12, 1999 Abstract: This invention relates to the use of 2-(diisopropylamino)-ethyl-1-phenylcyclopentane-carboxylate or 2-(diisopropylamino)-ethyl-1-phenyl-cyclohexanecarboxylate, or a pharmaceutically accceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome (IBS). Excerpt(s): The present invention relates to arylcycloalkane carboxylic esters having pharmacological properties, and to processes for their preparation. The invention also relates to pharmaceutical compositions containing arylcycloalkane carboxylic esters, methods of treating disorders related to urinary incontinence and irritable bowel syndrome (IBS), respectively, by administering an arylcycloalkane carboxylic ester, as well as methods for the manufacture of pharmaceutical compositions for treating disorders related to urinary incontinence and irritable bowel syndrome (IBS), respectively. A number of arylcycloalkane carboxylic esters, including arylcyclopropane, arylcyclobutane, arylcyclopentane and arylcyclohexane carboxylic acid esters, are known to possess anticholinergic activity. Some of them have a pronounced spasmolytic or anticonvulsant activity and have therefore been proposed to be used as substitutes for atropine in the treatment of sarin poisoning (sarin is an organophosphorous anticholinesterase agent acting as a nerve gas). Other activities related to that type of compounds are antipsychotic, anti-ischemic, anti-stroke and antidementia. Specific arylcyclopropane carboxylic esters having anticholinergic activities are, for example, described in Beres, J. A., et al., J. Pa. Acad. Sci. (1992), 66(1), 2; U.S. Pat. No. 4,418,202; Mnjoyan, A. L., et al., Arm. Khim. Zh. (1976), 29(2) 194-9; Kuzuna, S., et al., Takeda Kenyosho Hu (1975), 34(4), 467-73; and WO 92/02481.
136 Irritable Bowel Syndrome
Web site: http://www.delphion.com/details?pn=US06124354__ •
Bis (benzimidazole) derivatives serving as potassium blocking agents Inventor(s): Jensen; Bo Skaaning (Copenhagen S, DK), Olesen; S.o slashed.ren Peter (Klampenborg, DK), Peters; Dan (Arlov, DK), Str.o slashed.b.ae butted.k; Dorte (Farum, DK), Teuber; Lene (V.ae butted.rl.o slashed.se, DK) Assignee(s): Neurosearch A/S (Ballerup, DK) Patent Number: 6,194,447 Date filed: July 2, 1999 Abstract: This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions.Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression. Excerpt(s): This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression. Ion channels are transmembrane proteins, which catalyze the transport of inorganic ions across cell membranes. The ion channels participate in processes as diverse as the generation and timing of action potentials, synaptic transmissions, secretion of hormones, contraction of muscles, etc. Web site: http://www.delphion.com/details?pn=US06194447__
Patents 137
•
Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome Inventor(s): Perry; Stephen C. (205 Churchill Dr., Longwood, FL 32779) Assignee(s): none reported Patent Number: 6,203,797 Date filed: January 7, 2000 Abstract: A dietary supplement for use as a probiotic and for alleviating symptoms of irritable bowel syndrome, comprising freeze-dried aloe, fructo-oligosaccharides, and dahlia inulin juice mixture and optionally vitamin B6 (pyridoxine) manganese and Lglutamine. An additional alternate embodiments specifically for alleviation of symptoms of irritable bowel syndrome, including in the base formula bromelain and papain. Also for specific probiotic functions the following friendly bacteria: Lactobacillus bulgaricus, lactobacillus acidophilus, lactobacillus plantarum, and Bifidobacterium bifidum could be added to the base formula. Excerpt(s): Not applicable. The present invention relates to a dietary supplement and method for use as a probiotic(immuno-stimulant) and for alleviating the symptoms associated with irritable bowel syndrome. The use of dietary supplements for alleviating specific symptoms associated with particular human health problems is well known. Going back to ancient times, references are made to various dietary foods, herbs, and other naturally produced substances that are associated with improving the human health condition. Web site: http://www.delphion.com/details?pn=US06203797__
•
Method and apparatus for diagnosis of irritable bowel syndrome Inventor(s): Craine; Brian L. (Fairfax, CA) Assignee(s): Western Research Company, Inc. (Tucson, AZ) Patent Number: 6,228,040 Date filed: July 28, 1999 Abstract: A protocol for the recording of bowel sounds, a computerized algorithm for recognizing the start and stop time of bowel sounds in the digital sound recordings, metrics that can be calculated from the start and stop times and limits of these metrics which can be used to categorize individuals with respect to medical conditions which effect the gastrointestinal tract. The use of these methods and values allows for the diagnosis of certain gastrointestinal syndromes or diseases with a high degree of accuracy in a manner not previously possible. Excerpt(s): The invention relates to using a computerized analysis of bowel sounds recorded using an electronic sound input device to diagnose gastrointestinal complaints of pain, bloating, or alteration of bowel habits, with emphasis on the diagnosis of irritable bowel syndrome. Irritable bowel syndrome is characterized by bowel irregularity (constipation and/or diarrhea), gaseous distention and abdominal pain. Irritable bowel syndrome is the most common gastrointestinal complaint for which patients seek medical care, accounting for 30 to 50 percent of the gastrointestinal complaints that bring patients to a physician. Various studies indicate that patients with irritable bowel syndrome constitute a large portion of a typical family physician's practice and account for more than 25% of all gastrointestinal referrals. Irritable bowel
138 Irritable Bowel Syndrome
syndrome is listed as a primary diagnosis in about 96,000 patients per year treated in nonfederal hospitals, and the disorder was considered a secondary diagnosis in another 85,000 patients. Most patients with gastrointestinal complaints are subjected to a battery of laboratory studies. These usually include sigmoidoscopy, complete blood count, erythrocyte sedimentation rate, serum electrolytes, liver function tests, urinalysis, and stool examination for occult blood and parasites. For a patient with chronic or recurring symptoms, endoscopy or radiographic contrast evaluations can be performed (but should not be repeated unless there is objective evidence of a change in the clinical condition, such as blood in the stool). In western societies, irritable bowel syndrome occurs twice as often in women as in men. About half of the patients are first seen for this condition before they reach 35 years of age. Various studies indicate that almost half of the patients are between the ages of 35 and 49, although symptoms usually begin much earlier and are likely to continue throughout life. The true prevalence of irritable bowel syndrome may be reflected in several non-patient surveys in which as much as 20 percent of the general population reported symptoms consistent with this disorder. The majority of these people do not seek medical assistance, although it is possible that their symptoms could be alleviated through education, simple methods of stress reduction, and dietary changes. Web site: http://www.delphion.com/details?pn=US06228040__ •
Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists Inventor(s): Crain; Stanley M. (Leonia, NJ), Fleischner; Gerald M. (Chappaqua, NY), Shen; Ke-fei (Flushing, NY) Assignee(s): Albert Einstein College of Medicine of Yeshiva University (Bronx, NY) Patent Number: 6,194,382 Date filed: March 3, 1999 Abstract: This invention relates to a method for eating a subject with irritable bowel syndrome ("IBS") which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid receptor functions, in myenteric neurons in the intestinal tract as well as in neurons of the central nervous system ("CNS"). The administration of the opioid receptor antagonist at a low dose enhances the potency of the inhibitory effects of endogenous opioid peptides present in the intestinal tract and the CNS, thereby reducing abdominal pain and stool frequency resulting from abnormally supersensitized excitatory opioid receptor functions. The invention also relates to a composition for treating a subject with IBS, which comprises an effective dose of an opioid receptor antagonist, and a pharmaceutically acceptable carrier. Excerpt(s): This invention relates to a method for treating a subject with irritable bowel syndrome ("IBS") which comprises administering a low dose of an opioid receptor antagonist to the subject. Specifically, this invention relates to a method for treating a subject with IBS by the long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid receptor functions, in myenteric neurons in the intestinal tract as well as in neurons of the central nervous system ("CNS"). The administration of the opioid receptor antagonist at a low dose enhances the potency of the inhibitory effects of endogenous opioid peptides present in the intestinal tract and the CNS, thereby reducing abdominal pain and stool frequency resulting from
Patents 139
abnormally supersensitized excitatory opioid receptor functions. The invention also relates to a composition for treating a subject with IBS, which comprises an effective dose of an opioid receptor antagonist, and a pharmaceutically acceptable carrier. Irritable bowel syndrome is a functional bowel disorder in which abdominal pain is associated with defecation or a change in bowel habit. IBS has elements of an intestinal motility disorder, a visceral sensation disorder, and a central nervous disorder. While the symptoms of IBS have a physiological basis, no physiological mechanism unique to IBS has been identified. Rather, the same mechanisms that cause occasional abdominal discomfort in healthy individuals operate to produce the symptoms of IBS. The symptoms of IBS are therefore a product of quantitative differences in the motor reactivity of the intestinal tract, and increased sensitivity to stimuli or spontaneous contractions. Due to a lack of readily identifiable structural or biochemical abnormalities in this syndrome, the medical community has developed a consensus definition and criteria, known as the Rome criteria, to aid in diagnosis of IBS. According to the Rome criteria, IBS is indicated by abdominal pain or discomfort which is (1) relieved by defection and/or (2) associated with a change in frequency or consistency of stools, plus two or more of the following: altered stool frequency, altered stool form, altered stool passage, passage of mucus, and bloating or feeling of abdominal distention (Dalton, C. and Drossman, D. A., Am Fam Physician 1997 55(3):875-880). Thus, a hallmark of IBS is abdominal pain that is relieved by defecation, and which is associated with a change in the consistency or frequency of stools. IBS may be diarrhea-predominant, constipationpredominant, or an alternating combination of both. Web site: http://www.delphion.com/details?pn=US06194382__ •
Method for alleviation of lower gastrointestinal disorders in a human patient Inventor(s): Dave; Bhavin (262 Pine Valley Dr., Dover, DE 19904), Rubin; Walter (1708 Riverview Rd., Gladwyne, PA 19035) Assignee(s): none reported Patent Number: 6,156,771 Date filed: May 21, 1998 Abstract: A method of alleviating a lower GI symptom in a human patient afflicted with a lower GI disorder and a method of treating a human patient afflicted with a lower GI disorder, including, for example, a patient afflicted with irritable bowel syndrome or a patient afflicted with functional diarrhea, are provided. Each of these methods comprises inhibiting gastric secretion by the patient, such as by administering to the patient a pharmaceutical preparation comprising an effective amount of an inhibitor of gastric secretion. Excerpt(s): The field of the invention is alleviation of lower gastrointestinal (GI) disorders in a human patient and alleviation of lower GI symptoms associated with such disorders. Between about 5% and about 10% of the U.S. population suffers from chronic diarrhea for which an organic cause cannot be identified (Camilleri et al., 1977, Aliment Pharmacol Ther. 11:3-15; Talley et al., 1991, Gastroenterology 101:927-934). The diarrhea may be persistent or may alternate with periods of normal bowel habit or with periods of constipation. Chronic diarrhea which is not accompanied by abdominal. pain and which is not attributable to an organic cause is referred to as "functional diarrhea" (FD) or "chronic idiopathic diarrhea" (Drossman et al., 1997, Gastroenterology 112:21202137; Hasler et al., 1995, In: Textbook of Gastroenterology, 2nd ed., Yamada, Ed., J. B. Lippincott Co., Philadelphia, pp. 1832-1855; Camilleri et al., supra; Drossman et al., 1994,
140 Irritable Bowel Syndrome
The functional Gastrointestinal disorders: Diagnosis, Pathophysiology, and Treatment, Degnon and Associates, McLean, Va.; Thompson et al., 1992, Gastroenterol. Intl. 5:7591). Chronic diarrhea which is associated with abdominal pain and which is not attributable to an organic cause is referred to as "irritable bowel syndrome with a diarrhea predominance" (IBS; Hasler et al., supra; American Gastroenterological Association, 1997, Gastroenterol. 112:2118-2119; Drossman et al., 1997, Gastroenterol. 112:2120-2137; Camilleri et al., supra). Postprandial urgency or postprandial accentuation of lower GI symptoms are common manifestations of both IBS and FD. Patients afflicted with either IBS or FD frequently experience an urgency to defecate after eating, and sometimes attribute this urgency to the ingestion of particular foods other than lactose. Furthermore, some of these patients associate exacerbation of their symptoms with emotional stress. These symptoms have led investigators of IBS and FD to believe that abnormal physiological factors, psychological factors, or both, may be associated with IBS and FD (Drossman et al., supra; Hasler et al., supra; Camilleri et al., supra; Drossman et al., supra; Drossman et al., supra; O'Brien et al., 1996, Gastroenterol. Clin. N. Am. 25:147-162; Bazzocchi et al., 1991, Gastroenterology 101:1298-1306; Choi et al., 1997, Am. J. Gastroenterol. 92:297-306; Aggarwal et al., 1994, Gastroenterology 106:945-950; Quigley, 1996, Gastroenterol. Clin. N. Am. 25:113-145; Schmidt et al., 1996, Scand. J. Gastroenterol. 31:581-589; Evans et al., 1996, Gastroenterology 110:393-404; Gorard et al., 1994, Gut 35:203; Kellow et al., 1990, Gastroenterology 98:1208; Whitehead, 1996, Gastroenterol. Clin. N. Am. 25:21-34). No effective therapy has been established for the chronic diarrhea or the postprandial urgency associated with either IBS or FD (Drossman et al., 1997, supra; Hasler et al., supra; Camilleri et al., supra; Drossman et al., 1994, supra; Thompson et al., supra; Klein, 1988 Gastroenterology 95:232-241). Web site: http://www.delphion.com/details?pn=US06156771__ •
Method of collagen therapy using relaxin Inventor(s): Yue; Samuel K. (4928 Hoppy La., Edina, MN 55435) Assignee(s): none reported Patent Number: 6,048,544 Date filed: November 19, 1998 Abstract: A method of treating involuntary muscle dysfunctions includes administering a therapeuticaly effective amount of relaxin to a patient. Involuntary muscle dysfunctions amenable to treatment with relaxin include fibromyalgia, myofascial pain syndrome, chronic fatigue syndrome, dystonia, pelvic floor dysfunction, irritable bowel syndrome, and others. Excerpt(s): The present invention relates to the treatment of involuntary muscle dysfunctions. In particular, the present invention relates to the treatment of involuntary muscle dysfunction with relaxin hormone. Involuntary muscle dysfunction plagues a large portion of the chronic pain and chronic fatigue patient population. Two prominent conditions involving involuntary muscle dysfunction include fibromyalgia and myofascial pain syndrome, amongst others. Fibromyalgia is identified by the main symptoms of generalized chronic pain occurring mainly in the muscles and hyperalgesia, i.e. multiple tender points spread out over the body. The full range of symptoms include generalized pain, hyperalgesia, sleep disturbance, fatigue, muscle stiffness, hypersthesias, tension-type headaches, decreased muscle endurance and muscle weakness. Fibromyaglia has also been associated with irritable bowel syndrome, chronic fatigue syndrome, temporomandibular dysfunction syndrome,
Patents 141
migraines, primary dysmenhorrea (painful menstruation) and others conditions including Raynaud's phenomenon. See Yunnus, Fibromyalgia Syndrome: Clinical Features and Spectrum, The Fibromyalgic Syndrome: Current Research and Future Directions in Epidemiology, Pathogenesis, and Treatment, 1994, pp. 5-21. See also Wolfe, When to Diagnose Fibromyalgia, Rheumatic Disease Clinics Of North America, Vol. 20, Number 2, May 1994. See Henriksson, Pathogenesis of Fibromyalgia, Journal of Musculoskeletal Pain, 1993, Vol. 1, pp. 3-16. Web site: http://www.delphion.com/details?pn=US06048544__ •
METHOD OF DIAGNOSING IRRITABLE BOWEL SYNDROME AND OTHER DISORDERS CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH BY DETECTING THE PRESENCE OF ANTI-SACCHAROMYCES CERIVISIAE ANTIBODIES (ASCA) IN HUMAN SERUM Inventor(s): Lin; Henry C. (Manhattan Beach, CA), Pimentel; Mark (Los Angeles, CA) Assignee(s): Cedars-Sinai Medical Center (Los Angeles, CA) Patent Number: 6,562,629 Date filed: August 11, 1999 Abstract: Disclosed is a method of diagnosing small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder (ADHD), or an autoimmune disease by sampling serum from a human subject having a suspected diagnosis of any of these conditions and analyzing the serum for the presence of ASCA, which corroborates the suspected diagnosis. A method of determining a predisposition for developing Crohn's, in a human subject who does not present a set of symptoms characteristic of the disease and who has small intestinal bacterial overgrowth, involves sampling serum from the subject and analyzing the serum for the presence of ASCA. The presence of ASCA in the serum indicates a predisposition for developing Crohn's disease. Also disclosed is a kit for diagnosing and treating small intestinal bacterial overgrowth, irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, or an autoimmune disease, such as multiple sclerosis or systemic lupus erythematosus. The kit is useful to improve symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Excerpt(s): Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. This invention relates to the medical arts. It relates to a method of diagnosing or treating small intestinal bacterial overgrowth, irritable bowel syndrome and other disorders, such as Crohn's disease, chronic fatigue syndrome, fibromyalgia, depression, attention deficit/hyperactivity disorder, multiple sclerosis, systemic lupus erythematosus and other auto immune diseases in a human subject. Irritable bowel syndrome, Crohn's disease, chronic fatigue syndrome, fibromyalgia, depression, attention deficit/hyperactivity disorder, and autoimmune diseases, e.g., multiple sclerosis and systemic lupus erythematosus, are all clinical conditions of unclear etiology. Web site: http://www.delphion.com/details?pn=US06562629__
142 Irritable Bowel Syndrome
•
Method of screening for compounds that bind P2x receptor Inventor(s): Buell; Gary N (Geneva, CH), Valera; Soledad (Geneva, CH) Assignee(s): Glaxo Group Limited (Greenford, GB) Patent Number: 6,194,162 Date filed: July 30, 1999 Abstract: The P.sub.2X receptor of ATP has been cloned and expressed by recombinant DNA technology, so the receptor can be prepared free from other ATP receptors. The P.sub.2X receptor enables antibodies to be prepared and is useful in screening compounds for use in a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of the immune system, irritable bowel syndrome and premature ejaculation. Excerpt(s): This invention relate to the P.sub.2X -purinoceptor, its preparation and uses. The P.sub.2X -purinoceptor is a ligand-gated ion channel; that is, the receptor itself forms an ion channel which opens when extracellular adenosine 5'-triphosphate (ATP) binds to the receptor. There are five other classes of neurotransmitter receptors (nicotinic acetylcholine, glutamate, glycine, GABA.sub.A and 5-HT.sub.3); these form a structurally related superfamily of ligand-gated ion channels (Barnard, Trends Biochem. Sci. 17, 368-374, (1992)). The P.sub.2X -receptor now identifies a new family of this type of receptor. The unique structure of this receptor, the widespread distribution of this receptor throughout the body, and the numerous physiological roles this receptor may play, make it an important protein that can be used to identify new, therapeutically effective, compounds for the treatment of a number of pathological states. In 1929 the eminent physiologist Szent-Gyorgyi described powerful cardiovascular actions of extracellular purine nucleosides (e.g. adenosine) and nucleotides (e.g. ATP) (Drury & Szent-Gyorgyi, J. Physiol. 68 213-237 (1929)), but it was not until 1972 that pharmacological evidence was provided to suggest the existence of distinct receptors for extracellular ATP (ie. that recognise ATP but not adenosine) (Burnstock, Pharmacological Reviews 21 509-581 (1972)). The seminal and subsequent work on this area by Burnstock and colleagues was largely unaccepted throughout the 1970s and early 1980s until the development of a range of relatively selective ligands and techniques for directly measuring ATP release overwhelmingly substantiated Burnstock's hypothesis (Barnard et al., Trends Pharmacol. Sci. 15 67-70 (1994)). In the past four or five years, unequivocal evidence for the role of ATP as a neurotransmitter has been provided for sympathetic control of blood flow to the intestine and smooth muscle tone (contractility) in genitourinary tissue such as vas deferens, bladder and ureter (Barnard et al. (loc. cit.) and Evans & Surprenant, Brit. J. Pharmacol. 106 242-249 (1992)). Substantial indirect evidence also exists for the role of ATP as a neurotransmitter in a number of distinct neurones in the spinal cord, autonomic ganglia and certain nuclei in the central nervous system (Bean, Trends Pharmacol. Sci. 15 67-70 (1992), Evans et al., Nature 357, 503-505 (1992) and Edwards et al., Nature 359 144-147 (1992)). Web site: http://www.delphion.com/details?pn=US06194162__
Patents 143
•
Method of treating irritable bowel syndrome Inventor(s): Dunn; Peter James (Sandwich, GB), Humphrey; Michael John (Sandwich, GB), Quinn; Paul (Sandwich, GB) Assignee(s): Pfizer Inc. (New York, NY) Patent Number: 6,653,339 Date filed: August 13, 2002 Abstract: The present invention is directed to a a method for the treatment of irritable bowel syndrome comprising the multiple daily pulse dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred. Excerpt(s): The present invention is concerned with a method for the treatment of irritable bowel syndrome which involves the multiple daily dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred. Darifenacin is a muscarinic antagonist whose preparation and proposed use in the treatment of diseases associated with altered motility and/or tone of smooth muscle as found, for example, in the gut, trachea and bladder are described in U.S. Pat. No. 5,096,890. Specific diseases referred to include irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease. Of these, irritable bowel syndrome and urinary incontinence are particularly attractive targets for a muscarinic antagonist and controlled release formulations of darifenacin intended for use in the treatment of these diseases wherein at least 10% by weight of the darifenacin is released in the lower gastrointestinal tract are the subject of U.S. Pat. No. 6,106,864. The text of these patents and all other references cited in this specification are hereby incorporated by reference in their entirety. Web site: http://www.delphion.com/details?pn=US06653339__
•
Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride Inventor(s): Barberich; Timothy J. (Concord, MA), Rubin; Paul D. (Sudbury, MA) Assignee(s): Sepracor Inc. (Marlborough, MA) Patent Number: 6,048,879 Date filed: June 14, 1999 Abstract: Methods for the prevention, treatment or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer. Excerpt(s): The invention relates to methods of prevention, treatment, or management, of apnea, apnea disorders, bulimia, other disorders, or symptoms thereof. Apnea is defined in Stedman's Medical Dictionary, 26.sup.th Edition, Williams and Wilkins (1995), as the absence of breathing. There are a number of disorders associated with apnea, which are characterized by interrupted breathing in which a person stops breathing long enough to decrease the amount of oxygen and increase the amount of carbon dioxide in the blood and brain. Each type of apnea involves the absence of
144 Irritable Bowel Syndrome
airflow at the nose or the mouth, typically for at least 10 seconds. Various apnea disorders exist, including: central apnea, which results from medullary depression and inhibits respiratory movement; deglutition apnea, which is the inhibition of breathing during swallowing; obstructive or peripheral apnea, which is either a result of obstruction of air passages or inadequate respiratory muscle activity; sleep apnea, which is central and/or obstructive apnea during sleep; and sleep induced apnea, which results from failure of the respiratory center to stimulate adequate respiration during sleep. Web site: http://www.delphion.com/details?pn=US06048879__ •
Methods of modulating muscle contraction Inventor(s): Cote; Graham P. (Kingston, CA), Mak; Alan S. (Kingston, CA), Van Eyk; Jennifer E. (Kingston, CA) Assignee(s): Queen's University at Kingston (Kingston, CA) Patent Number: 6,248,549 Date filed: June 22, 1998 Abstract: Methods of modulating calcium independent smooth muscle contraction, and of modulating cardiac muscle contraction, by the administration of a PAK modulating agent are described. A method of treating a subject having a state characterized by smooth muscle contraction, (e.g., hypertension, asthma, irritable bowel syndrome, incontinence and menstrual cramps) or cardiac contractile dysfunction (e.g., heart failure and myocardial stunning) is also described. The method involves the administration, to a subject, of a therapeutically effective amount of a PAK modulating agent, e.g., a PAK inhibitor or stimulator. Assays, e.g., screening tests, to identify PAK modulating agents or agents that modulate muscle contraction are also provided. Excerpt(s): This invention relates to methods for modulating muscle contraction, and particularly, to methods for modulating smooth muscle contraction in the absence of calcium, and for increasing the calcium sensitivity of both smooth muscle and cardiac muscle. p21-activated kinase (PAK) proteins are serine/threonine protein kinases homologous to the yeast Ste20 kinase. Several distinct members of the PAK family have been identified in mammalian cells, including PAK1, PAK2, PAK3, and PAK65. It has been shown that PAK proteins can be activated by the small Rho-family GTP-binding proteins Cdc42 and Rac1, which are known to regulate assembly of the actin cytoskeletal structure (Zhang et al. 1995, J. Biol. Chem. 270:23934-36). Smooth muscle, in contrast to striated muscle (cardiac and skeletal muscle), is capable of maintaining force at low levels of intracellular calcium. One member of the small Rho-family of GTP-binding proteins, RhoA, has been shown recently to induce smooth muscle contraction independently of calcium. RhoA activates a serinet reonine kinase named ROK (RhoA associated kinase or p160ROK) which can cause smooth muscle calcium-independent contraction. Cardiac muscle, on the other hand, requires increased levels of intracellular calcium for contraction. Web site: http://www.delphion.com/details?pn=US06248549__
Patents 145
•
N-substituted pyrrolidine derivatives and process for preparing the same Inventor(s): Ando; Naoki (Nogi-machi, JP), Hoshino; Masato (Oyama, JP), Kobayashi; Fumiyoshi (Oyama, JP), Miyachi; Hiroyuki (Kazo, JP) Assignee(s): Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP) Patent Number: 6,071,950 Date filed: June 2, 1999 Abstract: Novel N-substituted pyrrolidine derivatives having a highly selective and potent antagonism against smooth muscle muscarine receptors and being useful for the treatment of irritable bowel syndrome and the like, characterized by being represented by general formula (1) wherein R represents a hydrogen atom, a halogen atom, or a lower alkoxy group and a process for preparing the same. Excerpt(s): The present invention relates to novel N-substituted pyrrolidine derivatives having a highly selective and potent antagonism against smooth muscle muscarine receptors rather than cardiac muscarine receptors and being useful for the treatment of altered smooth muscle motility and tone, such as irritable bowel syndrome, diverticulosis, urinary incontinence, esophageal achalasia and chronic obstructive airway disease, and process for preparing the same. As one of the therapeutic drugs for the irritable bowel syndrome, the anticholinergic agent has been used, but it brings no sufficient therapeutic effect due to, in part, deficit of tissue selectivity. Also, while compounds that was reported to have a selective antagonism against smooth muscle muscarine receptors are disclosed (Japanese Unexamined Patent Publication Nos. Hei 2282360 and Hei 7-149640, these compounds also do not sufficiently solve the adverse effect such as mydriasis. Moreover, these compounds have diphenylalkyl moiety linked to carbon atom of the pyrrolidine ring, making them different from the structure of the inventive compounds, in which it links to the nitrogen atom of the pyrrolidine ring. The invention is to provide novel N-substituted pyrrolidine derivatives having a highly selective and potent antagonism against smooth muscle muscarine receptors and being useful for the treatment of irritable bowel syndrome and the like. Web site: http://www.delphion.com/details?pn=US06071950__
•
Oxazepine derivatives and medicine containing the same Inventor(s): Sakata; Katsutoshi (Kawasaki, JP), Sasaki; Noriko (Kawasaki, JP), Takahashi; Kazuyoshi (Kawasaki, JP), Tsuji; Takashi (Kawasaki, JP) Assignee(s): Ajinomoto Co., Inc. (Tokyo, JP) Patent Number: 6,528,504 Date filed: July 9, 2001 Abstract: The present invention provides (R)-5,11-dihydro-5-[1-(4methoxyphenethyl)piperidine-2-ylmethyl]dibenzo[b, e][1,4]oxazepine, (R)-5,11-dihydro5-[1-(4-dimethylaminophenethyl)piperidine-2-ylmethyl]dibe nzo[b,e][1,4]oxazepine, compounds analogous to them and pharmaceutical compositions containing such a compound. These compounds are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, particularly irritable bowel syndrome. Excerpt(s): The present invention relates to 5,11-dihydrodibenzo [b,e][1,4]oxazepine derivatives antagonistic to calcium channel and useful for treating or preventing abnormal motor functions of gastrointestinal tracts, particularly intestinal diseases such
146 Irritable Bowel Syndrome
as irritable bowel syndrome, stereoisomers thereof, pharmacologically acceptable salts thereof or hydrates thereof, and pharmaceutical compositions containing them as active ingredients. It is disclosed in, for example, European Patent No. 0404359A1 that 5,11dihydrodibenzo[b,e][1,4]thiazepine derivatives are usable as calcium channel antagonists selectively effective on gastrointestinal tracts. Quinn, P. et al., Brit. J. Pharmacol. 1994, 112 (Suppl.), Abst 573P and Wallis R. M. et al. Brit. J. Pharmacol. 1994, 112 (Suppl.), Abst. 574P disclose that (S)-5-[[1-(4-methoxyphenyl)ethyl]pyrrolidine-2ylmethyl]-5,11-dihydrodiben zo[b,e][1,4]thiazepine maleate which is one of derivatives of those compounds has effects similar to the effects of them. Further, International Patent No. 9733885A1 discloses 5-(2-pyrrolidinyl-methyl)-5,11-dihydrodibenzo [b,e][1,4]oxazepine derivatives as medicines for improving motor insufficiency of gastrointestinal tracts. However, the activity and selectivity of these compounds toward gastrointestinal tracts are yet insufficient, and another defect of them is that they have an anticholinergic effect which causes side effects such as thirstiness and mydriasis. As social environments have been complicated recently, many of people feel the severe stress and patients with irritative bowel syndrome having cardinal symptoms of irregular bowel movement and abdominal pain are increasing in number. Medicines used for improving these diseases are, for example, cholinergic blocking agents, laxatives, antidiarrheal agents, intestinal drugs, mucosal paralyzers, gastrointestinal function regulators, autonomic nerve regulators, Chinese medicines, anxiolytic agents, antidepressant agents, sleep promoting drugs and neurotropic agents. However, the clinical effects of these medicines are yet insufficient and, in addition, they are not always satisfactory from the viewpoint of side effects of them. Under these circumstances, the development of medicines of a new type for improving the gastrointestinal function regulators, which have no side effect, is demanded. Web site: http://www.delphion.com/details?pn=US06528504__ •
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein Inventor(s): Efendic; Suad (Stjarnvagen 16B, 18134 Lidingo, SE), Hellstrom; Per (Svardsjovagen 1, 16775 Bromma, SE) Assignee(s): none reported Patent Number: 6,348,447 Date filed: February 3, 2000 Abstract: The invention relates to the new use of gastrointestinal peptide hormones selected from the class consisting of glucagon-like peptide-1 (GLP-1) and derivatives thereof having anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract for the manufacture of a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome. The invention also relates to a pharmaceutical composition comprising a combination of at least one member selected from said class consisting of GLP-1 and derivatives thereof with one or more other gastrointestinal peptide hormone(s) or derivative(s) thereof together with pharmacologically acceptable additives and to a method of treating functional dyspepsia or irritable bowel syndrome or both by administering an effective amount of at least one member of said class consisting of GLP-1 and derivatives thereof having effects and properties as mentioned above. Excerpt(s): This application is a 371 of PCT/SE99/00997 filed Jun. 8, 1999 which claims priority to Swedish application 98 02080-3 filed Jun. 11, 1998. The present invention
Patents 147
relates to a new use of a gastrointestinal peptide hormone or a derivative thereof, to a pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome, and to a method for such treatment. Functional diseases are characterized by disordered function of the organ or organ system and no obvious structural pathology can be detected neither macroscopically nor microscopically. This should be differentiated from morphologic pathological diseases where the structure of the organ is changed from normality to abnormality. This type of disease can always be diagnosed either macro- or microscopically, and may be followed by functional aberration of the organ. Web site: http://www.delphion.com/details?pn=US06348447__ •
Smooth muscle spasmolytic agents, compositions and methods of use thereof Inventor(s): Aberg; A. K. Gunnar (Sarasota, FL), Chen; Jan L. (Worcester, MA), Wright; George E. (Worcester, MA) Assignee(s): Bridge Pharma, Inc. (Sarasota, FL) Patent Number: 6,207,852 Date filed: December 23, 1998 Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, gastric hyperactivity (ex. Irritable Bowel Syndrome) and other smooth muscle contractile conditions.More particularly, the present invention relates to certain substituted esters, amides and ketones having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects. Excerpt(s): This application is a 371 of PCT/US97/11310 filed Jun. 30, 1997. More particularly, the present invention relates to certain substituted esters, amides and ketones having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects. Web site: http://www.delphion.com/details?pn=US06207852__
•
Substituted pyridines useful as modulators of acetylcholine receptors Inventor(s): Cosford; Nicholas D. (San Diego, CA), Vernier; Jean-Michel (San Diego, CA) Assignee(s): Merck & Co., Inc. (Rahway, NJ) Patent Number: 6,194,581 Date filed: December 22, 1998 Abstract: In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors, and are useful for a variety of therapeutic applications, such as the treatment of Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention
148 Irritable Bowel Syndrome
deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis; substance abuse including withdrawal syndromes and substitution therapy; neuroendocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders of nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma; cardiovascular dysfunction including hypertension and cardia arrhythmias, comedication in surgical procedures, and the like. Excerpt(s): The present invention relates to novel compounds which are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central or autonomic nervous systems including dementia, cognitive disorders, neurodegenerative disorders, extrapyramidal disorders, convulsive disorders, cardiovascular disorders, endocrine disorders, pain, gastrointestinal disorders, eating disorders, affective disorders, and drug abuse. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses therefor. By modulation of neurotransmitter release (including dopamine, norepinephrine, acetylcholine and serotonin) from different brain regions, acetylcholine receptors are involved in the modulation of neuroendocrine function, respiration, mood, motor control and function, focus and attention, concentration, memory and cognition, and the mechanisms of substance abuse. Ligands for acetylcholine receptors have been demonstrated to have effects on attention, cognition, appetite, substance abuse, memory, extrapyramidal function, cardiovascular function, pain and gastrointestinal motility and function. The distribution of acetylcholine receptors that bind nicotine, i.e., nicotinic acetylcholine receptors, is widespread in the brain, including the basal ganglia, limbic system, cerebral cortex and mid- and hind-brain nuclei. In the periphery, the distribution includes muscle, autonomic ganglia, the gastrointestinal tract and the cardiovascular system. Acetylcholine receptors have been shown to be decreased, inter alia, in the brains of patients suffering from Alzheimer's disease or Parkinson's disease, diseases associated with dementia, motor dysfunction and cognitive impairment. Such correlations between acetylcholine receptors and nervous system disorders suggest that compounds that modulate acetylcholine receptors will have beneficial therapeutic effects for many human nervous system disorders. Thus, there is a continuing need for compounds which can selectively modulate the activity of acetylcholine receptors. In response to such need, the present invention provides a new family of compounds which modulate acetylcholine receptors. Web site: http://www.delphion.com/details?pn=US06194581__ •
Therapeutically active compositions Inventor(s): Gardiner; Fiona Kate (Beverley, GB) Assignee(s): Reckitt & Colman Products Limited (Windsor, GB) Patent Number: 6,201,014 Date filed: December 7, 1999 Abstract: A pharmaceutical composition for the treatment of irritable bowel syndrome, diarrhoea, constipation, abdominal pain and/or bloating or abdominal distension, the composition including a carrier vehicle and a vanilloid compound. The carrier vehicle
Patents 149
enables the vanilloid compound to be released in the lower gastrointestinal tract. The vanilloid compound has the effect of desensitizing nerves in the lower gastrointestinal tract, thereby leading to symptomatic relief. Preferred vanilloid compounds are capsaicin and resiniferatoxin. Excerpt(s): The present invention relates to compositions for the treatment of irritable bowel syndrome (IBS) and more particularly to locally acting compositions which are active in the post-stomach region of the gastro-intestinal (GI) tract. Irritable Bowel Syndrome (IBS) is part of a spectrum of diseases known generally as Functional Gastrointestinal Disorders which include diseases such as non-cardiac chest pain, nonulcer dyspepsia, and chronic constipation or diarrhoea. These diseases are all characterised by chronic or recurrent gastrointestinal symptoms for which no structural or biochemical cause can be found. Irritable bowel syndrome in the UK alone is responsible for 30-50% of all gastroenterology referrals to secondary care. 2. two or more of the following on at least a quarter of occasions: altered stool frequency, altered stool form, altered stool passage, passage of mucus, and/or bloating or feeling of abdominal distension. Web site: http://www.delphion.com/details?pn=US06201014__ •
Use of orexin receptor antagonists Inventor(s): Irving; Elaine Alison (Bengeo, GB), Sanger; Gareth John (Sawbridgeworth, GB) Assignee(s): SmithKline Beecham p.l.c. (Brentford, GB) Patent Number: 6,506,774 Date filed: November 30, 2001 Abstract: The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. Excerpt(s): The present invention relates to the use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers. Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified and are disclosed in U.S. Pat. Nos. 5,935,814, 6,020,157 and 6,410,701. Polypeptides and polynucleotides encoding a second human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in U.S. Pat. No. 6,166,193. Web site: http://www.delphion.com/details?pn=US06506774__
150 Irritable Bowel Syndrome
•
Use of tropical root crops in effective intervention strategies for treating difficult and complex cases and chronic diseases Inventor(s): Slimak; Karen M. (P.O. Box 2444, Springfield, VA 22152) Assignee(s): none reported Patent Number: 6,632,461 Date filed: July 12, 2001 Abstract: This invention relates to an effective intervention plan. In one aspect, the invention relates to the treatment of various symptoms, conditions or diseases, such as diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to excessive and moderate to severe symptoms due to food allergies, sensitivities and intolerances, bloating, pain, headaches, leaky gut, hypersensitivity, sleep difficulties, severe under weight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid refulx, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms and seizures by withholding for a period of at least 5 days all foods except for root crops. Excerpt(s): This invention relates to an effective dietary intervention plan. In one aspect all food is withheld for a period of at least 5 days, except for tropical root crops. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject undergoes an effective dietary intervention plan in which at least five (5) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 5 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. In another aspect of the invention the subject
Patents 151
undergoes an effective dietary intervention plan in which at least seven (7) tropical root crops are selected, each eaten on a successive day, along with selected other meat, vegetables, and oils that the subject has never eaten before, eating a different selection of meat, vegetables, and oils each from different food families each day, with no food or food family being repeated for at least 7 days. In another aspect the invention relates to the treatment of various symptoms, conditions or diseases such as Diarrhea, constipation, congestion, eczema, asthma, fatigue, muscle weakness, tension, and spasms, irritable bowel syndrome, swelling, anxiety, multiple chemical sensitivities, moderate to extensive and moderate to severe symptoms due to food allergies, sensitivities, and intolerances, bloating, pain, headaches, leaky gut, hyperactivity, sleeping difficulties, severe underweight, eating disorders, obsessive, compulsive disorders, panic attacks, sensory sensitivities, Alzheimer's disease, acid reflux, irritability, delayed motor skills, delayed social skills, autism, PDD, infantile spasms, seizures by withholding from the patient for a period of at least 5 days all food except for concentrated forms of concentrated tropical root crops. Preferably the patient is also removed from external environmental sources of allergens. After the initial withholding period new foods may be introduced according to a particular selection and schedule. Web site: http://www.delphion.com/details?pn=US06632461__
Patent Applications on Irritable Bowel Syndrome As of December 2000, U.S. patent applications are open to public viewing.10 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to irritable bowel syndrome: •
2-substituted piperidines that are ligands for monoamine receptors and transporters Inventor(s): Aquila, Brian M.; (Marlborough, MA), Hauske, James R.; (Concord, MA) Correspondence: Foley Hoag, Llp; Patent Group, World Trade Center West; 155 Seaport Blvd; Boston; MA; 02110; US Patent Application Number: 20030073681 Date filed: August 6, 2002 Abstract: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.
10
This has been a common practice outside the United States prior to December 2000.
152 Irritable Bowel Syndrome
Excerpt(s): This application claims the benefit of priority to U.S. Provisional Patent Application serial No. 60/313,934, filed Aug. 21, 2001; and U.S. Provisional Patent Application serial No. 60/353,517, filed Jan. 31, 2002. Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in pairs, or as a group, promise to serve as agents effective in the treatment of a wide range of maladies, conditions and diseases that afflict mammals due to atypical activities of these neurotransmitters. For example, depression is believed to result from dysfunction in the noradrenergic, dopaminergic, or serotonergic systems. Furthermore, the noradrenergic system appears to be associated with increased drive, whereas the serotonergic system relates more to changes in mood. Therefore, it is possible that the different symptoms of depression may benefit from drugs acting mainly on one or the other of these neurotransmitter systems. On the other hand, a single compound that selectively affects both the noradrenergic and serotonergic systems should prove effective in the treatment of depression comprising symptoms related to dysfunction in both systems. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
3-Azabicyclo[3.1.0]hexane derivatives useful in therapy Inventor(s): Banks, Bernard Joseph; (County of Kent, GB), Critcher, Douglas James; (County of Kent, GB), Fenwick, Ashley Edward; (County of Kent, GB), Gethin, David Morris; (County of Kent, GB), Gibson, Stephen Paul; (County of Kent, GB) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20030207876 Date filed: April 8, 2002 Abstract: Compounds of formula I, 1where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma. Excerpt(s): This claims application claims priority under 35 U.S.C. 120 of U.S. Ser. No. 09/883,567, filed Jun. 18, 2001. This invention relates to pharmaceutically useful compounds, in particular compounds that bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). Compounds that bind to such receptors are likely to be useful in the treatment of diseases modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; and pruritic dermatoses, such as allergic dermatitis and atopy in animals and humans. Compounds that bind to opiate receptors have also been indicated in the treatment of eating disorders, opiate overdoses, depression, smoking and alcohol addiction, sexual dysfunction, shock, stroke, spinal damage and head trauma. There is a particular need for an improved treatment of itching. Itching, or pruritus, is a common dermatological symptom that can give rise to considerable distress in both humans and animals. Pruritus is often associated with inflammatory skin diseases which may be caused by hypersensitivity reactions, including reactions to insect bites, such as flea bites, and to environmental allergens,
Patents 153
such as house dust mite or pollen; by bacterial and fungal infections of the skin; or by ectoparasite infections. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and tetrahydro-9H-pyrimidino[4,5-b]indole derivatives: CRF1 specific ligands
5,6,7,8-
Inventor(s): Darrow, James W.; (Wallingford, CT), Horvath, Raymond F.; (North Branford, CT), Maynard, George D.; (Clinton, CT) Correspondence: Steven J. Sarussi; Mcdonnell Boehnen Hulbert & Berghoff; 32nd Floor; 300 S. Wacker Drive; Chicago; IL; 60606; US Patent Application Number: 20030105117 Date filed: August 27, 2002 Abstract: Disclosed are compounds of the formula: 1whereinAr, R.sup.1, W, X and m are substituents as defined herein.These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I. Excerpt(s): The present invention relates to aminoalkyl substituted 5,6,7,8-tetrahydro9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives, pharmaceutical compositions containing such compounds and their use in treating psychiatric disorders, neurological diseases, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med. 2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J. E. Blalock, Physiological Reviews 69:1 (1989); J. E. Morley, Life Sci. 41:527 (1987)]. Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and
154 Irritable Bowel Syndrome
amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E. B. De Souza, Hosp. Practice 23:59 (1988)]. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Bifidobacterium in the treatment of inflammatory disease Inventor(s): Collins, John Kevin; (Duncloyne, IE), O'Mahony, Liam; (Cork, IE), O'Sullivan, Gerald Christopher; (Cork, IE), Shanahan, Fergus; (Kinsale, IE) Correspondence: Jacobson Holman Pllc; 400 Seventh Street N.W.; Suite 600; Washington; DC; 20004; US Patent Application Number: 20030170217 Date filed: March 3, 2003 Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. Excerpt(s): This invention relates to probiotic Bifidobacterium strains which have various applications in foodstuffs and in medicine. More particularly, the invention relates to probiotic strains of bifidobacteria which are capable of beneficially modifying and consequently alleviating observable symptoms in inflammatory disease. Consumers are becoming increasingly aware of matters which may be necessary for maintenance of their environment, health and nutrition. In response, scientific research has focussed upon the roles that diet, stress, and modern medical practices (e.g. antibiotics and radiotherapy) may play in threatening human health. In particular, population dynamics shifting towards older societies are increasing the incidence of illnesses which may be caused by deficient or compromised microflora such as gastrointestinal tract (GIT) infections, constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD)--Crohn's disease and ulcerative colitis, food allergies, antibiotic-induced diarrhoea, cardiovascular disease, and certain cancers (e.g. colorectal cancer). Probiotics have been defined as live microbial food supplements which beneficially affect the host by improving the intestinal microbial balance, or more broadly, as living microorganisms, which upon ingestion in certain numbers, exert health effects beyond inherent basic nutrition. Cocktails of various micro-organisms particularly species of Lactobacillus and Streptococcus, have traditionally been used in fermented dairy products to promote health. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 155
•
Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders Inventor(s): Carlson, Kenneth E.; (West Windsor, NJ), Macor, John E.; (Guilford, CT) Correspondence: Stephen B. Davis; Bristol-myers Squibb Company; Patent Department; P O Box 4000; Princeton; NJ; 08543-4000; US Patent Application Number: 20030069169 Date filed: March 4, 2002 Abstract: Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive coadministration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury. Excerpt(s): This application claims the benefit of priority of U.S. applications Serial Nos. 60/273,206, and 60/273,291, filed Mar. 2, 2001, and U.S. Serial No. 60/289,719 filed May 9, 2001, the entire contents of which are incorporated herein by reference. The present invention relates to methods for treating diseases associated with intracellular levels of cAMP comprising co-administration of at least one compound that is a melanocortin receptor agonist and at least one compound that is a cAMP-PDE inhibitor, and to pharmaceutical compositions for practicing the claimed methods. Cyclic adenoise 3',5' monophosphate (cyclic AMP or cAMP) is a nucleotide messenger associated with inflammatory cell activity; it mediates the functional responses of cells to a multitide of hormones and neurotransmitters, including NF-.kappa.B. NF-.kappa.B is a pivotal component of the pro-inflammatory cascade, and its activation is a central event in initiating many inflammatory diseases. In a typical inflammatory response, NF-.kappa.B is activated in response to an inflammatory stimulus and once activated, induces expression of a wide array of pro-inflammatory genes. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Compositions comprising sibutramine phosphodiesterase inhibitors
metabolites
in
combination
with
Inventor(s): Fang, Qun K.; (Wellesley, MA), Jerussi, Thomas P.; (Framingham, MA), Senanayake, Chrisantha H.; (Shrewsbury, MA) Correspondence: Pennie & Edmonds Llp; 1667 K Street NW; Suite 1000; Washington; DC; 20006 Patent Application Number: 20030096792 Date filed: October 23, 2002 Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse
156 Irritable Bowel Syndrome
including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound. Excerpt(s): This application is a continuation-in-part of U.S. patent application Ser. No. 09/662,135, filed Sep. 14, 2000, which is a continuation-in-part of U.S. patent application Ser. No. 09/372,158, filed Aug. 11, 1999, both of which are incorporated herein by reference in their entireties. The invention relates to methods of using and compositions comprising dopamine reuptake inhibitors such as racemic and optically pure metabolites of sibutramine, optionally in combination with other pharmacologically active compounds. Sibutramine, chemically named [N-1-[1-(4-chlorophenyl)cyclobutyl]3- -methylbutyl]-N,N-dimethylamine, is a neuronal monoamine reuptake inhibitor which was originally disclosed in U.S. Pat. Nos. 4,746,680 and 4,806,570. Sibutramine inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin and dopamine. See, e.g., Buckett et al., Prog. Neuro-psychopharm. & Biol. Psychiat., 12:575-584, 1988; King et al., J. Clin. Pharm., 26:607-611 (1989). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Cyclic amino acids and derivatives thereof useful as pharmaceutical agents Inventor(s): Bryans, Justin Stephen; (Balsham, GB), Horwell, David Christopher; (Cambridge, GB), Thorpe, Andrew John; (Ann Arbor, MI), Wustrow, David Juergen; (Ann Arbor, MI), Yuen, Po-Wai; (Ann Arbor, MI) Correspondence: Warner-lambert Company; 2800 Plymouth RD; Ann Arbor; MI; 48105; US Patent Application Number: 20030220397 Date filed: May 30, 2003 Abstract: The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included. Excerpt(s): This is a continuation of Ser. No. 09/485,382 filed Feb. 8, 2000, which is a 371 filing of PCT/US98/19876 filed Sep. 23, 1998, which claims priority to U.S. Provisional Serial No. 60/063,644 filed Oct. 27, 1997, and U.S. Provisional Serial No. 60/097,685 filed Aug. 24, 1998. wherein R.sub.1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in U.S. Pat. No. 4,024,175 and its divisional U.S. Pat. No. 4,087,544. The uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference. wherein R to R.sup.14 are as defined below. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 157
•
Early detection marker for chronic inflammatory associated diseases Inventor(s): Pereira, Heloise Anne; (Edmond, OK) Correspondence: Dunlap, Codding & Rogers P.C.; PO Box 16370; Oklahoma City; OK; 73114; US Patent Application Number: 20030170745 Date filed: March 7, 2003 Abstract: The present invention in one embodiment is an early detection marker for chronic inflammatory-associated diseases, including atherosclerosis, Alzheimer's disease, asthma, rheumatoid arthritis, osteoarthritis, and inflammatory diseases of the bowel such as Crohn's disease, Ulcerative colitis, Irritable bowel syndrome and Inflammatory bowel disease. The method, for example may comprise (1) obtaining a fluid sample from the subject, wherein the subject does not have an acute bacterial or viral infection when the fluid sample is obtained, (2) testing the fluid sample for a circulating or secreted CAP37 protein, and (3) concluding that the subject has a chronic inflammatory-associated disease when the CAP37 protein is detected in the fluid sample. The fluid sample may comprise serum, plasma, or cerebrospinal fluid, for example, or any other body fluid exposed to endothelial, vascular, or neuronal secretions. Excerpt(s): This application claims the benefit of U.S. Serial No. 60/363,114, filed Mar. 8, 2002, which is hereby expressly incorporated herein by reference in its entirety. The present invention relates to, but is not limited to, methods for detecting inflammatoryassociated diseases by detecting CAP37 proteins in a body fluid. Cationic Antimicrobial Protein of M.sub.r 37 kDa (CAP37) was originally isolated from granule extracts of human polymorphonuclear leukocytes (PMN) in 1984 (1). The amino acid sequence of PMN-CAP37 revealed its relation to members of the serine protease family that have a conserved catalytic active site consisting of his-57, asp-102 and ser-195 in the charge relay system (2). Of these sites, the conserved histidine and serine of the catalytic triad have been replaced with serine and glycine residues, respectively, rendering CAP37 ineffective as a serine protease (2,3). However, CAP37 has been demonstrated to have a diverse and exciting repertoire of functions. It was first analyzed regarding its bactericidal properties against Gram negative bacteria including, but not limited to, Salmonella typhimurium, Escherichia coli and Pseudomonas aeruginosa (4) and its ability to bind to and neutralize lipopolysaccharide (LPS)(5). Subsequently we showed CAP37 to be a potent chemoattractant for monocytes (6). Additionally, regarding its effects on the monocyte, CAP37 has been reported to stimulate their survival and thrombospondin secretion (7), also to enhance the LPS-stimulated release of prostaglandin E2 (8), interleukin 6 (IL-6)(9) and tumor necrosis factor-alpha (TNF.alpha.)(8-10). To add even further to its extensive range of known functions, CAP37 has been demonstrated to stimulate the reversible contraction of fibroblasts and endothelial cells (7) and to activate endothelial cell protein kinase C (PKC)(11). Recently, CAP37 released from stimulated PMN was reported to be taken up and sequestered in nearby endothelial mitochondria and has been suggested to protect against apoptosis (12). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
158 Irritable Bowel Syndrome
•
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility Inventor(s): Goeke, Burkhard; (Gauting, DE), Schirra, Joerg; (Kirchhain, DE) Correspondence: Arnold & Porter; Attn: IP Docketing Department, Room 1126b; 555 Twelfth Street, NW; Washington; DC; 20004-1206; US Patent Application Number: 20030216292 Date filed: June 9, 2003 Abstract: The present invention provides an effective method for inhibiting antroduodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP-1 slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures. Excerpt(s): The present invention relates to inhibiting antro-duodenal motility with GLP-1 and methods to alleviate discomfort during endoscopy and to alleviate symptoms of gastrointestinal disorders. Glucagon has been widely used to cause a variable reduction in gastroduodenal motility. The effect of glucagon appears to be dose-dependent with a minimally effective dose being 0.5 mg. Glucagon, however, does not facilitate colonoscopic evaluation (Norfleet, Gastrointest. Endosc., 24, 164-5, 1978), and at doses as high as 2 mg glucagon does not reduce contractions in the antrum (Gregerson et al., Scand. J. Gastroenterol. 23 (Supp 152), 42-47 (1988)). Furthermore, glucagon is contraindicated in persons with diabetes (Paul & Freyschmidt, ROFO Rortschr. Geb. Rontgenstr. Nuklearmed., 125, 31-7 (1996)), is expensive and its efficacy has been questioned. Side effects associated with the use of glucagon include nausea and vomiting. The effects are dose-dependent and can appear at a dose of 1 mg (Larsen et al., Scand. J. Gastroenterol. 21, 634-640, 1986; Gregersen et al., supra, Diamant Handbook Experimental Pharm, Lefevre ed., Vol. 66/2, 611-643, 1983). As dosages required to sufficiently reduce motility frequently exceed 1 mg, side effects from glucagon use are common. Such side effects render the patient extremely uncomfortable and often cause the endoscopic procedure to be interrupted or aborted. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Heterocyclic derivatives useful as pharmaceutical agents Inventor(s): Blakemore, David Clive; (Cambridge, GB), Bryans, Justin Stephen; (Balsham, GB), Williams, Sophie Caroline; (Cambridge, GB) Correspondence: David R. Kurlandsky; Warner-lambert Company Llc; 2800 Plymouth Road; Ann Arbor; MI; 48105; US Patent Application Number: 20030203945 Date filed: May 5, 2003 Abstract: This invention relates to novel heterocyclic derivatives of the formula (VII), (VIII) or (IX) 1in which P, Q, R.sup.1-R.sup.6, m and n are as defined in the specification, and to pharmaceutically acceptable salts thereof. The compounds and pharmaceutical compositions containing them are useful in the treatment of a range of disorders including epilepsy, faintness attacks, hypokinesia, cranial disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases and gastrointestinal disorders, especially irritable bowel syndrome.
Patents 159
Excerpt(s): This invention relates to novel heterocyclic derivatives useful as pharmaceutical agents, to processes for their production, to pharmaceutical compositions containing them, and to their use for the treatment of the neurological conditions set out below. in which R.sub.1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6. These compounds are described U.S. Pat. No. 4,024,175 and its divisional U.S. Pat. No. 4,087,544. Their disclosed uses are: the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The disclosures of the above two patents are hereby incorporated by reference. in which R.sup.1 to R.sup.10 are each independently selected from straight or branched chain C.sup.1-C.sup.6 alkyl, substituted or unsubstituted benzyl or phenyl which substituents are selected from halogen, alkoxy, alkyl, hydroxy, carboxy, carboalkoxy, trifluoromethyl and nitro, any of R.sup.1 to R.sup.10 which is not one of the above being hydrogen. They are useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain and neuropathological disorders. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome Inventor(s): Bakthavatchalam, Rajagopal; (US), Gilligan, Paul J.; (US), Wilde, Richard G.; (US) Correspondence: Stephen B. Davis; Bristol-myers Squibb Company; Patent Department; P O Box 4000; Princeton; NJ; 08543-4000; US Patent Application Number: 20030220342 Date filed: May 1, 2003 Abstract: Provided herein are methods for treating a subject afflicted with irritable bowel syndrome comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises a pharmaceutically acceptable carrier and a compound of the formula 1wherein:X is CHR.sup.5, NR.sup.5, O, S, S(O).sub.n or a single bond, wherein n is equal to 0, 1 or 2;D is aryl or heteroaryl attached through an unsaturated carbon atom and wherein said aryl or heteroaryl is optionally substituted at any available position with from 1-5 of A.sup.1, A.sup.2, A.sup.3, A.sup.4 and A.sup.5; andR.sup.2 is C.sub.1-4 alkyl or C.sub.3-8 cycloalkyl, each of which is optionally substituted with from 1-3 hydroxy, halogen or C.sub.1-4 alkoxy, or wherein when X is a bond, R.sup.2 is CN, CF.sub.3, or C.sub.2F.sub.5. Excerpt(s): This application is a continuation of co-pending U.S. application Ser. No. 09/905,097, filed Jul. 13, 2001, now allowed, which in turn claims priority of provisional application Serial No. 60/218,339. These priority applications are hereby incorporated herein in their entireties. This invention relates to compounds which are novel imidazo[1,2-a]pyrazines, and to the use of such compounds as CRF receptor antagonists in the treatment of various neurological disorders. Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC)-derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm.
160 Irritable Bowel Syndrome
Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med. 2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J. E. Blalock, Physiological Reviews 69:1 (1989); J. E. Morley, Life Sci. 41:527 (1987)]. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients Inventor(s): Biesheuvel, Egbertus Hendrikus Evert; (Weesp, NL), Caras, Steven David; (Marietta, GA), Cautreels, Werner L. M.; (Weesp, NL), Krause, Heinz Guenter; (Burgdorf, DE), Plekkenpol, Albertus Hermannus Dirk; (Hilversum, NL), Steinborn, Claus Rudolf; (Seelze, DE) Correspondence: Crowell & Moring Llp; Intellectual Property Group; P.O. Box 14300; Washington; DC; 20044-4300; US Patent Application Number: 20030125349 Date filed: January 22, 2003 Abstract: The present invention relates to the use of cilansetron for the treatment of nonobstipative male IBS patients. Excerpt(s): This application claims priority of U.S. Provisional Patent Application No. 60/220,848, filed Jul. 26, 2000. Convention priority is also claimed based on Federal Republic of Germany Patent Application Nos. DE 100 36 645.7, filed Jul. 26, 2001 and DE 101 23 447.3, filed May 14, 2001. The present invention relates to a novel medicinal use of cilansetron or the acid addition salts thereof. Cilansetron is a 5HT.sub.3-receptor antagonist which falls within the scope of European Patent No. EP 297,651 B1 and has the chemical name (R)-(-)-4,5,6,8,9,10-hexahydro-10-[(2-methyl-1H-imidazol-1yl)methyl]-11H- -pyrido-[3,2,1-jk]-carbazol-11-one. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Method and apparatus for distinguishing crohn's disease from ulcerative colitis and other gastrointestinal diseases by detecting the presence of fecal antibodies to saccharomyces cerevisiae Inventor(s): Boone, James Hunter; (Christiansburg, VA), Lyerly, David Maxwell; (Radford, VA), Wilkins, Tracy Dale; (Riner, VA) Correspondence: Shook, Hardy & Bacon Llp; 1200 Main Street; Kansas City; MO; 641052118; US Patent Application Number: 20030143649 Date filed: October 25, 2002 Excerpt(s): This application claims the benefit of priority to U.S. Provisional Application No. 60/335,812 filed on Oct. 26, 2001, the entirety of the disclosure of which is hereby incorporated by reference. Not Applicable. A method and apparatus for the differentiation of Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome, using the presence of fecal anti-Saccharomyces cerevisiae antibodies (ASCA) as a marker for Crohn's disease are provided. The
Patents 161
apparatus includes an enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobulins for the measurement of total endogenous ASCA in a human fecal sample. The method and apparatus may be used by healthcare providers to distinguish Crohn's disease from other gastrointestinal illnesses, such as ulcerative colitis and irritable bowel syndrome. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method and composition for treatment of irritable bowel disease Inventor(s): Bergeron, Raymond J. JR.; (Gainesville, FL) Correspondence: Miles & Stockbridge; Suite 500; 1751 Pinnacle Drive; Mclean; VA; 22102-3833; US Patent Application Number: 20030153582 Date filed: August 1, 2002 Abstract: A method and composition for treating irritable bowel syndrome in a subject in need of such treatment, utilizing an amount of a polyamine having the formula:R-NH--(CH.sub.2).sub.a--NH--(CH.sub.2).sub.bH--(CH.sub.2).sub.c--NH.sub.2, 1)CF.sub.3--C.sub.6H.sub.5--(CH.sub.2).sub.a--NH--(CH.sub.2).sub.b--NH--(CH.sub.2).sub.c--NH--(CH.sub.2).sub.d--NH--(CH.sub.2).sub.e--C.sub.6H.sub.5--- CF.sub.3, 2)R--NH--(CH.sub.2).sub.a--NH--C.sub.6H.sub.6--NH--(CH.sub.2).sub.b--NH--R and 3)PIP--(CH.sub.2).sub.aNH--(CH.sub.2).sub.b--NH--(CH.sub.2).sub.c--PIP, 4)wherein:R is alkyl, aryl, aralkyl, alkaryl, or cyclo-alkyl having up to about 10 carbon atoms, and any of the alkyl chains may optionally be interrupted by at least one etheric oxygen atom,PIP is piperidine anda, b, c, d, and e may be the same or different and are integers from 1-10 effective to treat irritable bowel syndrome. Excerpt(s): The present invention relates to pharmaceutical compositions and methods for the treatment of irritable bowel disease (IBD) [also termed: irritable bowel syndrome (IBS)]; more particularly for the treatment of diarrhea-predominant IBD. Irritable bowel syndrome (IBS), a chronic or recurring gastrointestinal disorder, afflicts as many as 24% of women and 19% of men in the U.S., Europe, Japan, and China. IBS produces abdominal pain or discomfort in its victims and accounts for about one-eighth of primary care and more than one-fourth of gastroenterology practice. IBS has tremendous societal and economic impact since persons with IBS symptoms miss three times as many work days as those without and incur 70% higher health care costs. The American Gastroenterological Association has recently underscored the importance of IBS by issuing both a position statement (American Gastroenterological Association (AGA) Medical Position Statement: Irritable Bowel Syndrome. Gastroenterology 112:2118-2119 (1997)) and a technical review (Drossman D A, Whitehead W E, Camilleri M., "Irritable bowel syndrome: a technical review for practice guideline development", Gastroenterology 112:2120-2137 (1997)) on IBS. The description herein of IBS is based chiefly on these documents and on other current literature (such as that reviewed in Snape W J Jr., "Irritable bowel syndrome", In: Bockus Gastroenterology, 5th edition (W. S. Haubrich, F. Schoffner, ed.) Philadelphia: W. B. Saunders, pp. 1619-1636 (1995)). IBS presents itself as abdominal pain accompanied by altered bowel habits. There is no established biological marker for IBS, which appears to result from faulty regulation in both the gastrointestinal and nervous systems. Once clinicians rule out other possible causes of IBS symptoms, they must devise a treatment plan based upon the severity and nature of the symptoms as well as other factors such as the degree of impairment the individual is experiencing in the activities of daily living. At present, treatment options
162 Irritable Bowel Syndrome
range from education and dietary modification to drug therapy to psychological therapy. Drug and/or psychological therapy is called for in those 30% of IBS patients with moderate or severe symptoms. Given an IBS prevalence of 19% to 24%, IBS sufferers requiring such therapy represent 6-7% of the population at large, or well over 100 million individuals in continual need of such therapy in the U.S., Europe, Japan, and China. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method for the stereoselective synthesis of cyclic amino acids Inventor(s): Blakemore, David Clive; (Cambridge, GB), Bryans, Justin Stephen; (Balsham, GB), Williams, Sophie Caroline; (Cambridge, GB) Correspondence: Elizabeth M Anderson; Warner Lambert Company; 2800 Plymouth Road; Ann Arbor; MI; 48105; US Patent Application Number: 20030069438 Date filed: June 6, 2002 Abstract: 1The instant invention is a route to stereospecific 3-substituted 5-membered ring isomers of Formula (A). The final products are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammation especially arthritis, sleep disorders, premenstrual syndrome, and hot flashes. The invention provides novel routes to synthesize stereoselectively analogs of gabapentin (Neurontin.TM.) of Formulas (I), (II), (III) and (IV) wherein R is C.sub.1-C.sub.10 alkyl or C.sub.3-C.sub.10 cycloalkyl and pharmaceutically acceptable salts thereof. Excerpt(s): wherein R.sub.1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in U.S. Pat. No. 4,024,175 and its divisional U.S. Pat. No. 4,087,544. The uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference. or a pharmaceutically acceptable salt thereof wherein R is hydrogen or a lower alkyl; and R.sub.1 to R.sub.8 are each independently selected from hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, benzyl, fluorine, chlorine, bromine, hydroxy,. hydroxymethyl, amino, aminomethyl, trifluoromethyl, -CO.sub.2H, --CO.sub.2R.sub.15, --CH.sub.2CO.sub.2H, --CH.sub.2CO.sub.2R.sub.15, -OR.sub.15 wherein R.sub.15 is a straight or branched alkyl of from 1 to 6 carbons, phenyl, or benzyl, and R.sub.1 to R.sub.8 are not simultaneously hydrogen. This patent application is hereby incorporated by reference. when R.sub.3, R.sub.5, Z.sub.1, Z.sub.2, or Z.sub.3 is X(CH.sub.2).sub.nR.sub.8 and n is not zero, X is oxygen or NR.sub.6 when R.sub.8 is OR.sub.6 or CO.sub.2H. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 163
•
Methods for treating apnea, apnea disorders, and other disorders using optically pure (-) norcisapride Inventor(s): Barberich, Timothy J.; (Concord, MA), Rubin, Paul D.; (Sudbury, MA) Correspondence: Pennie & Edmonds Llp; 1667 K Street NW; Suite 1000; Washington; DC; 20006 Patent Application Number: 20030158229 Date filed: February 26, 2003 Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (-) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer. Excerpt(s): The invention relates to methods of prevention, treatment, or management, of apnea, apnea disorders, bulimia, other disorders, or symptoms thereof. Apnea is defined in Stedman's Medical Dictionary, 26.sup.th Edition, Williams and Wilkins (1995), as the absence of breathing. There are a number of disorders associated with apnea, which are characterized by interrupted breathing in which a person stops breathing long enough to decrease the amount of oxygen and increase the amount of carbon dioxide in the blood and brain Each type of apnea involves the absence of airflow at the nose or the mouth, typically for at least 10 seconds. Various apnea disorders exist, including: central apnea, which results from medullary depression and inhibits respiratory movement; deglutition apnea, which is the inhibition of breathing during swallowing; obstructive or peripheral apnea, which is either a result of obstruction of air passages or inadequate respiratory muscle activity; sleep apnea, which is central and/or obstructive apnea during sleep; and sleep induced apnea, which results from failure of the respiratory center to stimulate adequate respiration during sleep. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Methods for treating irritable bowel syndrome Inventor(s): Mangel, Allen Wayne; (Chapel Hill, NC), Northcutt, Allison Ruth; (Raleigh, NC) Correspondence: David J Levy, Corporate Intellectual Property; Glaxosmithkline; Five Moore DR., PO Box 13398; Research Triangle Park; NC; 27709-3398; US Patent Application Number: 20030036549 Date filed: June 10, 2002 Abstract: This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients. Excerpt(s): The invention relates to a new medical use for compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors. 5-HT.sub.3 receptor antagonists may be identified by methods well known in the art, for example by their ability to inhibit 3-(5-methyl-1H-imidazole4-yl)-1-[1-[.sup.3H]-methyl-1H-indol-3-yl]-1prop- anone binding in rat entorhinal cortex homogenates (following the general procedure described by G Kilpatrick et al, Nature, 1987, 330, 746-748), and/or by their effect on the 5-HT-induced Bezold-Jarisch (B-J) reflex in the cat (following the general
164 Irritable Bowel Syndrome
method described by A Butler et al, Br. J. Pharmacol., 94, 397412 (1988)). A number of different 5-HT.sub.3 receptor antagonists have been disclosed, for example those of group A: indisetron, Ro-93777, YM-114, granisetron, talipexole, azasetron, tropisetron, mirtazapine, ramosetron, ondansetron, lerisetron, alosetron, N-3389, zacopride, cilansetron, E-3620, lintopride, KAE-393, itasetron, mosapride and dolasetron. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth Inventor(s): Lin, Henry C.; (Manhattan Beach, CA), Pimentel, Mark; (Los Angeles, CA) Correspondence: Sidley Austin Brown & Wood Llp; 555 West Fifth Street; Los Angeles; CA; 90013-1010; US Patent Application Number: 20030031625 Date filed: March 26, 2002 Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease. Excerpt(s): This application is a division of Ser. No. 09/374,142, which was filed Aug. 11, 1999. Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains. This invention relates to the medical arts. It relates to a method of diagnosing and treating irritable bowel syndrome and other disorders, such as Crohn's disease, chronic fatigue syndrome, fibromyalgia, depression, attention deficit/hyperactivity disorder, multiple sclerosis, systemic lupus erythematosus and other autoimmune diseases in a human subject. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 165
•
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use Inventor(s): De Tejada, Inigo Saenz; (Madrid, ES), Earl, Richard A.; (Westford, MA), Garvey, David S.; (Dover, MA), Khanapure, Subhash P.; (Clinton, MA) Correspondence: Edward D Grieff; Hale & Dorr Llp; 1455 Pennsylvania Ave, NW; Washington; DC; 20004; US Patent Application Number: 20030023087 Date filed: August 13, 2002 Abstract: The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3',5'-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS). Excerpt(s): This is a continuation-in-part of U.S. application Ser. No. 09/145,142, filed Sep. 1, 1998, allowed, which is a continuation-in-part of U.S. application Ser. No. 08/740,764, filed Nov. 1, 1996, issued as U.S. Pat. No. 5,874,437; and is a continuation-inpart of PCT/US97/19870, filed Oct. 31, 1997, which claims priority to U.S. application Ser. No. 08/740,764, filed Nov. 1, 1996, issued as U.S. Pat. No. 5,874,437. The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions comprising at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of
166 Irritable Bowel Syndrome
cyclic guanosine 3',5'-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, and glucoma, and diseases characterized by disorders of gut motility, such as irritable bowel syndrome (IBS). Adequate sexual function is a complex interaction of hormonal events and psychosocial relationships. There are four stages to sexual response as described in the International Journal of Gynecology & Obstetrics, 51(3):265-277 (1995). The first stage of sexual response is desire. The second stage of sexual response is arousal. Both physical and emotional stimulation may lead to breast and genital vasodilation and clitoral engorgement (vasocongestion). In the female, dilation and engorgement of the blood vessels in the labia and tissue surrounding the vagina produce the "orgasmic platform," an area at the distal third of the vagina where blood becomes sequestered. Localized perivaginal swelling and vaginal lubrication make up the changes in this stage of sexual response. Subsequently, ballooning of the proximal portion of the vagina and elevation of the uterus occurs. In the male, vasodilation of the cavernosal arteries and closure of the venous channels that drain the penis produce an erection. The third stage of sexual response is orgasm, while the fourth stage is resolution. Interruption or absence of any of the stages of the sexual response cycle can result in sexual dysfunction. One study found that 35% of males and 42% of females reported some form of sexual dysfunction. Read et al, J. Public Health Med., 19(4):387-391 (1997). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Novel 5-HT3 receptor antagonists and methods of use Inventor(s): Becker, Cyrus; (Menlo Park, CA), Druzgala, Pascal; (Santa Rosa, CA), Pfister, Jurg R.; (Los Altos, CA), Zhang, Xiaming; (Campbell, CA) Correspondence: Saliwanchik Lloyd & Saliwanchik; A Professional Association; 2421 N.W. 41st Street; Suite A-1; Gainesville; FL; 326066669 Patent Application Number: 20030158221 Date filed: January 21, 2003 Abstract: The subject invention provides useful and novel 5-HT3 antagonists. The subject invention also provides methods for synthesizing the compounds of invention. The invention also provides methods for the treatment of irritable bowel syndrome and other such conditions. Excerpt(s): This application claims the benefit of U.S. Provisional Application Serial No. 60/350,504, filed Jan. 18, 2002. Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorder thought to result from dysregulation of intestinal motor, sensory and CNS function. In the United States, the estimated prevalence is 15% to 20%, and 75% of patients are women. Despite its prevalence, IBS is poorly understood. It is one of over 20 functional gastrointestinal (GI) disorders that are not explained by identifiable structural or biochemical abnormalities. IBS is characterized by persistent or recurrent symptoms of abdominal pain with diarrhea and/or constipation. IBS is believed to relate to abnormalities in motility and/or afferent sensitivity as
Patents 167
mediated by the central nervous system. Patients with IBS have a diminished quality of life and use significant health care resources. Treatment for patients diagnosed with IBS has included antidepressant drugs, tranquilizers and laxatives. Pharmacological intervention in diarrhea-predominant IBS focuses on the reduction of bowel motility, spasms and transit times. Peripherally acting opiod ligands such as the petidine congeners diphenoxylate and loperamide and the k-opiod agonist fedotozine slow gastrointestinal transit by their effects on the circular and longitudinal muscle. While these drugs show some effects on intestinal motility, their effects on IBS-related abdominal pain and intestinal relief is generally insufficient. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same Inventor(s): Yi, Jung Bum; (Kyunggi-do, KR), Kim, Hee Doo; (Seoul, KR), Lee, Jee Woo; (Seoul, KR), Oh, Uh Taek; (Kyunggi-do, KR), Park, Hyeung Geun; (Seoul, KR), Park, Young Ho; (Seoul, KR), Suh, Young Ger; (Kyunggi-do, KR) Correspondence: Finnegan, Henderson, Farabow, Garrett & Dunner; Llp; 1300 I Street, NW; Washington; DC; 20005; US Patent Application Number: 20030203944 Date filed: February 3, 2003 Abstract: The present invention relates to an antagonist against vanilloid receptor and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fevescence, stomachduodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases. Excerpt(s): The present invention relates to thiocarbamic acid derivatives and the pharmaceutical compositions containing the same, and particularly, to novel thiocarbamic acid derivatives as an antagonist against vanilloid receptor (VR) and the pharmaceutical compositions thereof. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomachduodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides pharmaceutical compositions for prevention or treatment of these diseases. Yet, the diseases described above are only for enumeration, not to limit the scope of clinical application of vanilloid receptor antagonist. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
168 Irritable Bowel Syndrome
•
Novel thiourea derivatives and the pharmaceutical compositions containing the same Inventor(s): Choi, Jin Kyu; (Kyunggi-do, KR), Jeong, Yeon Su; (Kyunggi-do, KR), Joo, Yung Hyup; (Seoul, KR), Kim, Hee Doo; (Seoul, KR), Kim, Jin Kwan; (Seoul, KR), Kim, Sun Young; (Kyunggi-do, KR), Koh, Hyun Ju; (Seoul, KR), Lee, Jee Woo; (Seoul, KR), Lee, Yong Sil; (Seoul, KR), Lim, Kyung Min; (Kyunggi-do, KR), Moh, Joo Hyun; (Kyunggi-do, KR), Oh, Uh Taek; (Kyunggi-do, KR), Oh, Young Im; (Kyunggi-do, KR), Park, Hyeung Geun; (Seoul, KR), Park, Ok Hui; (Chungchongnam-do, KR), Park, Young Ho; (Seoul, KR), Suh, Young Ger; (Kyunggi-do, KR), Yi, Jung Bum; (Kyunggi-do, KR) Correspondence: Finnegan Henderson; Farabow Garrett & Dunner; 1300 I Street N W; Washington; DC; 20005-3315; US Patent Application Number: 20030153596 Date filed: July 9, 2002 Abstract: The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases. Excerpt(s): The present invention relates to novel thiourea derivatives and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions thereof. Here, the modulator means the thing that can be bonded to the receptor to act as an antagonist or an agonist. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arttralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulnonary disease, irritation of skin, eye or mucous membrane, fervescence, stomachduodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides pharmaceutical compositions for prevention or treatment of these diseases. Yet, the diseases described above are only for enumeration, not to limit the scope of clinical application of vanilloid receptor modulator. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a main pungent component in hot peppers. Hot peppers have been used, for a long time, not only as a spice but also as traditional medicine in the treatment of gastric disorders and when applied locally, for the relief of pain and inflammation (Szallasi and Blumberg, 1999, Pharm, Rev. 51, ppl59-211). Capsaicin has a wide spectrum of biological actions, and not only exhibits effects on the cardiovascular and respiratory systems but also induces pain and irritancy on local application. Capsaicin, however, after such induction of pain, induces desensitization, both to capsaicin itself and also to other noxious stimuli to make the pain stopped. Based on this property, capsaicin and its analogues such as olvanil, nuvanil, DA-5018, SDZ-249482, resiniferatoxin are either used as analgesic agent, therapeutic agent for incontinentia urinae or skin disorder, or under development (riggleworth and Walpole, 1998, Drugs of the Future 23, pp 531-538).
Patents 169
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Inventor(s): Gymer, Geoffrey; (Sandwich, GB), Kawamura, Kiyoshi; (Aichi-ken, JP), Mihara, Sachiko; (Aichi-ken, JP), Morita, Mikio; (Aichi-ken, JP), Nukui, Seiji; (Aichi-ken, JP), Stobie, Alan; (Sandwich, GB), Uchida, Chikara; (Aichi-ken, JP) Correspondence: Pfizer INC.; Patent Department, Ms8260-1611; Eastern Point Road; Groton; CT; 06340; US Patent Application Number: 20030207875 Date filed: January 7, 2003 Abstract: This invention provides compounds of the formula (I) and (II): 1or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R.sup.1 is hydrogen or halo; R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-6 alkyl; R.sup.6 is hydrogen, C.sub.1-12 alkyl, C.sub.1-6 alkoxy (C.sub.1-6)alkyl or C.sub.1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C.sub.3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R.sup.7 and R.sup.8 are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R.sup.9 is C.sub.1-6 alkyl or C.sub.3-8 cycloalkyl; R.sup.10 is C.sub.1-6 alkyl or NR.sup.11R.sup.12; L is (CR.sup.11R.sup.12).sub.n or NR.sup.11; M is NR.sup.11 or (CR.sup.11R.sup.12).sub.n; R.sup.11 and R.sup.12 are independently hydrogen or C.sub.1-6 alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C.sub.1-6 alkyl; with the proviso that when R.sup.9 is C.sub.1-6 alkyl, L is not NR.sup.11.These compounds have 5-HT.sub.4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound. Excerpt(s): This invention relates to novel oxo or oxy-pyridine compounds. These compounds have 5-HT.sub.4 receptor binding activity (e.g., agonist or antagonist activities), and thus are useful for the treatment of or prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety, cardiovascular disorder or the like, in mammalian, especially human. The present invention also relates to a pharmaceutical composition comprising the above compounds. Serotonin (5-HT) receptors are known to have a plurality of subtypes such as 5-HT.sub.1, 5-HT.sub.2, 5HT.sub.3 and 5-HT.sub.4. These 5-HT.sub.4 receptors are disclosed in, for example, European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410. 5-HT.sub.4 receptor modulators (e.g., agonists and antagonists) are found to be useful for the treatment of a variety of diseases such as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, nonulcer dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, and cardiovascular disorders such as cardiac failure and heart arryhthmia (See TiPs, 1992, 13, 141; Ford A.
170 Irritable Bowel Syndrome
P. D. W. et al., Med. Res. Rev., 1993, 13, 633; Gullikson G. W. et al., Drug Dev. Res., 1992, 26, 405; Richard M. Eglen et al, TiPS, 1995, 16, 391; Bockaert J. Et al., CNS Drugs, 1, 6; Romanelli M. N. et al., Arzheim Forsch./Drug Res., 1993, 43, 913; Kaumann A. et al., Naunyn-Schmiedeberg's. 1991, 344, 150; and Romanelli M. N. et al., Arzheim Forsch./Drug Res., 1993, 43, 913). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Pharmaceutical composition and method of modulating cholinergic function in a mammal Inventor(s): Coe, Jotham W.; (Niantic, CT), Sands, Steven B.; (Stonington, CT) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20030008892 Date filed: March 25, 2002 Abstract: A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multiinfarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed. Excerpt(s): The present invention relates to pharmaceutical compositions for modulating cholinergic function in a mammal comprising a nicotinic receptor partial agonist compound in combination with an anti-emetic/anti-nausea agent and a pharmaceutically acceptable carrier. The nicotinic receptor partial agonists (NRPAs) included herein are aryl fused azapolycyclic compounds. NRPAs are not limited to those described here. The term NRPA refers to all chemical compounds which bind at neuronal nicotinic acetylcholine specific receptor sites in mammalian tissue and elicit a partial agonist response. A partial agonist response is defined here to mean a partial, or incomplete functional effect in a given functional assay. Additionally, a partial agonist will also exhibit some degree of antagonist activity by its ability to block the action of a full agonist (Feldman, R. S., Meyer, J. S. & Quenzer, L. F. Principles of Neuropsychopharmacology, 1997; Sinauer Assoc. Inc.). The present invention may be used to treat mammals (e.g. humans) for inflammatory bowel disease (including but not
Patents 171
limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multiinfarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome with a decrease in the incidence and severity of unwanted side effects such as nausea and/or stomach upset. The present invention also relates to the combination use of NRPAs and anti-emetic/anti-nausea agents resulting in modulation of cholinergic function without nausea. The combination will provide an improved treatment paradigm than NRPAs alone. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Predicting patient responsiveness to serotonergic therapy Inventor(s): Camilleri, Michael L.; (Rochester, MN), Urrutia, Raul A.; (Rochester, MN) Correspondence: Fish & Richardson P.C.; 3300 Dain Rauscher Plaza; 60 South Sixth Street; Minneapolis; MN; 55402; US Patent Application Number: 20030143548 Date filed: January 28, 2002 Abstract: Methods to predict a patient's responsiveness to 5-HT.sub.3 receptor antagonists are disclosed. The methods allow a clinician to predict a patient's responsiveness to 5-HT.sub.3 receptor antagonists by determining the correlation that exists between a genotype in the promoter region of the gene encoding a serotonin transporter protein and patient response to 5-HT.sub.3 receptor antagonist therapy. In addition, methods to treat patients suffering from diarrhea-predominant irritable bowel syndrome and methods to identify a patient population for inclusion in a 5-HT.sub.3 receptor antagonist clinical trial are disclosed. Excerpt(s): Funding for the work described herein was provided in part by the Federal Government, which may have certain rights in the invention. This invention relates to serotonergic therapy, and more particularly to predicting a patient's responsiveness to serotonergic receptor antagonists. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder in western populations, with an adult prevalence of approximately 15%. The cardinal features of IBS are recurrent abdominal pain and altered bowel habits. Diarrhea-predominant IBS has been associated with accelerated small bowel and/or colonic transit and with rectal hypersensitivity. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
172 Irritable Bowel Syndrome
•
Probiotic lactobacillus casei strains Inventor(s): Collins, John Kevin; (Doughcloyne, IE), Kiely, Barry; (Passage West, IE), O'Mahony, Liam; (Cork, IE), O'sullivan, Gerald Christopher; (Cork, IE), Shanahan, Fergus; (Kinsale, IE) Correspondence: Jacobson Holman; Professional Limited Liability Company; 400 Seventh STREET. N.W.; Washington; DC; 20004; US Patent Application Number: 20030113306 Date filed: July 25, 2002 Abstract: A Lactobacillus casei strain or a mutant or variant thereof isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. In particular a Lactobacillus casei strain, AH101, AH104, AH111, AH112 or AH113 or mutants or variants are thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome. Excerpt(s): The invention relates to Lactobacillus casei strains and their use as probiotic bacteria in particular as immunomodulatory biotherapeutic agents. The defense mechanisms to protect the human gastrointestinal tract from colonization by intestinal bacteria are highly complex and involve both immunological and non-immunological aspects (1). Innate defense mechanisms include the low pH of the stomach, bile salts, peristalsis, mucin layers and anti-microbial compounds such as lysozyme (2). Immunological mechanisms include specialized lymphoid aggregates, underlying M cells, called peyers patches which are distributed throughout the small intestine and colon (3). Luminal antigens presented at these sites result in stimulation of appropriate T and B cell subsets with establishment of cytokine networks and secretion of antibodies into the gastrointestinal tract (4). In addition, antigen presentation may occur via epithelial cells to intraepithelial lymphocytes and to the underlying lamina propria immune cells (5). Therefore, the host invests substantially in immunological defense of the gastrointestinal tract. However, as the gastrointestinal mucosa is the largest surface at which the host interacts with the external environment, specific control mechanisms must be in place to regulate immune responsiveness to the 100 tons of food which is handled by the gastrointestinal tract over an average lifetime. Furthermore, the gut is colonized by over 500 species of bacteria numbering 10.sup.11-10.sup.12/g in the colon. Thus, these control mechanisms must be capable of distinguishing non-pathogenic adherent bacteria from invasive pathogens, which would cause significant damage to the host. In fact, the intestinal flora contributes to defense of the host by competing with newly ingested potentially pathogenic micro-organisms. Bacteria present in the human gastrointestinal tract can promote inflammation. Aberrant immune responses to the indigenous microflora have been implicated in certain disease states, such as inflammatory bowel disease. Antigens associated with the normal flora usually lead to immunological tolerance and failure to achieve this tolerance is a major mechanism of mucosal inflammation (6). Evidence for this breakdown in tolerance includes an increase in antibody levels directed against the gut flora in patients with IBD. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 173
•
Proceture to use staphylococcal bacteria Inventor(s): Gottfries, Carl-Gerhard; (Goteborg, SE), Regland, Bjorn; (Molndal, SE) Correspondence: Drum & Roth; 53 West Jackson Boulevard; Chicago; IL; 60604-3606; US Patent Application Number: 20020192238 Date filed: June 20, 2002 Abstract: The Invention relates to a procedure for the use of staphylococcal bacteria or a product derived therefrom. The aforementioned staphylococcal bacteria or a product derived therefrom are intended for the production of a pharmaceutical preparation for the treatment of and/or for the prevention of irritable bowel syndrome. Excerpt(s): The present invention relates to a procedure for the use of staphylococcal bacteria or a product derived therefrom. Irritable Bowel Syndrome (IBS) is a bowel disease with variable symptoms, which may be referred to in Swedish as the equivalent of "irritable large intestine". There are no biological markers for the disease. Two systems of classification based on the symptoms have been drawn up to define the disease. One is known as the "Manning criteria" and the other as the "Rome criteria". In Manning, A. P., Thompson, W. G., Heaton, K. W., Morris, A. F. (1978), "Towards Positive Diagnosis of the Irritable Bowel", Br. Med. J., 2:653-654, four symptoms are identified which, in a significant fashion, distinguish patients with IBS from patients with some other known organic disease; these are tension and swelling in the abdomen, pain alleviation in conjunction with bowel activity, more frequent bowel motions in conjunction with abdominal pains and looser bowel motions in conjunction with abdominal pains. In addition to these, it was also stated that two symptoms are also often encountered, namely mucous-like motions and a sense of incomplete evacuation of the bowel. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Stable hydrate of a muscarinic receptor antagonist Inventor(s): Dunn, Peter James; (Sandwich, GB), Matthews, John George; (Sandwich, GB), Newbury, Trevor Jack; (Sandwich, GB), O'Connor, Garry; (Sandwich, GB) Correspondence: Pfizer INC.; Patent Department, Ms8260-1611; Eastern Point Road; Groton; CT; 06340; US Patent Application Number: 20030191176 Date filed: March 25, 2003 Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells. Excerpt(s): In addition, the invention relates to pharmaceutical compositions containing the hydrate of the invention and to uses of said hydrate in medicine. Such pharmaceutical compositions are particularly relevant to the treatment of conditions for which an antagonist of muscarinic receptors is required, such as irritable bowel
174 Irritable Bowel Syndrome
syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder including symptoms of incontinence, urge and frequency, urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells. European patent 0388054 describes a family of 3substituted pyrrolidine derivatives including darifenacin and pharmaceutically acceptable salts thereof as muscarinic receptor antagonists. The pharmaceutically acceptable salts include acid addition salts, specifically the hydrochloride, hydrobromide, hydrofluoride, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, besylate, citrate, fumarate, gluconate, lactate, maleate, mesylate, succinate and tartrate salts. The hydrobromide salt of darifenacin has been the preferred compound for medical usage. The salt is produced from the corresponding anhydrous free base. However, a problem associated with the free base is that it is very unstable, having a shelf life of only one month. Additionally it can be difficult to produce the free base in a sufficiently pure form for pharmaceutical use. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Substituted homopiperidinyl benzimidazole analogues as fundic relaxants Inventor(s): Guillemont, Jerome Emile Georges; (Issy-les-Moulineaux, FR), Janssens, Frans Eduard; (Beerse, BE), Sommen, Francois Maria; (Beerse, BE) Correspondence: Philip S Johnson; Johnson & Johnson; One Johnson & Johnson Plaza; New Brunswick; NJ; 08933-7003; US Patent Application Number: 20030139393 Date filed: June 19, 2002 Abstract: The present invention relates to compounds of formula (I) 1their prodrugs, Noxides, addition salts, quaternary amines and stereochemically isomeric forms, wherein the bivalent radical --{circle over (A)}-- represents a saturated or an unsaturated homopiperidinyl having one double bond, and wherein said bivalent radical --{circle over (A)}-- is substituted with R.sup.2 being hydrogen, hydroxy, C.sub.1-4alkyl, or C.sub.1-4alkyloxy; -a.sup.1=a.sup.2-a.sup.3=a.sup.4represents an optionally substituted bivalent radical; R.sup.1 is hydrogen, C.sub.1-6alkyl, aryl.sup.1, C.sub.16alkyl substituted with aryl.sup.1, C.sub.1-4alkyloxycarbonyl, aryl.sup.1carbonyl, aryl.sup.1C.sub.1-6alkylarbonyl C.sub.1-4alkylcarbonyl, trifluoromethyl, trifluoromethylcarbonyl, C.sub.1-6alkylsulfonyl, aryl.sup.1sulfonyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl; X represents O, S or NR.sup.3, wherein R.sup.3 is hydrogen, C.sub.1-6alkyl, methanesulfonyl, benzenesulfonyl, trifluoromethanesulfonyl, dimethylsulfamoyl, C.sub.1-4alkyl substituted with aryl.sup.2 and optionally with hydroxy, C.sub.1-4alkylcarbonylC.sub.1-4alkyl substituted with aryl.sup.2; aryl.sup.1 is optionally substituted phenyl, optionally substituted pyridinyl, naphthyl, quinolinyl, or 1,3-benzodioxolyl; aryl.sup.2 is optionally substituted phenyl; fundic relaxating activity. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating dyspeptic symptoms, irritable bowel syndrome and other conditions related to a hampered or impaired relaxation of the fundus. Excerpt(s): The present invention is concerned with novel compounds of formula (I) having fundic relaxating activity. The invention further relates to methods for preparing
Patents 175
such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds. EP-A-0,079,545 discloses piperazinyl substituted benzimidazole derivatives with antihistaminic acitivity. Unexpectedly, it was found that the present novel compounds of formula (I) have fundic relaxating properties and are therefore useful to alleviate symptoms resulting from an impaired relaxation of the fundus to food ingestion. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Thiophenyl triazol-3-one derivatives as smooth muscle relaxants Inventor(s): Hewawasam, Piyasena; (Middletown, CT), King, Dalton; (Hamden, CT), Lodge, Nicholas J.; (Madison, CT), Starrett, John E.; (Middletown, CT), Sun, Li-Quang; (Glastonbury, CT) Correspondence: Stephen B. Davis; Bristol-myers Squibb Company; Patent Department; P O Box 4000; Princeton; NJ; 08543-4000; US Patent Application Number: 20030144333 Date filed: October 8, 2002 Abstract: The present invention provides novel [1,2,4]triazole-3-one derivatives having the general formula (I) 1wherein:Q is 2and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined herein or a nontoxic pharmaceutically acceptable salt or solvate thereof which are smooth muscle relaxants and useful in treating disorders responsive to relaxation of smooth muscle such as asthma, irritable bowel syndrome, male erectile dysfunction and urinary incontinence. Excerpt(s): This is a non-provisional application which claims the benefit of U.S. Provisional Application No. 60/336,865 filed Nov. 2, 2001. The present invention is directed to novel 2phenyl-5thiophenyl-2,4-- dihydro-[1,2,4]-triazol-3-one derivatives which are smooth muscle relaxants and therefore are useful in treating disorders responsive to relaxation of smooth muscle such as asthma, irritable bowel syndrome, male erectile dysfunction and particularly urinary incontinence. The present invention is also directed to a method of treatment with the novel compounds and to pharmaceutical compositions containing them. Urinary incontinence is a common condition that is the frequent cause of confinement to nursing homes among the elderly. It afflicts significant numbers among both men and women and all ages. In addition studies show some degree of daily incontinence reported among as many as 17% of young apparently healthy women. Safe and reliable methods for treating incontinence are clearly needed. Urinary incontinence is a manifestation of the failure to control the muscles of the bladder or urinary sphincter. Incontinence results when the pressure within the bladder is too great as a result of excessive force exerted by the bladder muscles, or when the sphincter muscles are too weak. Urinary incontinence can be a manifestation of other diseases such as Parkinsonism, multiple sclerosis, lesions of the central nervous system, or bladder infections. Interstitial cysts can result in instability of the bladder detusor muscles and a particularly unpleasant form of urge incontinence. Urinary incontinence is believed to currently affect over 12 million people in the United States alone, and to occur in between 15 and 30% of the population over 60. The current standard of care is quite unsatisfactory. All of the current drugs now utilized to treat urinary incontinence suffer from polypharmacology and unwanted side effects. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
176 Irritable Bowel Syndrome
•
Treating irrtable bowel syndrome or disease Inventor(s): Cadwallader, Dianne; (Auckland, NZ), Heatley, Craig Leonard; (Auckland, NZ), Meakin, Timothy David; (Auckland, NZ) Correspondence: Jacobson Holman Pllc; 400 Seventh Street N.W.; Suite 600; Washington; DC; 20004; US Patent Application Number: 20030171432 Date filed: March 27, 2003 Abstract: The treatment of humans or other mammals for irritable bowel syndrome (IBS) or irritable bowel disease (IBD) using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate. Excerpt(s): The present invention relates to a method of treatment and/or prophylaxis of irritable bowel syndrome (IBS) and irritable bowel disease (IBD). IBS is a medical condition in which the gut functions improperly because of increased sensitivity to pain and abnormal movements. Symptoms may include abdominal discomfort or pain, often in association with urgency and diarrhea and/or constipation; bloating, spasms and painful cramping. Some hypersensitivity can be triggered by inflammation, as seen in dysentery. Colonic inflammation in can be prolonged by emotional stress. IBD, this is also referred to as, Crohns and Colitis is a disorder involving inflammation and possible ulceration of the digestive tract. Symptoms include diarrhea, fever, anorexia, weight loss, gas, and abdominal tenderness. There may be bloody diarrhea if intestinal bleeding occurs. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil Inventor(s): Devane, John; (Althlone, IE), Kelly, John; (Dublin, IE) Correspondence: Finnegan, Henderson, Farabow; Garrett & Dunner, L.L.P.; 1300 I Street, N.W.; Washington; DC; 20005-3315; US Patent Application Number: 20030092765 Date filed: September 27, 2002 Abstract: The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using (R)verapamil, as well as compositions and formulations containing the same. Excerpt(s): This application claims priority to U.S. Provisional Patent Application No. 60/335,959, filed Nov. 15, 2001, the entire disclosure of which is incorporated herein by reference. The present invention is generally directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility. Such abnormal increases may be caused by one or more intestinal conditions, including, but not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestine, and symptoms of any of the foregoing. In particular, the invention relates to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility with stereo-specific forms of calcium channel blockers, including but not limited to, (R)-
Patents 177
verapamil. Irritable Bowel Syndrome (IBS) results in about 3.5 million physician visits per year, and is the most common diagnosis made by gastroenterologists, accounting for about 25% of all patients diagnosed (Camilleri and Choi, Aliment Pharmacol. Ther., 11(1):3-15, 1997). Individuals afflicted with IBS visit doctors more frequently, enjoy a lower quality of life, and miss work more often relative to those with no bowel symptoms (Drossman et al., Dig. Dis. Sci., 38:1569-1580, 1993). As a consequence, individuals suffering from IBS incur significantly higher health care costs than those without the condition (Talley et al., Gastroenterology, 109:1736-1741, 1995). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Treatment of functional gastrointestinal disorders Inventor(s): Fowler, David; (Cambridge, GB) Correspondence: Davidson, Davidson & Kappel, Llc; 485 Seventh Avenue, 14th Floor; New York; NY; 10018; US Patent Application Number: 20030119916 Date filed: November 18, 2002 Abstract: Tramadol or a pharmaceutically acceptable salt thereof is used in the manufacture of a pharmaceutical preparation for the treatment of functional gastrointestinal disorders such as irritable bowel syndrome. Excerpt(s): The present invention relates to the treatment of functional gastrointestinal (GI) disorders, especially irritable bowel syndrome (IBS). In particular the present invention relates to pharmaceutical preparations containing tramadol for the treatment of such disorders and the use of tramadol in the manufacture of such preparations. Tramadol (2-[(Dimethylamino) methyl]-1-(3-methoxy phenyl) cyclohexanol is a nonnarcotic opioid analgesic which was first described in the 1960's (see UK Patent 997399). It was first marketed in Germany in 1977 and subsequently in various countries and by 1980 a total of 34 different tramadol formulations in immediate release oral and injectable form were on the market. In 1996 controlled release preparations containing tramadol were introduced, for example TRAMUNDIN RETARD capsules of Mundipharma GmbH, TRAMAL LONG 100 tablets of Grunenthal GmbH and ZYDOL SR tablets of G